0001709401-23-000005.txt : 20230227 0001709401-23-000005.hdr.sgml : 20230227 20230227073615 ACCESSION NUMBER: 0001709401-23-000005 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38586 FILM NUMBER: 23670059 BUSINESS ADDRESS: STREET 1: C/O VERDOLINO & LOWEY, P.C. STREET 2: 124 WASHINGTON STREET, SUITE 101 CITY: FOXBORO STATE: MA ZIP: 02035 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: C/O VERDOLINO & LOWEY, P.C. STREET 2: 124 WASHINGTON STREET, SUITE 101 CITY: FOXBORO STATE: MA ZIP: 02035 10-K 1 ruby-20221231.htm 10-K ruby-20221231
2022FY0001709401falsehttp://fasb.org/us-gaap/2022#RestructuringCostsAndAssetImpairmentCharges00017094012022-01-012022-12-3100017094012022-06-30iso4217:USD00017094012023-01-31xbrli:shares00017094012022-12-310001709401us-gaap:DomesticCountryMember2022-12-310001709401us-gaap:StateAndLocalJurisdictionMember2022-12-3100017094012021-12-31iso4217:USDxbrli:shares00017094012021-01-012021-12-3100017094012020-01-012020-12-310001709401us-gaap:CommonStockMember2019-12-310001709401us-gaap:AdditionalPaidInCapitalMember2019-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001709401us-gaap:RetainedEarningsMember2019-12-3100017094012019-12-310001709401us-gaap:CommonStockMember2020-01-012020-12-310001709401us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001709401us-gaap:RetainedEarningsMember2020-01-012020-12-310001709401us-gaap:CommonStockMember2020-12-310001709401us-gaap:AdditionalPaidInCapitalMember2020-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001709401us-gaap:RetainedEarningsMember2020-12-3100017094012020-12-310001709401us-gaap:CommonStockMember2021-01-012021-12-310001709401us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001709401us-gaap:RetainedEarningsMember2021-01-012021-12-310001709401us-gaap:CommonStockMember2021-12-310001709401us-gaap:AdditionalPaidInCapitalMember2021-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001709401us-gaap:RetainedEarningsMember2021-12-310001709401us-gaap:CommonStockMember2022-01-012022-12-310001709401us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001709401us-gaap:RetainedEarningsMember2022-01-012022-12-310001709401us-gaap:CommonStockMember2022-12-310001709401us-gaap:AdditionalPaidInCapitalMember2022-12-310001709401us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001709401us-gaap:RetainedEarningsMember2022-12-310001709401ruby:A2022StrategicRestructuringPlanMember2022-09-132022-09-13xbrli:pure0001709401ruby:LoanAgreementMember2018-12-210001709401ruby:A2022StrategicRestructuringPlanMember2022-11-022022-11-02ruby:employee0001709401us-gaap:ComputerEquipmentMember2022-01-012022-12-310001709401ruby:LaboratoryEquipmentMember2022-01-012022-12-310001709401us-gaap:FurnitureAndFixturesMember2022-01-012022-12-310001709401ruby:ManufacturingEquipmentMember2022-01-012022-12-310001709401us-gaap:ManufacturingFacilityMember2022-01-012022-12-310001709401us-gaap:LeaseholdImprovementsMember2022-01-012022-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:FairValueMeasurementsRecurringMember2022-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:FairValueMeasurementsRecurringMember2021-12-310001709401us-gaap:LandMember2022-12-310001709401us-gaap:LandMember2021-12-310001709401us-gaap:ManufacturingFacilityMember2022-12-310001709401us-gaap:ManufacturingFacilityMember2021-12-310001709401ruby:ManufacturingEquipmentMember2022-12-310001709401ruby:ManufacturingEquipmentMember2021-12-310001709401ruby:LaboratoryEquipmentMember2022-12-310001709401ruby:LaboratoryEquipmentMember2021-12-310001709401us-gaap:ComputerEquipmentMember2022-12-310001709401us-gaap:ComputerEquipmentMember2021-12-310001709401us-gaap:FurnitureAndFixturesMember2022-12-310001709401us-gaap:FurnitureAndFixturesMember2021-12-310001709401us-gaap:LeaseholdImprovementsMember2022-12-310001709401us-gaap:LeaseholdImprovementsMember2021-12-310001709401us-gaap:AssetUnderConstructionMember2022-12-310001709401us-gaap:AssetUnderConstructionMember2021-12-310001709401ruby:A2022RestructuringPlanMemberruby:ImpairmentOfPropertyPlantAndEquipmentMember2022-01-012022-12-310001709401ruby:LoanAgreementMember2018-12-212018-12-21ruby:tranche0001709401ruby:LoanAgreementMember2019-06-012019-06-300001709401ruby:LoanAgreementMember2020-06-012020-06-300001709401ruby:LoanAgreementMember2021-06-220001709401us-gaap:LondonInterbankOfferedRateLIBORMemberruby:LoanAgreementMember2021-06-222021-06-220001709401us-gaap:LondonInterbankOfferedRateLIBORMemberruby:LoanAgreementMembersrt:MaximumMember2021-06-222021-06-220001709401srt:MinimumMemberruby:LoanAgreementMember2021-06-222021-06-220001709401ruby:LoanAgreementMember2021-06-222021-06-220001709401ruby:LoanAgreementMember2022-10-132022-10-130001709401ruby:LoanAgreementMember2022-01-012022-12-31ruby:vote00017094012018-07-200001709401ruby:AtMarketOfferingMember2019-08-010001709401ruby:AtMarketOfferingMember2022-01-012022-12-310001709401ruby:OfferingMember2021-03-182021-03-1800017094012022-07-0600017094012022-07-070001709401ruby:EquityIncentivePlan2018Member2018-07-060001709401ruby:EquityIncentivePlan2018Member2022-12-310001709401ruby:EquityIncentivePlan2018Member2022-01-012022-01-010001709401ruby:A2018ESPPMember2022-01-012022-12-310001709401ruby:A2018ESPPMember2021-01-012021-12-310001709401ruby:A2018ESPPMember2020-01-012020-12-310001709401us-gaap:EmployeeStockOptionMember2021-12-310001709401us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001709401us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001709401us-gaap:EmployeeStockOptionMember2022-12-310001709401us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001709401ruby:MarketBasedAndServiceBasedVestingMember2018-10-012018-10-310001709401srt:ExecutiveOfficerMember2018-10-012018-10-310001709401srt:ExecutiveOfficerMember2022-12-310001709401ruby:MarketBasedAndServiceBasedVestingMember2022-01-012022-12-310001709401ruby:MarketBasedAndServiceBasedVestingMember2021-01-012021-12-310001709401ruby:MarketBasedAndServiceBasedVestingMember2020-01-012020-12-310001709401ruby:VestingBasedOnPerformanceMember2022-01-012022-12-310001709401ruby:VestingBasedOnPerformanceMember2021-01-012021-12-310001709401ruby:VestingBasedOnPerformanceMember2020-01-012020-12-310001709401ruby:MarketBasedStockOptionsMember2021-01-012021-12-310001709401ruby:MarketBasedStockOptionsMember2020-01-012020-12-310001709401ruby:MarketBasedStockOptionsMember2022-01-012022-12-310001709401us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-12-310001709401us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-12-310001709401us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001709401us-gaap:RestrictedStockUnitsRSUMember2021-12-310001709401us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001709401us-gaap:RestrictedStockUnitsRSUMember2022-12-310001709401us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001709401us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001709401us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001709401us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001709401us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001709401us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001709401us-gaap:LicenseAndMaintenanceMembersrt:MaximumMemberruby:WhiteheadInstituteForBiomedicalResearchMember2022-01-012022-12-310001709401ruby:WhiteheadInstituteForBiomedicalResearchMember2022-01-012022-12-3100017094012018-01-012018-01-310001709401srt:MaximumMember2018-01-012018-01-31ruby:leaseruby:dateruby:property00017094012018-01-3100017094012018-11-3000017094012018-11-012018-11-3000017094012022-10-012022-12-310001709401srt:ScenarioForecastMember2023-01-012023-03-310001709401ruby:EmbeddedLeaseContractsMember2022-12-310001709401us-gaap:RestrictedStockMember2022-01-012022-12-310001709401us-gaap:RestrictedStockMember2021-01-012021-12-310001709401us-gaap:RestrictedStockMember2020-01-012020-12-310001709401us-gaap:StockOptionMember2022-01-012022-12-310001709401us-gaap:StockOptionMember2021-01-012021-12-310001709401us-gaap:StockOptionMember2020-01-012020-12-310001709401ruby:A2022RestructuringPlanMember2022-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-01-012022-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2021-01-012021-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2020-01-012020-12-310001709401ruby:A2022RestructuringPlanMemberruby:ImpairmentOfPropertyPlantAndEquipmentMember2021-01-012021-12-310001709401ruby:A2022RestructuringPlanMemberruby:ImpairmentOfPropertyPlantAndEquipmentMember2020-01-012020-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:ContractTerminationMember2022-01-012022-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:ContractTerminationMember2021-01-012021-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:ContractTerminationMember2020-01-012020-12-310001709401ruby:A2022RestructuringPlanMember2022-01-012022-12-310001709401ruby:A2022RestructuringPlanMember2021-01-012021-12-310001709401ruby:A2022RestructuringPlanMember2020-01-012020-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2021-12-310001709401ruby:A2022RestructuringPlanMember2022-07-012022-09-300001709401us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberruby:A2022RestructuringPlanMemberus-gaap:ManufacturingFacilityMember2022-12-310001709401us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberruby:A2022RestructuringPlanMemberus-gaap:ManufacturingFacilityMember2022-01-012022-12-310001709401us-gaap:ContractTerminationMember2022-01-012022-12-310001709401ruby:A2022RestructuringPlanMemberus-gaap:ContractTerminationMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-38586
RUBIUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware46-2688109
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
c/o Verdolino & Lowey, P.C.
124 Washington Street,Suite 101
Foxborough,Massachusetts02035
(Address of principal executive offices)(Zip code)
(508) 543-1720
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareRUBYThe Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐ No ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
1
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of common stock held by non-affiliates of the registrant computed by reference to the price of the registrant’s common stock as of June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately (based on the last reported sale price on the NASDAQ Global Select Market as of such date) was $28.4 million.
As of January 31, 2023 the registrant had 90,397,732 shares of common stock, $0.001 par value per share, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this Annual Report on Form 10-K incorporates by reference certain information permitted to be so incorporated pursuant to Regulation 14A from the registrant’s definitive Proxy Statement to the extent such Proxy Statement is filed no later than 120 days after the registrant’s fiscal year end of December 31, 2022. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.



2
Rubius Therapeutics, Inc.
Table of Contents
Page No.


3
CAUTIONARY STATEMENT

As previously announced, on February 20, 2023, following the conclusion of our review of strategic alternatives, our Board of Directors unanimously approved the dissolution and liquidation of Rubius Therapeutics, Inc., or the Dissolution, pursuant to a plan of complete liquidation and dissolution, or the Plan of Dissolution, which plan is subject to stockholder approval. We intend to call a special meeting of the stockholders to seek approval of the Plan of Dissolution. We plan to file a preliminary proxy statement relating to the special meeting with the SEC, and to subsequently file and provide stockholders with a definitive proxy statement, as soon as practical.

Rubius Therapeutics, Inc., or the Company, cautions that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual value realized, if any, by holders of the Company’s securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plan and objectives of management are forward-looking statements. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements involve various risks and uncertainties that could cause actual outcomes or results to differ materially from those indicated in these statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:

•plans and expectations for the Dissolution;

•beliefs about our available options and financial condition;

•our ability to fund our planned operations for the next twelve months and our ability to continue as a going concern;

•expectations that our cash will be sufficient to fund our operating expenses into the future;

•estimates for our expenses and capital requirements; and

•our expectations regarding our ability to maintain the listing of our common stock on the Nasdaq Global Select Market.

All of our forward-looking statements are as of the date of this Annual Report on Form 10-K only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form 10-K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Therefore, you should not place undue reliance on forward-looking statements. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form 10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report on Form 10-K that modify or impact any of the forward-looking statements contained in this Annual Report on Form 10-K will be deemed to modify or supersede such statements in this Annual Report on Form 10-K.



4
Summary of the Material Risks Associated with Our Business

Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:

•our Board of Directors recently approved, subject to stockholder approval, the dissolution and liquidation of the Company, pursuant to a Plan of Dissolution. We may not be able to complete the Dissolution in a timely manner or at all. Further, there can be no assurances as to the amount of distributions, if any, to our stockholders upon dissolution;

•if our stockholders do not approve the Dissolution, we would not be able to continue our business operations;

•our cash has been significantly depleted by the payoff of our credit facility with SLR Investment Corp., the fees paid in connection with our lease termination and the payment of our other creditor obligations; and

•if we fail to maintain the listing of our common stock with a United States national securities exchange, the liquidity of our common stock could be adversely affected.

The summary risk factors described above should be read together with the text of the full risk factors below and in the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. If any such risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.


5
PART I
Except where the context otherwise requires or where otherwise indicated, the terms “Rubius,” “Rubius Therapeutics,” “we,” “us,” “our,” “our company,” “the Company,” and “our business” refer to Rubius Therapeutics, Inc. and its consolidated subsidiary.
Solely for convenience, the trademarks, service marks and trade names referred to in this annual report are listed without the ®, (sm) and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names.
Item 1. Business
Overview
We are a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines called Red Cell Therapeutics, or RCTs, for the treatment of cancer and autoimmune diseases.

As previously announced, on February 20, 2023, following the conclusion of our review of strategic alternatives, our Board of Directors unanimously approved the dissolution and liquidation of Rubius, or the Dissolution, pursuant to a plan of complete liquidation and dissolution, or the Plan of Dissolution, which plan is subject to stockholder approval. As such, the following discussion and analysis of our business, financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, and should also take into account our recent announcement regarding our planned Dissolution. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans, operations, intellectual property and other matters related to our business, includes forward-looking statements that involve risks and uncertainties, including risks associated with our planned Dissolution. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

On November 2, 2022, we announced that, in light of our financial condition and the early stage of our programs, our Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of our assets, and to significantly and immediately reduce our operations, which we refer to as our strategic plan. In connection with the strategic plan, we terminated 42 of our employees (representing 82% of our then-current employee base), leaving a core team of individuals to lead the strategic review process.

On September 13, 2022, our Board of Directors approved certain operational and organizational steps that we undertook in connection with a new strategic reorganization plan and related cost-saving measures. We discontinued our ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructured the organization to support advancing drug candidates based on our next generation platform. Under this plan, we reduced our overall workforce by approximately 75%, primarily consisting of employees who were focused on clinical development of RTX-240 and RTX-224, with the remainder coming from our manufacturing and general and administrative functions.

Although we ceased enrolling patients in 2022, with more than 80 patients dosed across three clinical trials, we demonstrated that engineered red blood cells, or RBCs, can be manufactured at scale and observed initial evidence of tolerability clinical activity in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors. Based on these early findings, we firmly believe in the potential of RCTs for the treatment of cancer and autoimmune diseases.

September 2022 Restructuring

Following careful review of technical progress made during 2022 in an alternative format for making RCTs, we determined that this alternative process had the potential for substantive improvements over our first generation RED PLATFORM, and, therefore, continued investment in our two clinical candidates was no longer justified. As a result, in September 2022, we announced that we would be discontinuing our ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and implemented a new strategic reorganization plan focused on advancing drug candidates based on this next generation RBC-based cell conjugation platform and related cost-saving measures.

The next generation platform leverages chemical conjugation to produce RCTs. Cell conjugation creates a covalent link between the cell surface and the molecule of interest. Compared to our first generation RED PLATFORM, this new approach is intended to:
6

•deliver a higher effective dose by enabling a longer circulation time and/or administering a higher cell dose;

•be more versatile, enabling the conjugation of different payloads, immunomodulatory agents, small molecules and proteins on the cell for enhanced potency; and

•reduce the cost of goods manufacturing by utilizing blood-banked RBCs versus biologically engineering and differentiating early progenitor cells into reticulocytes that express proteins.

These attributes have the potential to result in greater efficacy, a similar safety profile given the restricted biodistribution of RBCs to the spleen and vasculature, and a significant reduction in overall cost structure.

To enable continued investment in the new platform, the cost-saving measures implemented in September 2022 included:

•implementing an approximately 75% reduction in workforce, primarily focused on clinical development, manufacturing and general and administrative personnel;

•discontinuing our ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors; and

•exploring the sale of our manufacturing facility in Smithfield, Rhode Island.

With these cost-saving measures, our operations were significantly reduced and were focused on maintaining the new platform and related preclinical programs for purposes of exploring strategic alternatives.

Overview of Discontinued Clinical Programs

Phase 1/2 Clinical Trial of Monotherapy RTX-240

36 patients were dosed in the monotherapy arm of the Phase 1/2 clinical trial of RTX-240 in advanced solid tumors. To date, RTX-240 has been well tolerated with no treatment-related Grade 3/4 adverse events, or AEs.

Phase 1 Clinical Trial of RTX-240 + Pembrolizumab in Advanced Solid Tumors

Sixteen patients were dosed in the dose-escalation/expansion portion of the Phase 1 clinical trial evaluating RTX-240 in combination with pembrolizumab in advanced solid tumors. To date, the combination of RTX-240 with pembrolizumab has been well tolerated with no treatment or investigator-identified immune-related Grade 3/4 AEs.

Phase 1 Clinical Trial of RTX-224 in Select Advanced Solid Tumors

Seven patients were dosed across two dose cohorts in the Phase 1 clinical trial evaluating RTX-224 in select advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. To date, there have been no treatment-related Grade 3/4 AEs.

Termination of Credit Facility

On October 13, 2022, we entered into a payoff letter with SLR Investment Corp. (f/k/a Solar Capital Ltd.), or SLR, our senior lender, under which we voluntarily prepaid SLR approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under our Loan and Security Agreement, dated December 21, 2018, with SLR (as amended, the “Loan Agreement”) and related security documents. The payoff letter also provided for the termination of all commitments and obligations under the Loan Agreement and related documents and release of all liens held by SLR on our assets.

November 2022 Restructuring

On November 2, 2022, we announced that, in light of our financial condition, including the repayment and termination of our $75.0 million credit facility with SLR, and the early stage of our programs, our Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of our assets, and to
7
significantly and immediately reduce our operations, which we refer to as our strategic plan. In connection with the strategic plan, we terminated 82% of our employee base as of November 2, 2022, leaving a core team of individuals to lead the strategic review process.

Sale of Manufacturing Facility

On December 6, 2022, we entered into a Purchase and Sale Agreement with DIV Acquisition V, LLC for the sale of our Smithfield, Rhode Island manufacturing facility and certain related fixtures and personal property, for an aggregate purchase price of $18,500,000, subject to adjustment. The transaction closed on December 21, 2022.

Termination of Lease Agreement

On December 12, 2022, or the Effective Date, we entered into an Agreement for Termination of Lease, or the Lease Termination Agreement, with ARE-MA Region No. 58, LLC, or ARE, relating to our corporate headquarters located at 399 Binney Street, Cambridge, Massachusetts 02139, or the Cambridge Facility. Under the Lease Termination Agreement, our Lease Agreement, dated as of January 18, 2018, with ARE (as amended, the “Lease”) for the Cambridge Facility terminated on January 31, 2023.

Under the terms of the Lease Termination Agreement, we paid to ARE a lease termination payment of approximately $6,973,308, consisting of (i) ARE’s right to draw the full amount of a letter of credit that it held under the Lease, in the amount of $1,573,308, (ii) an initial payment of $4,300,000, inclusive of rent previously paid by us to ARE for the month of December 2022 in the amount of $910,060, and (iii) a subsequent payment of $1,100,000. We also conveyed ownership to ARE of certain items of personal property, furniture, fixtures and equipment located within the Cambridge Facility. Pursuant to the Lease Termination Agreement, we have no further rent obligations to ARE pursuant to the Lease following the Effective Date.

IND Withdrawals

In connection with the strategic plan, we withdrew our Investigational New Drug Applications, or INDs, for RTX-134 and RTX-321 on December 9, 2022. We withdrew our INDs for RTX-224 and RTX-240 on December 13, 2022 and December 14, 2022, respectively.

Approval of Plan of Dissolution

On February 20, 2023, following the conclusion of our review of strategic alternatives, our Board of Directors unanimously approved the Dissolution, pursuant to the Plan of Dissolution, which plan is subject to stockholder approval. We intend to call a special meeting of the stockholders to seek approval of the Plan of Dissolution. We plan to file a preliminary proxy statement relating to the special meeting with the SEC, and to subsequently file and provide stockholders with a definitive proxy statement, as soon as practicable.

The Company cautions that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual value realized, if any, by holders of the Company’s securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Intellectual property

We have a broad portfolio of patent applications, know how, trade secrets, and other intellectual property that covers our platform technologies as well as our product discoveries. We believe the breadth and depth of our intellectual property is a strategic asset that has the potential to provide a significant competitive advantage over other cell therapy companies.

We have striven to protect and enhance the proprietary technology, inventions and improvements in our intellectual property portfolio, including seeking, maintaining and defending patent rights, whether developed internally or licensed from collaborators or other third parties. Our policy has been to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and product discoveries. We have also historically relied on trade secrets and know-how relating to our proprietary technology and product discoveries and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of engineered red blood cell therapeutics.

8
We believe that we have a strong global intellectual property position and possess substantial know-how and trade secrets relating to our proprietary product discoveries, technology and platform, including related manufacturing processes and technology. As for our product discoveries, platform, and the processes we have developed, we have pursued, as appropriate, patent protection or trade secret protection relating to compositions, methods of use, treatment of indications, dosing, formulations and methods of manufacturing. Our former product candidates – RTX-240, RTX-321 and RTX-224 – are covered by three varieties of U.S. patent claims: (1) composition of matter; (2) method of treatment; and (3) method of making. As of January 31, 2023, our patent portfolio consists of 30 patent families (not including provisional applications and including licensed patent families), including 20 issued U.S. patents (including in-licensed U.S. patents), 30 patents issued outside the United States (including in-licensed patents outside of the United States), 22 owned or in-licensed pending U.S. utility patent applications, and more than 130 owned or in-licensed pending patent applications in jurisdictions outside of the United States (including Patent Cooperation Treaty, or PCT, applications) that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. Examples of the products and technology areas covered by our intellectual property portfolio are described below.

Disease-related intellectual property

The disease-related patent rights in our intellectual property portfolio relate to pathological conditions and disorders and provide coverage for our former RCT product candidates to specifically address those conditions and the associated disease states. The disease-related patent applications include those described below. Each of the disease-related patent rights and applications described below are owned by us and are not licensed from any third party:

RTX-240 and RTX-224 for certain oncology indications

We developed RTX-240, our former RCT product candidate engineered to express 4-1BBL and IL-15TP (a fusion of the cytokine IL-15 and IL-15 receptor alpha), for the treatment of patients suffering from hematological or solid cancers that have lost response to conventional therapies, including anti-PD-1 therapies or other immune-oncology therapies, and to prevent the emergence of resistance to checkpoint inhibitors and other immune-oncology therapies. RTX-240 was designed to induce the proliferation and activation of two key target cells, the NK cell and CD8+ memory T cell.

We developed RTX-224, our former RCT product candidate engineered to co-express 4-1BBL and IL-12, for the treatment of patients suffering from solid tumors where a T cell mechanism of action is critical. The introduction of membrane-bound IL-12 is thought to have very broad T cell-based activation, including all subsets of CD8+ and CD4+ T cells, while sparing the induction of the CD4+ regulatory T cells.
•This aspect of our patent portfolio relates to RCTs that express 4-1BBL, RCTs that express IL-15 or IL-15TP, RCTs that express IL-12, RCTs that co-express 4-1BBL and IL-15TP, RCTs that co-express 4-1BBL and IL-12, methods of activating CD8+ T cells and NK cells, methods of treating cancer, methods of making RCTs that express 4-1BBL and IL-15TP, including RTX-240, and methods of making RCTs that express 4-1BBL and IL-12, including RTX-224.

•As of January 31, 2023, the patent rights relating to this technology includes five issued U.S. patents, two pending U.S. utility patent applications, and 18 pending foreign patent applications derived from National Stage entries, relating to RCT compositions of matter, methods of activating immune cells, methods of treatment, and methods of making RTX-240 and RTX-224. We expect the issued patents and patent applications in this portfolio, if issued, to expire between 2037 and 2039, without taking into account any patent term adjustments or extensions we may obtain.

RTX-321, an artificial antigen presenting cell for the treatment of HPV-positive tumors

We developed our former product candidate RTX-321, an artificial antigen presenting cell RCT, to express an HPV 16 peptide antigen bound to MHC class I, 4-1BBL and IL-12 on the cell surface to mimic human T cell-APC interactions. RTX-321 was formerly in development for the treatment of HPV 16-positive tumors.

•This aspect of our patent portfolio relates to RCTs that express 4-1BBL, RCTs that express IL-12, RCTs that co-express 4-1BBL and IL-12, RCTs that express an HPV 16 peptide antigen bound to MHC class I, 4-1BBL, and IL-12, methods of treating cancer, and methods of making RCTs that express an HPV 16 peptide antigen bound to MHC class I, 4-1BBL and/or IL-12, including RTX-321.

•As of January 31, 2023, the patent rights relating to this technology includes four issued U.S. patents, three pending U.S. patent applications, and 32 pending foreign patent applications derived from National Stage entries,
9
relating to RCT compositions of matter, methods of treatment and methods of making RTX-321. We expect the issued patents and patent applications in this portfolio, if issued, to expire between 2037 and 2039, without taking into account any patent term adjustments or extensions we may obtain.

Additional oncology intellectual property

We own disease-related patent applications directed to RCTs for use in oncology, including immuno-oncology. These patent applications relate to RCT compositions that comprise a variety of agents, including anti-tumor antibodies, tumor starvation enzymes, pro-apoptotic proteins, costimulatory molecules, immune checkpoint inhibitors, tumor antigens, MHC molecules and numerous combinations thereof. These patent applications also cover the use of RCTs to treat cancer, including lung cancer, melanoma, renal cancer, bladder cancer, gastric cancer, squamous cell carcinoma, Hodgkin lymphoma, hepatocellular carcinoma, Merkel cell carcinoma, colorectal cancer, and acute myeloid leukemia, as well as various relapsed or refractory cancers.

We expect the patent applications in this portfolio, if issued, to expire between 2034 and 2040, without taking into account any patent term adjustments or extensions we may obtain.

Autoimmune disease intellectual property

We own disease-related patent applications directed to RCTs for use in treating autoimmune diseases. These patent applications relate to RCT compositions having autoimmune antigens, anti-cytokine antibodies, agents for cleaving autoimmune antibodies and numerous combinations thereof. The RCTs covered by these patent applications operate through various mechanisms, including through induction of tolerance to self-antigens, clearance of autoimmune antibodies from the bloodstream, clearance of cytokines from the bloodstream and inactivation of autoimmune antibodies. The patent applications also cover the use of these RCTs to treat a number of diseases, such as Type 1 diabetes, membranous nephropathy, autoimmune hepatitis, myasthenia gravis, celiac disease and neuromyelitis optica.

We expect the patent applications in this portfolio, if issued, to expire between 2034 and 2040, without taking into account any patent term adjustments or extensions we may obtain.

Cardio-metabolic disorders intellectual property

We own disease-related patent applications directed to RCT compositions and their use in treating cardiac disorders and metabolic disorders, including diabetes, obesity heart failure, atherosclerosis and hemophilia. We expect the patent applications in this portfolio, if issued, to expire in 2037, without taking into account any patent term adjustments or extensions we may obtain.

Infectious disease intellectual property

We own disease-related patent applications directed to RCT compositions and their use in treating infectious diseases, such as a viral infection (e.g., cytomegalovirus or HIV) or a bacterial infection (e.g., bacteremia). We expect the patent applications in this portfolio, if issued, to expire between 2034 and 2040 without taking into account any patent term adjustments or extensions we may obtain.

Platform-related intellectual property

In addition to the disease-related intellectual property, our intellectual property portfolio also includes know-how and patent applications directed to our first and second generation RED PLATFORM and other technologies developed internally and exclusively in-licensed from the Whitehead Institute for Biomedical Research, or WIBR, that relate to the engineering and culturing of RCTs. Exemplary platform technologies that are the subject of such patent applications include:

•methods related to the in vitro production of enucleated red blood cells;

•gene editing and transcriptional modulation systems for engineering RCTs;

•targeted lipid nanoparticle compositions and RNA delivery techniques;

•amplifiable nucleic acid constructs for optimizing protein production;
10

•methods for chemically conjugating biotherapeutic proteins to cell surfaces; and

•methods for increasing percent enucleation during RCT production.

Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for 20 years from the earliest effective filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.

Trademark protection

As of January 31, 2023, our trademark portfolio contains approximately 59 registrations and pending applications. For the RUBIUS THERAPEUTICS mark, we have issued registrations in the U.S., Argentina, Canada, Brazil, the United Kingdom, and Hong Kong, and an International Registration designating Australia, China, the E.U., India, Indonesia, Israel, Japan, Mexico, New Zealand, Norway, Russia, Singapore, South Korea, and Switzerland. In addition, we have two U.S. trademark registrations for the RUBIUS mark. For the RCT mark, we have a U.S. registration, as well as an International Registration designating China, the E.U., India, and Japan. Under this International Registration, the mark is registered in all listed countries. In addition, we have issued registrations for the RCT mark in the United Kingdom and Canada. We also have issued U.S. registrations for the RED CELL THERAPEUTICS mark, as well as an International Registration designating Japan. Under this International Registration, the mark is registered in Japan. In addition, we have a pending application in Singapore for the RED CELL THERAPEUTICS mark. We have issued registrations for the RED PLATFORM mark in the U.S. and the United Kingdom, as well as an International Registration designating China, the E.U., India, Japan and Russia. Under this International Registration, the mark is registered in all listed countries. In addition, we have a registration for this mark in Canada. We have issued registrations for the REALIZING THE POWER OF RED mark in the U.S. and the United Kingdom, as well as an International Registration designating Canada, China, the E.U., India, Japan, and Russia. Finally, we have a U.S. registration for the RTX mark.

Trade secrets

We have historically relied, in some circumstances, on trade secrets to protect our technology and aspects of our platform. However, trade secrets are difficult to protect. We have sought to protect our technology and product discoveries, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators and advisors. We have also sought to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by third parties. To the extent that our employees, contractors, consultants, collaborators and advisors have used intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology, inventions, improvements and products, please see the section on “Risk factors—Risks related to intellectual property.”

Licenses

In January 2016, we entered into an exclusive license with WIBR that grants us an exclusive, worldwide, sublicensable license under patent rights comprising two patent families to research, develop, make and commercialize products and processes covered by such patent rights for all uses, or the WIBR License. The WIBR License was amended in December 2017 to grant us an exclusive license to the commercialization rights under a third patent family jointly owned by WIBR and Tufts University, or Tufts. The WIBR License was amended in July 2018 to grant us an exclusive license to the commercialization rights under a fourth patent family owned by WIBR. As of January 31, 2023, the patent portfolio licensed from WIBR includes five issued U.S. patents, and 19 pending U.S. and foreign patent applications and issued foreign patents. We expect these WIBR-licensed patent applications, if issued, to expire between 2034 and 2038, without taking into account any patent term adjustments or extensions that may be obtained.
11

The patent rights licensed to us under the WIBR License are directed, in part, to the in vitro production of RBCs and the use of the enzyme sortase to conjugate a protein of interest to the cell surface. We have certain diligence obligations under the WIBR License, which include using commercially reasonable efforts to develop and commercialize any products under the patents and achieving certain milestones as further described in the WIBR License. Additionally, under certain circumstances, we may in the future be obligated to negotiate in good faith field-limited, non-exclusive sublicenses to allow third parties to exploit the patent rights licensed to us under the WIBR License.

WIBR retains the right with respect to all four patent families licensed to us to (i) practice the patent rights licensed under the agreement for research, teaching and educational purposes, including sponsored research and collaboration, and (ii) grant non-exclusive licenses to academic and not-for-profit research institutes to practice under the patent rights for research, teaching and educational purposes (excluding sponsored research), while Tufts retains such rights only with respect to the patent family that it co-owns. Pursuant to a Defense Advanced Research Projects Agency agreement between WIBR and a global biopharmaceutical company, the biopharmaceutical company funded research resulting in one of the licensed patent families and WIBR granted the biopharmaceutical company the right to retain a worldwide, irrevocable, non-exclusive, royalty-free right to use this patent family for research and development purposes. In addition, under the WIBR agreement, the U.S. federal government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded invention claimed in the patent rights, as set forth in 35 U.S.C. §§ 201-211 and Executive Order 12591.

As partial consideration for the license, we issued 366,667 shares of our common stock to WIBR. In addition, we paid WIBR an upfront payment and are required to pay annual license maintenance fees, creditable against royalties and milestone payments. Under the terms of the license, we are obligated to pay to WIBR low single-digit royalties based on any annual net sales by us, our affiliates and our sublicensees of licensed products and licensed services that are covered by a valid claim of the licensed patent rights at the time and in the country of sale. On a country-by-country basis, upon expiration of the last valid claim of the licensed patent rights covering such licensed product or licensed service in such country, our license becomes royalty-free, perpetual and irrevocable with respect to such country. The terms of the WIBR License require us to make aggregate milestone payments of up to $1.6 million upon the achievement of specified preclinical, clinical and regulatory milestones. In addition, we are required to pay to WIBR a percentage of the non-royalty payments that we receive from sublicensees of the patent rights licensed to us by WIBR. This percentage varies from low single digits to low double digits and will be based upon the clinical stage of the product at the time of the sublicense.

Under the WIBR License, WIBR controls the prosecution and maintenance of the patent rights licensed to us and we have the right to review and comment on such prosecution and maintenance. We have the first right to enforce the patent rights licensed to us against third party infringers. We may terminate the WIBR License for convenience upon three months prior written notice to WIBR. WIBR may terminate the WIBR License upon written notice to us if we, along with our affiliates and sublicensees, cease to carry on business related to the WIBR License for more than six months. WIBR may terminate the WIBR License for our material breach that remains uncured for sixty days after receiving notice thereof, if we fail to pay amounts due under the agreement within thirty days after receiving notice of such failure, or if we challenge the validity or enforceability of any of the licensed patent rights.

Government regulation

Although our operations are currently focused on winding down our operations in connection with our anticipated Dissolution, we remain subject to numerous federal, state and local laws and regulations, including securities, tax, anti-bribery and privacy laws and regulations.

Human Capital Resources

As of January 31, 2023, we had six full-time U.S.-based employees engaged to facilitate exploration and consummation of a strategic transaction. None of our employees are represented by labor unions or covered by collective bargaining agreements. As discussed more fully elsewhere in this Annual Report on Form 10-K, our Board of Directors recently approved the Dissolution of the Company pursuant to the Plan of Dissolution. In connection therewith, our employee base has been further reduced. Going forward, any continuing employees will be focused on facilitating the wind-down of the Company.

Facilities

Until January 31, 2023, our corporate headquarters were located in approximately 85,000 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts. As described further under the section captioned
12
“Business—Termination of Lease Agreement” above, on December 12, 2022, we entered into a Lease Termination Agreement with our landlord ARE, pursuant to which our lease for this facility terminated on January 31, 2023.

As of February 1, 2023, in light of our exit from our previous headquarters and in connection with our planned Dissolution, we have engaged Verdolino & Lowey, P.C. to provide administrative services to Rubius, including serving as our virtual principal executive office, and they are located at 124 Washington St., Suite 101, Foxborough, Massachusetts 02035.

We formerly owned a 135,000 square foot clinical manufacturing facility located in Smithfield, Rhode Island. On December 6, 2022, we entered into a Purchase and Sale Agreement with DIV Acquisition V, LLC for the sale of this facility and certain related fixtures and personal property for an aggregate purchase price of $18,500,000, subject to adjustment. The transaction closed on December 21, 2022.

Legal Proceedings

We are not currently a party to any material legal proceedings.

Corporate Information

Rubius was incorporated in April 2013 as VL26, Inc. under the laws of the State of Delaware. In January 2015, the Company changed its name to Rubius Therapeutics, Inc. Our principal executive office is located at c/o Verdolino & Lowey, P.C., 124 Washington Street, Suite 101, Foxborough, Massachusetts, 02035 and our telephone number is (508) 543-1720.

Financial Information and Segments

The financial information required under this Item 1 is incorporated herein by reference to the section of this Annual Report titled “Part II—Item 8—Consolidated Financial Statements and Supplementary Data.” The company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The company has developed a platform and pipeline focused on creating RCTs for the treatment of patients with severe diseases. All of the Company’s tangible assets are held in the United States. See Note 2 to our consolidated audited financial statements included in this Annual Report on Form 10-K. For financial information regarding our business, see “Part II—Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Annual Report on Form 10-K and our consolidated audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K.

Available Information

Our Internet address is www.rubiustx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the “Investors and Media” portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not to be deemed to be incorporated by reference in, and is not part of, this Annual Report on Form 10-K or any of our other securities filings, unless specifically incorporated herein by reference, and should not be relied upon in making a decision as to whether or not to purchase our common stock. Our filings with the SEC may be accessed through the SEC’s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.
13

Item 1A. Risk Factors

Our business is subject to numerous risks. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and “Management’s discussion and analysis of financial condition and results of operations,” and in our other filings with the Securities and Exchange Commission. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

Risks related to our recently announced Dissolution

We cannot predict the timing of distributions, if any, to our stockholders.

Our current intention is that, if approved by our stockholders, a Certificate of Dissolution would be filed promptly after such approval however, the decision of whether or not to proceed with the Dissolution will be made by our Board of Directors, or the Board, in its sole discretion. No further stockholder approval would be required to effect the Dissolution. However, if the Board determines that the Dissolution is not in our best interest or the best interest of our stockholders, the Board may, in its sole discretion, abandon the Dissolution or may amend or modify the Plan of Dissolution to the extent permitted by Delaware law without the necessity of further stockholder approval. After the Certificate of Dissolution has been filed, revocation of the Dissolution would require stockholder approval under Delaware law.

Under Delaware law, before a dissolved corporation may make any distribution to its stockholders, it must pay or make reasonable provision to pay all of its claims and obligations, including all contingent, conditional or unmatured contractual claims known to the corporation. Furthermore, we may be subject to potential liabilities relating to indemnification obligations, if any, to third parties or to our current and former officers and directors. It might take significant time to resolve these matters, and as a result we are unable to predict the timing of distributions, if any are made, to our stockholders.

If our stockholders do not approve the Dissolution proposal, we would not be able to continue our business operations.

On November 2, 2022, we announced that, in light of our financial condition and the early stage of our programs, our Board had approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of our assets, and to significantly and immediately reduce our operations (which we refer to herein as the “strategic plan”). In connection with the strategic plan, we terminated all but a core team of individuals to lead the strategic review process, and most individuals that remain are doing so on a part-time and consulting basis. While the strategic plan resulted in the sale of our Smithfield, Rhode Island manufacturing facility and certain related fixtures and personal property, for an aggregate purchase price of $18.5 million, we have been unable to identify a merger partner or purchaser of our Company or most of our other assets. If our stockholders do not approve the Dissolution proposal, the Board will continue to explore what, if any, alternatives are available for the future of the Company in light of its discontinued business activities; however, those alternatives are likely limited to seeking voluntary dissolution at a later time with potentially diminished assets, seeking bankruptcy protection (should our net assets decline to levels that would require such action) or investing our cash in another operating business. It is unlikely that these alternatives would result in greater stockholder value than the proposed Plan of Dissolution and the Dissolution.

The Board may determine not to proceed with the Dissolution.

Even if the Dissolution proposal is approved by our stockholders, the Board may determine in its sole discretion not to proceed with the Dissolution. If our Board elects to pursue any alternative to the Plan of Dissolution, our stockholders may not receive any of the funds that might otherwise be available for distribution to our stockholders. After the Certificate of Dissolution has been filed, revocation of the Dissolution would require stockholder approval under Delaware law.

Risks related to our financial condition and capital requirements

We do not currently have sufficient working capital to fund our planned operations for the next twelve months and may not be able to continue as a going concern, and our cash has been significantly depleted by our payoff of the SLR loan and other obligations. Further, we have recently announced that the Board unanimously approved the Dissolution of the Company pursuant to a Plan of Dissolution.

14
As of February 27, 2023, the issuance date of the consolidated financial statements, there is substantial doubt about our ability to continue as a going concern, as we currently do not have adequate financial resources to fund our forecasted operating costs for at least twelve months from the filing of this Annual Report on Form 10-K. As of December 31, 2022, we have incurred a cumulative deficit of $856.7 million. For the years ended December 31, 2022, 2021, and 2020, we reported net losses of $179.7 million, $196.5 million, and $167.7 million, respectively. In addition, during the years ended December 31, 2022, 2021, and 2020, we used $137.2 million, $63.8 million and $27.2 million in operating and investing activities, respectively, resulting in a cash and cash equivalents balance of $14.9 million, $225.8 million, and $176.3 million as of December 31, 2022, 2021, and 2020, respectively. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof, even after taking into account our significantly reduced operations, and we would need to raise additional capital to continue our operations, which capital is unlikely to be available on favorable terms or at all.

Our operating history and near-term forecast of incurring net losses and negative operating cash flows raise substantial doubt about our ability to continue as a going concern. Our cash position has required us to significantly reduce our operations and liquidate certain assets to remain afloat.

As previously announced, on February 20, 2023, following the conclusion of our review of strategic alternatives, our Board unanimously approved the dissolution and liquidation of Rubius, pursuant to a Plan of Dissolution, which plan is subject to stockholder approval. We intend to call a special meeting of the stockholders to seek approval of the Plan of Dissolution. We plan to file a preliminary proxy statement relating to the special meeting with the SEC, and to subsequently file and provide stockholders with a definitive proxy statement, as soon as practicable.

The Company cautions that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual value realized, if any, by holders of the Company’s securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

We have significantly reduced our employee base and operations.

In September 2022, we announced a corporate restructuring that resulted in a 75% reduction in workforce and refocused our efforts on preclinical research and platform development. In November 2022, we announced the strategic plan, significantly further reducing our operations and personnel and shifting our focus to a review of strategic alternatives. Following these restructurings and further headcount downsizing in January 2023, as of January 31, 2023, we had only six full-time employees, each focused on reviewing and, if appropriate, pursuing strategic alternatives.

As discussed more fully elsewhere in this Annual Report, our Board of Directors recently approved the Dissolution of the Company pursuant to the Plan of Dissolution. In connection therewith, our employee base has been further reduced. Going forward, any remaining employees will be engaged to facilitate the wind-down of the Company.

We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.

Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception in 2013. For the years ended December 31, 2022, 2021, and 2020, we reported net losses of $179.7 million, $196.5 million, and $167.7 million, respectively. As of December 31, 2022, we had an accumulated deficit of $856.7 million. Further, our cash resources have been significantly depleted, including $75.7 million used to extinguish our long-term debt and satisfy our obligations under the loan and security agreement with SLR Investment Corp. As noted elsewhere in this report, there is substantial doubt as to our ability to fund our planned operations for the next twelve months and to continue to operate as a going concern. As previously announced, on February 20, 2023, following the conclusion of our review of strategic alternatives, our Board of Directors unanimously approved the Dissolution pursuant to the Plan of Dissolution, which plan is subject to stockholder approval.

Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital and may result in holders of our common stock and other securities suffering a total loss of their investment.

15
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

Our results of operations and general business strategy could be adversely affected by general conditions in the global economy and in the global financial markets. In the past several years, global credit and financial markets have experienced volatility, instability and disruptions, including as a result of the ongoing COVID-19 pandemic. From time to time, this volatility, instability and disruption has caused, and may cause in the future, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. For example, since early 2020, the coronavirus, or COVID-19, pandemic has caused disruption in the financial markets both globally and in the United States. While certain negative effects of the ongoing COVID-19 pandemic have lessened as vaccines are distributed and administered and prevention and treatment methods improve, there have been and may continue to be resurgences of cases, including as a result of the emergence of variants that may be more contagious or more resistant to the vaccine and treatment options available, placing renewed and prolonged strain on both health care facilities and our workforce. Given the inter-connectivity of the global economy, pandemic disease and health events have the potential to continue to negatively impact economic activities in many countries, including the United States. The ongoing spread of the coronavirus, including variants thereof and resurgences in geographies experiencing some relief, could have a negative material impact on our business, prospects, financial condition and results of operations of the Company.

In addition, our results of operations and financial condition may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions.
As of December 31, 2022, we had cash and cash equivalents of $14.9 million. While we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since December 31, 2022, no assurance can be given that further deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.

Changes in tax law could adversely affect our business and financial condition.

The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our business. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.

The amount of and our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty.

As of December 31, 2022, we had federal and state net operating loss, or NOL, carryforwards of $584.8 million and $583.6 million, respectively, which may be available to offset future taxable income. The federal NOLs include $37.2 million which expire at various dates through 2037 and $547.6 million which carryforward indefinitely. The state NOLs expire at various dates through 2041. As of December 31, 2022, we also had federal and state research and development tax credit carryforwards of $29.5 million and $19.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2026, respectively.

Federal NOLs generated in taxable years after December 31, 2017 generally may not be carried back to prior taxable years, and while such federal NOLs generated in taxable years beginning after December 31, 2017 will not be subject to expiration, the deduction for such NOL in any taxable year will be limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. However, the Coronavirus Aid, Relief and Economic Security Act repeals the 80% limitation on the utilization of such federal NOLs generated in taxable years beginning after December 31, 2017 and beginning before January 1, 2021 and allows for federal NOLs generated in taxable years beginning after December 31, 2017 and before January 1, 2021, to be carried back to each of the five taxable years preceding the taxable year in which the loss arises. It is uncertain whether this change in law temporarily allowing for the carryback of federal NOLs will produce any material benefit for our business.

16
In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs or tax credits, or NOLs or credits (including federal research and development tax credits), to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, including in connection with our earlier private placements, IPO, our previous underwritten offering and other transactions. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code and limit our ability to utilize our NOLs and our credits. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U. S. federal and state taxable income. As described above under this section captioned “Risk factors—Risks related to our financial condition and capital requirements,” we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or credits that are subject to limitation by Sections 382 and 383 of the Code.

Risks related to our intellectual property

If we are unable to obtain and maintain patent protection for any intellectual property we have developed, third parties could develop and commercialize products or technology similar or identical to our inventions, and our ability to successfully monetize any product candidates or technologies we have developed may be adversely affected.

The value of our intellectual property portfolio depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product discoveries, RED PLATFORM and other technologies we have developed. We have sought to protect our proprietary position by in-licensing intellectual property and filing patent applications in the United States and abroad relating to our product discoveries, RED PLATFORM and other technologies. Given that the development of our technology and product discoveries is at an early stage, our intellectual property portfolio with respect to certain aspects of our technology and product discoveries is also at an early stage.

With respect to our patent portfolio, as of January 31, 2023, most of the patent rights that we own or in-license are currently pending patent applications, except that we own 15 issued U.S. patents and we have five in-licensed U.S. patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from third parties.

We have filed patent applications directed to the composition of matter of our product discoveries and various processes of our RED PLATFORM; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product discoveries and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications.

Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. Although we have secured issued United States composition of matter patents related to our former product candidates RTX-240, RTX-321 and RTX-224, we cannot be certain that the claims in our pending patent applications covering the composition of matter of all of our product discoveries will be considered patentable by the United States Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions of matter relating to our product discoveries, RED PLATFORM and other technologies, and instead may need to rely on patent applications with claims covering a method of use and/or method of manufacture. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a third party from making and marketing a product that is identical to our invention for an indication that is outside the scope of the patented method. Moreover, even if third parties do not actively promote their products for our targeted indications, physicians may prescribe these products “off-label” for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.
17
There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our product discoveries and RED PLATFORM could have a material adverse effect on the value of our intellectual property portfolio and on our financial condition, results of operations, and prospects.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. There is no assurance that all potentially relevant prior art relating to our patents and patents applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents successfully issue, and even if such patents cover our inventions, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product discoveries, or prevent others from designing around our claims. Additionally, the patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. Any of these outcomes could have an adverse impact on the value of our intellectual property portfolio.

Our rights relating to our product discoveries and RED PLATFORM are subject, in part, to the terms and conditions of licenses granted to us by others.

We have relied upon licenses to certain patent rights and proprietary technology from third parties that have been important or necessary to the development of our product discoveries and RED PLATFORM. For example, under our license agreement with the Whitehead Institute for Biomedical Research, or WIBR, as amended (the "WIBR License"), WIBR grants us an exclusive, worldwide, sublicensable license under four patent families to research, develop, make, and commercialize products and processes covered by such patent rights for all uses. The portfolio of patent rights licensed to us under the WIBR License is directed, in part, to the in vitro production of red blood cells, including the use of the enzyme sortase to conjugate a protein of interest to the cell surface. Patent rights that we in-license may be subject to a reservation of rights by one or more third parties. For example, our in-licensed patent rights from WIBR under the WIBR License were funded in part by the U.S. government. As a result, the U.S. government may have certain rights to such intellectual property. Furthermore, pursuant to a Defense Advanced Research Projects Agency Agreement between WIBR and a global biopharmaceutical company, the biopharmaceutical company funded research resulting in one of the patent families licensed to us under the WIBR License and retained a worldwide, irrevocable, non-exclusive, royalty-free right to use the inventions and technologies covered by this patent family for research and development purposes.

WIBR also retains the right with respect to all four patent families licensed to us to (i) to practice the patent rights licensed under the agreement for research, teaching and educational purposes, including sponsored research and collaboration, and (ii) to grant non-exclusive licenses to academic and not-for-profit research institutes to practice under the patent rights for research, teaching and educational purposes (excluding sponsored research), while Tufts University, or Tufts, which co-owns certain of our in-licensed patent rights with WIBR, retains such rights only with respect to the patent family that it co-owns.

Further, our licensors may co-own the patent rights we in-license with other third parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patent rights are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patent rights, who are not parties to our license agreements. For example, under the WIBR License, we license certain patents rights co-owned by WIBR and Tufts. Our rights to Tufts’ interest in such patent rights depends on an inter-institutional agreement between WIBR and Tufts, pursuant to which WIBR controls the licensing of such patent rights. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners’ interest in such patent rights or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, who could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patent rights in order to enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on the value of our intellectual property portfolio, and on our financial conditions, results of operations, and prospects.

In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution and maintenance, and we may not have the right to control the enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, under the WIBR License, WIBR controls prosecution of the patent rights licensed to us, and we control enforcement of the patent rights. We cannot be certain that our in-licensed patent applications (and any patents issuing therefrom) that are controlled by our licensors will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with our best interests. If our
18
licensors fail to prosecute, maintain, enforce, and defend such patents rights, or lose rights to those patent applications (or any patents issuing therefrom), the rights we have licensed may be reduced or eliminated, the right to exploit any of our product discoveries and RED PLATFORM technologies that are the subject of such licensed rights could be adversely affected, and it may not be possible to prevent third parties from making, using and selling competing inventions. Moreover, we cannot be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. Finally, subject to the terms of any such license agreements, the licensor may be able to terminate the license without our consent, as further described below.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose important license rights.

The WIBR License imposes various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. WIBR may terminate the WIBR License upon written notice to us if we, along with our affiliates and sublicensees, cease to carry on business related to the WIBR License for more than six months. WIBR may also terminate the WIBR License for our material breach that remains uncured for sixty days after receiving notice thereof, if we fail to pay amounts due under the agreement within thirty days after receiving notice of such failure, or if we challenge the validity or enforceability of any of the licensed patent rights. In spite of our efforts, WIBR or a future licensor might conclude that we have materially breached our obligations under such license agreements and seek to terminate the license agreements, thereby removing or limiting the ability to exploit the intellectual property covered by these license agreements. If these in-licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, third parties would have the freedom to seek regulatory approval of, and to market, products and technologies identical to our product discoveries and/or RED PLATFORM technologies. Any of the foregoing could have a material adverse effect on the value of our intellectual property portfolio and on our financial conditions, results of operations, and prospects.

Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:

•the scope of rights granted under the license agreement and other interpretation-related issues;

•the extent to which a licensee’s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

•the sublicensing of patent and other rights that are the subject of the licensing agreement;

•the licensee’s diligence obligations under the license agreement and what activities satisfy those diligence obligations;

•the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property;

•whether and the extent to which inventors are able to contest the assignment of their rights to the licensors; and

•the priority of invention of patented technology.

The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to exploit such
19
intellectual property, which could have a material adverse effect on our financial conditions, results of operations, and prospects.

If we are unable to protect the confidentiality of our trade secrets, the value of our intellectual property portfolio would be adversely affected.

In addition to seeking patents for our product discoveries, RED PLATFORM and other technologies, we have also relied on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.

We have sought to protect our know-how, trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements, and including in our vendor and service agreements terms protecting our confidential information, know-how and trade secrets, with parties who have access to such information. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We have also sought to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems.

Despite our efforts, any of the aforementioned parties may breach the agreements and disclose our proprietary information, including our trade secrets, or there may be a lapses or failures in our physical and electronic security systems which lead to our proprietary information being disclosed, and we may not be able to obtain adequate remedies in the event of any such breaches. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that has been licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a third party, we would have no right to prevent them from using that technology or information. If any of our trade secrets were to be disclosed to or independently developed by a third party, the value of our intellectual property portfolio would be materially and adversely affected.

Third-party claims of intellectual property infringement, misappropriation or other violation against us or our licensors may adversely affect our intellectual property portfolio.

The field of cellular therapeutics is competitive and dynamic. Due to the focused research and development that is taking place by several companies in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, there may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third-party, intellectual property and proprietary rights in the future.

The value of our intellectual property portfolio depends in part on our and our licensors’ ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have been implemented. This reform adds uncertainty to the possibility of challenge to our patents in the future.

Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist relating to red blood cell technologies and therapeutic proteins, and in the fields in which we have developed our pipeline products. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product discoveries, RED PLATFORM technologies and other technologies may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product discoveries, RED PLATFORM technologies and other technologies that we have developed will not infringe patents owned by third parties. We may not be aware of patents that have already been issued and that a third party might assert are infringed by our product discoveries, RED PLATFORM or other
20
technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product discoveries, RED PLATFORM or other technologies.

It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product discoveries, RED PLATFORM or other technologies, could be found to be infringed by our product discoveries, RED PLATFORM or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product discoveries, RED PLATFORM or other technologies may infringe. We cannot provide any assurances that third-party patents do not exist which might be enforced against our technology, including our RED PLATFORM technologies, manufacturing methods, product discoveries.

Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our product discoveries, RED PLATFORM or other technologies infringes upon these patents. We are aware of an issued patent outside the United States that is directed to erythrocytes that comprise exogeneous polypeptides. While we believe that we have reasonable defenses against a claim of infringement should such a claim be brought, including that certain claims in this patent are invalid, there can be no assurance that we will prevail in any such action by the holder of the patent. In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our product discoveries, RED PLATFORM or other technologies. In this case, the holders of such patents may be able to block the ability to exploit the applicable intellectual property unless a license under the applicable patents is obtained, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all.

Defense of infringement claims, regardless of their merit, would involve substantial litigation expense. In addition, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement.
Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive and time-consuming.

We or our licensors may also be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patent rights, trade secrets, or other intellectual property as an inventor or co-inventor. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our intellectual property portfolio. Even if we are successful in defending against such claims, litigation could result in substantial costs.

The occurrence of any of the foregoing could have a material adverse effect on the value of our intellectual property portfolio and on our financial condition, results of operations and prospects.

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.

Third parties may infringe our patents or the patents of our licensing partners and, if litigated in an infringement proceeding, a court may decide that a patent owned or in-licensed by us is invalid or unenforceable or that the other party’s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. §271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for operations. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.

21
Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations. For example:

•others may be able to make products that are similar to our product discoveries or utilize similar technology but that are not covered by the claims of the patents that we license or own;

•we or our licensors might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own;

•we or our licensors, might not have been the first to file patent applications covering certain of our or their inventions;

•others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;

•it is possible that our pending owned or licensed patent applications will not lead to issued patents;

•coverage claimed in a patent application can be significantly reduced before the patent is issued resulting in an issued patent that fails to provide any meaningful protection, or a patent’s scope can be reinterpreted after issuance;

•issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by third parties, which could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product discoveries, RED PLATFORM technologies, or other technologies;

•changes in U.S. and international patent law could impair our ability to protect our intellectual property;

•laws of foreign countries may not protect our rights to the same extent as the laws of the United States;

•we may have failed to identify patentable aspects of our research and development output in time to obtain patent protection;

•although we have entered into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection;

•third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competing inventions;

•the patents of others may harm our business (for example, third parties may have blocking patents that could be used to prevent the exploitation of our proprietary inventions); and

•we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on the value of our intellectual property portfolio and on our financial condition, results of operations and prospects.

Risks related to our common stock

The price of our stock has been and may continue to be volatile, and our stockholders could lose all or part of their investment.
22

The trading price of our common stock has been highly volatile and could continue to be subject to large fluctuations in response to the risk factors discussed in this section and elsewhere in this Annual Report on Form 10-K, and other risk factors beyond our control, including:

•the recent announcement that our Board of Directors unanimously approved the dissolution and liquidation of the Company, subject to stockholder approval;

•actual or anticipated variations in quarterly operating results;

•our cash position;

•our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

•publication of research reports about us or our industry, or cellular therapies in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•changes in the market valuations of similar companies;

•overall performance of the equity markets;

•sales of our common stock by us or our stockholders in the future;

•trading volume of our common stock;

•adoption of new accounting standards;

•ineffectiveness of our internal controls;

•disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•significant lawsuits, including patent or stockholder litigation; and

•general political and economic conditions.

In recent years, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Since our common stock began trading on The Nasdaq Global Select Market on July 18, 2018, our stock price has traded at prices as low as $0.14 per share and as high as $38.71 per share through January 31, 2023.

Additionally, technical factors in the public trading market for our stock may produce price movements that may or may not comport with macro, industry or company-specific fundamentals, including, without limitation, the sentiment of retail investors (including as may be expressed on financial trading and other social media sites), speculation in the press, in the investment community, or on the internet, including on online forums and social media, about us, our industry or our securities, the amount and status of short interest in our securities (including a “short squeeze”), access to margin debt, trading in options and other derivatives on our common stock and other technical trading factors. We may incur rapid and substantial decreases in our stock price in the foreseeable future that are unrelated to our operating performance or prospects. There can be no guarantee that our stock price will remain at current prices or that future sales of our common stock will not be at prices lower than the sales price in previous offerings. If the market price of our common stock does not exceed their purchase price, our stockholders may not realize any return on their investment in us and may lose some or all of their investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs, which would harm our business, operating results or financial condition.
23

If we fail to maintain the listing of our common stock with a United States national securities exchange, the liquidity of our common stock could be adversely affected.

As previously disclosed, on July 27, 2022, we received written notice from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, indicating that, based upon the closing bid price for our common stock for the previous 30 consecutive business days, we no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (which we refer to as the "Minimum Bid Price Requirement"). In accordance with the Nasdaq Listing Rules, we were afforded a 180-calendar day grace period, through January 23, 2023, to regain compliance with the Minimum Bid Price Requirement.

On February 6, 2023, we were notified by the Staff that, based upon our non-compliance with the Minimum Bid Price Requirement as of January 23, 2023, and the Staff’s determination that we are a “public shell” as that term is defined in Nasdaq Listing Rule 5101, we would be delisted at the opening of business on February 15, 2023 unless we were to timely request a hearing before a Nasdaq Hearings Panel, or the Panel, to address the deficiencies and present a plan to regain compliance.

On February 13, 2023, we timely requested a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel, unless we determine to withdraw our hearing request in connection with the Dissolution. Unless we determine to withdraw our hearing request, our common stock will remain listed and eligible for trading on Nasdaq pending the ultimate conclusion of the hearing process. However, there can be no assurance that we will successfully appeal the delisting determination, or that, if successful, we will be able to maintain compliance with any of the other Nasdaq continued listing requirements. Further, in connection with our planned Dissolution, we may determine not to move forward with the hearing.

If our common stock is ultimately delisted by Nasdaq, our common stock may be eligible to trade on the OTC Bulletin Board or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We currently anticipate that we will retain future earnings for the operation of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited in the foreseeable future to the appreciation of their stock.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors and their affiliates beneficially hold, in the aggregate, over 43% of our outstanding voting stock. These stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest as one of our stockholders.

We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.

As a public company, even with our reduced operations, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive
24
compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as “say on pay” and proxy access.

As of December 31, 2021, we ceased to be eligible for the emerging growth company provisions of the Jumpstart Our Business Startups Act, or the JOBS Act, as of such date and are no longer able to avail ourselves of exemptions from various reporting requirements applicable to non-emerging growth companies. Accordingly, we will no longer have the option to delay the adoption of new or revised accounting standards until such time as those standards apply to private companies. As a result, we may incur additional expenses or challenges relating to our loss of emerging growth company status. Further, stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

The rules and regulations applicable to public companies substantially increase our legal and financial compliance costs and make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock is influenced by research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

We have broad discretion in the use of our existing cash, cash equivalents and investments and may not use them effectively.

Our management has broad discretion in the application of our cash, cash equivalents and investments, including as we wind down our operations in connection with our planned Dissolution. Because of the number and variability of factors that will determine our use of our cash, cash equivalents and investments, their ultimate use may vary substantially from their currently intended use. Our management might not apply our cash, cash equivalents and investments in ways that ultimately increase the value of our stockholders’ investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest our cash in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not use our resources in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.

Risks related to corporate governance

Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:

•a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;

25
•a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;

•a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;

•advance notice requirements for stockholder proposals and nominations for election to our board of directors;

•a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;

•a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and

•the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for our stockholders and other stockholders to elect directors of their choosing or cause us to take other corporate actions they desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.

Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.

Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claim for (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim against us governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts is the sole and exclusive forum (1) for resolving any complaint asserting a cause of action arising under the Securities Act or the rules and regulations promulgated thereunder, and (2) of all suits in equity and actions at law brought to enforce any liability or duty created by the Securities Act or the rules and regulations thereunder, or the Federal Forum Provision, as our principal executive offices are located in Cambridge, Massachusetts. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.

We recognize that the Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our amended and restated by-laws may limit our stockholders’ ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and
26
employees even though an action, if successful, might benefit our stockholders. While the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are “facially valid” under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. The Federal Forum Provision may also impose additional litigation costs on us and/or our stockholders who assert that the provision is invalid or unenforceable, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

Item 1B. Unresolved Staff Comments
None.

Item 2. Properties
Until January 31, 2023, our corporate headquarters were located in approximately 85,000 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts. As described further under the section captioned “Business—Termination of Lease Agreement” above, on December 12, 2022, we entered into a Lease Termination Agreement with our landlord, ARE, pursuant to which our lease for this facility terminated on January 31, 2023.

We formerly owned a 135,000 square foot manufacturing facility located in Smithfield, Rhode Island. On December 6, 2022, we entered into a Purchase and Sale Agreement with DIV Acquisition V, LLC, for the sale of this facility and certain related fixtures and personal property, for an aggregate purchase price of $18,500,000, subject to adjustment.
The transaction closed on December 21, 2022.

Item 3. Legal Proceedings
We are not currently a party to any material legal proceedings.

Item 4. Mine Safety Disclosures
Not applicable.
27
PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Certain Information Regarding the Trading of Our Common Stock

Our common stock trades under the symbol “RUBY” on the Nasdaq Global Select Market and has been publicly traded since July 18, 2018. Prior to this time, there was no public market for our common stock.

Holders of Our Common Stock

As of January 31, 2023, there were approximately 13 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in “nominee” or “street” name.

Dividends

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

Stock Performance Graph

The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.

The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq Biotechnology Index from July 18, 2018 (the first date that shares of our common stock were publicly traded) through December 31, 2022. The comparison assumes $100 was invested in our common stock and in each of the foregoing indices after the market closed on July 18, 2018, and it assumes reinvestment of dividends, if any. The stock price performance included in this graph is not necessarily indicative of future stock price performance.
ruby-20221231_g1.jpg
Securities Authorized for Issuance Under Equity Compensation Plans

Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.

28
Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Equity Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K.

Item 6. Reserved

29
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Objective
The purpose of the following discussion and analysis is to provide material information relevant to an assessment of our financial condition and results of operations from management’s perspective, including to describe and explain key trends, events and other factors that impacted our reported results and that are reasonably likely to impact our future performance.

As previously announced, on February 20, 2023, following the conclusion of our review of strategic alternatives, our Board of Directors unanimously approved the dissolution and liquidation of Rubius, or the Dissolution, pursuant to a plan of complete liquidation and dissolution, or the Plan of Dissolution, which plan is subject to stockholder approval. As such, the following discussion and analysis of our business, financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, and should also take into account our recent announcement regarding our planned Dissolution. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans, operations, intellectual property and other matters related to our business, includes forward-looking statements that involve risks and uncertainties, including risks associated with our planned Dissolution. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

Overview
We are a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines called Red Cell Therapeutics, or RCTs, for the treatment of cancer and autoimmune diseases.

On November 2, 2022, we announced that, in light of our financial condition and the early stage of our programs, our Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of our assets, and to significantly and immediately reduce our operations, which we refer to as the “strategic plan.” In connection with the strategic plan, we terminated 42 of our employees (representing 82% of our then-current employee base), leaving a core team of individuals to lead the strategic review process. On February 20, 2023, following the conclusion of our review of strategic alternatives, our Board unanimously approved the dissolution and liquidation of the Company pursuant to a Plan of Dissolution, which plan is subject to stockholder approval.

The Company cautions that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual value realized, if any, by holders of the Company’s securities. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Nasdaq Delisting Notification

As previously disclosed, on July 27, 2022, we received a deficiency letter from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (which we refer to as the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we were provided a period of 180 calendar days, or until January 23, 2023 (which we refer to as the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.
On February 6, 2023, we were notified by the Staff that, based upon our non-compliance with the Minimum Bid Price Requirement as of January 23, 2023, and the Staff’s determination that we are a “public shell” as that term is defined in Nasdaq Listing Rule 5101, we would be delisted at the opening of business on February 15, 2023 unless we were to timely request a hearing before a Nasdaq Hearings Panel, or the Panel, to address the deficiencies and present a plan to regain compliance.
On February 13, 2023, we timely requested a hearing before the Panel, which request will stay any further delisting action by the Staff at pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel, unless we determine to withdraw our hearing request in connection with the Dissolution. Unless we determine to withdraw our hearing request, our common stock will remain listed and eligible for trading on Nasdaq pending the ultimate conclusion of the hearing process.

30
However, there can be no assurance that we will successfully appeal the delisting determination, or that, if successful, we will be able to maintain compliance with any of the other Nasdaq continued listing requirements. Further, in connection with our planned Dissolution, we may determine not to move forward with the hearing.

Components of Our Results of Operations
Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products given our significant reduction in operations and focus on review of strategic alternatives.
Operating Expenses
Research and Development Expenses
Research and development expenses consist of costs incurred for our research activities conducted during the periods presented, including our drug discovery efforts, and the development and manufacturing of our since-discontinued product candidates during such time, which include:
•employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research and development functions;
•expenses incurred in connection with the preclinical and clinical development of such product candidates and the wind-down of our research and clinical programs, including under agreements with third parties, such as consultants, contractors and contract research organizations, or CROs;
•the cost of developing and scaling our manufacturing process and the manufacturing of product candidates for use in our preclinical studies and clinical trials, including those produced in our manufacturing facility as well as components produced under agreements with third parties, such as consultants, contractors and contract manufacturing organizations, or CMOs;
•laboratory supplies and research materials;
•facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; and
•payments made under third-party licensing agreements.
We expense research and development costs as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.
Our direct research, manufacturing and development expenses are tracked on a program-by-program basis. These consist mostly of fees, reimbursed materials, testing and other costs paid to consultants, contractors, CMOs and CROs, as well as the cost of materials incurred for internal manufacturing. In addition, we allocate the cost of operating our manufacturing facility to research and development program costs, consisting of associated personnel costs, other than stock-based compensation expense, and manufacturing facility costs, including depreciation. We do not allocate costs associated with our platform development, early-stage research and shared research and development, including associated personnel costs, laboratory supplies, non-manufacturing facilities expenses and other indirect costs, to research and development programs, because these costs are deployed across multiple programs and our technology platform and, as such, are not separately classified.
Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, due to the increased size and duration of later-stage clinical trials.
General and Administrative Expenses
General and administrative expenses include salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs, as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.
31
Restructuring and Impairment Charges
During the year ended December 31, 2022, we undertook certain operational and organizational steps in connection with a strategic reorganization plan and related cost-saving measures that we initiated in the third quarter of 2022. These measures included discontinuing the ongoing clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and reducing our overall workforce. We also initiated a plan to review strategic alternatives in the fourth quarter of 2022 in which we significantly and immediately reduced our operations, which included terminating all of our remaining employees except for a core team of individuals retained to lead the strategic review process.
Other Income (Expense)
Interest Income
Interest income consists of interest earned on our invested cash balances.

Interest Expense
Interest expense consists of interest owed on outstanding borrowings under our Loan Agreement (as defined below), as well as amortization of debt discount.
Other Income, Net
Other income, net consists of miscellaneous income and expense unrelated to our core operations.

Income Taxes
Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our research and development tax credits generated, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss, or NOL, carryforwards and tax credits will not be realized. As of December 31, 2022, we had U.S. federal and state net operating loss carryforwards of $584.8 million and $583.6 million, respectively, which may be available to offset future taxable income. The federal NOLs include $37.2 million, which expire at various dates through 2037, and $547.6 million, which carryforward indefinitely. The state NOLs expire at various dates through 2041. As of December 31, 2022, we also had U.S. federal and state research and development tax credit carryforwards of $29.5 million and $19.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2026, respectively. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date.

32
Results of Operations
Comparison of the Years Ended December 31, 2022 and 2021
The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:
Year Ended December 31,
20222021Change
(in thousands)
Revenue$— $— $— 
Operating expenses:
Research and development96,414 141,587 (45,173)
General and administrative30,835 53,029 (22,194)
Restructuring and impairment charges51,197 — 51,197 
Total operating expenses178,446 194,616 (16,170)
Loss from operations(178,446)(194,616)16,170 
Other income (expense):
Interest income819 91 728 
Interest expense(3,863)(6,434)2,571 
Other income, net1,824 4,412 (2,588)
Total other income (expense), net(1,220)(1,931)711 
Net loss$(179,666)$(196,547)$16,881 

Research and Development Expenses

Twelve Months Ended December 31,
20222021Change
(in thousands)
Research and development program expenses:
Rare disease$—$284$(284)
Cancer50,13874,080(23,942)
Platform development, early-stage research and unallocated expenses:
Personnel-related19,44527,827(8,382)
Stock-based compensation expense6,86312,338(5,475)
Contract research and development3,8397,115(3,276)
Laboratory supplies and research materials4,7425,186(444)
Facility-related and other11,38714,757(3,370)
Total research and development expenses$96,414$141,587$(45,173)

Research and development expenses were $96.4 million for the year ended December 31, 2022, compared to $141.6 million for the year ended December 31, 2021. The decrease in research and development program expenses of $45.2 million related to the deprioritization of RTX-321 in May 2022 and RTX-240 AML and monotherapy studies in September 2022. This decrease was partially offset by an increase in clinical costs related to RTX-224 that were incurred prior to the discontinuation of the ongoing clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors. We do not expect to incur these costs in future periods as our research and development has stopped and all remaining costs have been accrued as of December 31, 2022. Platform development, early-stage research and unallocated expenses decreased by $20.9 million principally due to decreases of $8.4 million in personnel-related expenses resulting from our headcount reductions and $5.5 million in stock-based compensation expense resulting from expense reversals on forfeited equity awards in the third and fourth quarters of 2022. In addition, contract research and development decreased $3.3 million and laboratory supplies and research materials decreased $0.4 million as drug discovery activities and platform development
33
were discontinued in the current year. The reduction in facility-related and other expenses of $3.4 million was primarily due to the termination of our lease for office and laboratory facilities in Cambridge, Massachusetts.
General and Administrative Expenses
Twelve Months Ended December 31,
20222021Change
(in thousands)
Personnel-related$8,220$13,895$(5,675)
Stock-based compensation expense8,92023,272(14,352)
Professional and consultant fees8,4919,278(787)
Facility-related and other5,2046,584(1,380)
Total general and administrative expenses$30,835$53,029$(22,194)

General and administrative expenses for the year ended December 31, 2022 were $30.8 million, compared to $53.0 million for the year ended December 31, 2021. The decrease in general and administrative expenses of $22.2 million was primarily due to a decrease in stock-based compensation expense of $14.4 million, which was driven by expense reversals on forfeited equity awards in the third and fourth quarters of 2022, as well as a reduction in the market price of our common stock, resulting in a lower valuation of stock options granted in 2022. Additionally, personnel-related expenses decreased by $5.7 million driven by headcount reductions in general and administrative functions during 2022, facility-related and other expenses decreased $1.4 million primarily due to the termination of our lease for office and laboratory facilities in Cambridge, Massachusetts, and professional and consultant fees decreased $0.8 million due to the reduction in operations in the fourth quarter of 2022.
Restructuring and Impairment Charges
Twelve Months Ended December 31,
20222021Change
(in thousands)
Employee termination benefits$12,929 $— $12,929
Impairment of property, plant and equipment25,841 — 25,841
Contract termination costs12,427 — 12,427
Total restructuring and impairment charges$51,197$—$51,197
During the year ended December 31, 2022, we recorded charges of $12.9 million, $25.8 million and $12.4 million related to employee termination benefits, impairment of property, plant and equipment and contract termination costs, respectively, due to the reorganization plan we initiated in the third quarter of 2022 and the plan to review strategic alternatives initiated in the fourth quarter of 2022. We paid or otherwise settled $22.6 million of employee termination benefits and contract termination costs during the year ended December 31, 2022 and expect to pay or otherwise settle approximately $26.0 million in total to implement the two plans.
Interest Income
Interest income was $0.8 million for the year ended December 31, 2022, compared to $0.1 million for the year ended December 31, 2021. Interest income increased due to higher prevailing interest rates.
Interest Expense
Interest expense was $3.9 million for the year ended December 31, 2022, compared to $6.4 million for the year ended December 31, 2021. The decrease in interest expense was principally due to a gain of $1.1 million on the extinguishment of our Loan Agreement (as defined below).
Other Income, Net
34
Other income, net was $1.8 million for the year ended December 31, 2022, compared to $4.4 million for the year ended December 31, 2021. The decrease in other income, net was due to greater monetization of certain tax credits during the prior period.

Liquidity and Capital Resources
Since our inception, we have incurred significant operating losses. We have not commercialized any product candidates and we do not expect to generate revenue from sales of any products given our significant reduction in operations and focus on review of strategic alternatives. To date, we have funded our operations with proceeds from the sale of preferred stock, with borrowings under our recently terminated Loan Agreement, with proceeds from our IPO and with proceeds from our March 2021 Offering, described and defined further below. In July 2018, we completed our IPO, pursuant to which we issued and sold 12,055,450 shares of common stock, inclusive of 1,572,450 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares. We received proceeds of $254.3 million, after deducting underwriting discounts and commissions and other offering costs. In December 2018, we entered into a Loan and Security Agreement with SLR Investment Corp. (f/k/a Solar Capital Ltd.) (the "Loan Agreement"), which was amended in June 2021, and which provided for aggregate borrowings of up to $75.0 million. In March 2021, we completed the March 2021 Offering, pursuant to which we issued and sold 6,896,552 shares of common stock. We received proceeds of $187.2 million, after deducting underwriting discounts and commissions and other offering costs. In October 2022, pursuant to a payoff letter, we voluntarily prepaid approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under the Loan Agreement, considerably depleting our cash resources.

As of December 31, 2022, we had cash and cash equivalents of $14.9 million and as of January 31, 2023, we had cash and cash equivalents of $11.7 million, which includes the proceeds from the sale of our Rhode Island facility for an aggregate purchase price of $18.5 million. As noted elsewhere in this report, there is substantial doubt as to our ability to fund our planned operations for the next twelve months and to continue to operate as a going concern. Further, we have recently announced that our Board unanimously approved the dissolution and liquidation of the Company pursuant to a Plan of Dissolution, which plan is subject to stockholder approval.

Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
Year Ended December 31,
202220212020
(in thousands)
Cash used in operating activities$(150,142)$(145,122)$(127,648)
Cash provided by investing activities12,94481,351100,432 
Cash provided by (used in) financing activities(75,470)198,45326,484
Net increase (decrease) in cash, cash equivalents and restricted cash$(212,668)$134,682$(732)
Operating Activities
During the year ended December 31, 2022, operating activities used $150.1 million of cash, primarily resulting from our net loss of $179.7 million, offset by net non-cash charges of $47.0 million, predominantly consisting of impairment charges and stock-based compensation expense. Net cash used in our operating assets and liabilities for the year ended December 31, 2022 consisted of a net decrease in accounts payable, accrued expenses and other current liabilities, other long-term liabilities and operating lease liabilities of $27.3 million, offset by a $9.7 million increase in prepaid expenses and other current assets, operating lease, and right-of-use assets.
During the year ended December 31, 2021, operating activities used $145.1 million of cash, primarily resulting from our net loss of $196.5 million, partially offset by net non-cash charges of $44.7 million, predominantly consisting of stock-based compensation expense. Net cash used in our operating assets and liabilities for the twelve months ended December 31, 2021 consisted of a $0.1 million decrease in accounts payable, accrued expenses and other current liabilities, other long-term liabilities and operating lease liabilities, offset by a decrease in prepaid expenses and other current assets, other assets and operating lease, right-of-use asset of $6.6 million.
During the year ended December 31, 2020, operating activities used $127.6 million of cash, primarily resulting from our net loss of $167.7 million, partially offset by net non-cash charges of $40.0 million, predominantly consisting of stock-
35
based compensation expense. Net cash used in our operating assets and liabilities for the twelve months ended December 31, 2020 consisted of a $6.5 million decrease in accounts payable, accrued expenses and other current liabilities, other long-term liabilities and operating lease liabilities, offset by a decrease in prepaid expenses and other current assets, other assets and operating lease, right-of-use asset of $6.6 million.
Changes in accounts payable, accrued expenses and other current liabilities and prepaid expenses and other current assets in all periods presented were generally due to growth in our business, the advancement of our research programs and the timing of vendor invoicing and payments.
Investing Activities
During the year ended December 31, 2022, net cash provided by investing activities was $12.9 million, consisting of sales and maturities of investments of $83.9 million and sales of property, plant and equipment of $17.9 million, offset by purchases of investments of $83.6 million and purchases of property, plant and equipment of $5.3 million. Our property, plant and equipment sales primarily relate to the sale of our manufacturing facility in Smithfield, Rhode Island.
During the year ended December 31, 2021, net cash provided by investing activities was $81.4 million, consisting of sales and maturities of investments of $85.0 million, offset by purchases of property, plant and equipment of $3.6 million. Our cash purchases of property, plant and equipment primarily relate to the purchase of computer and laboratory equipment installed in our manufacturing facility in Smithfield, Rhode Island and our laboratory space in Cambridge, Massachusetts.

During the year ended December 31, 2020, net cash provided by investing activities was $100.4 million, consisting of sales and maturities of investments of $228.6 million, offset by net purchases of investments of $122.7 million and purchases of property, plant and equipment of $5.5 million. Our cash purchases of property, plant and equipment consisted of $2.9 million for purchases related to our manufacturing facility in Smithfield, Rhode Island, largely driven by payments for manufacturing equipment purchases and construction costs incurred in 2019, and $2.6 million for the purchase of computer and laboratory equipment installed in our manufacturing facility and our laboratory space in Cambridge, Massachusetts.

Financing Activities

During the year ended December 31, 2022, net cash used in financing activities of $75.5 million consisted of the repayment of our long-term debt under the Loan Agreement.
During the year ended December 31, 2021, net cash provided by financing activities of $198.5 million consisted primarily of proceeds of $187.2 million, after deducting underwriting discounts and commissions and other offering costs, from the March 2021 Offering, as well as proceeds received from issuance of common stock upon exercise of stock options and under the employee stock purchase plan of $11.0 million. Net cash used in financing activities includes $0.4 million of offering cost payments in connection with the March 2021 Offering and $0.2 million of debt issuance cost payments related to our Loan Agreement in June 2021.
During the year ended December 31, 2020, net cash provided by financing activities of $26.5 million consisted of $25.0 million proceeds received from borrowings under our Loan Agreement and $1.5 million proceeds received from issuance of common stock upon exercise of stock options.
Contractual Obligations and Commitments
The following table summarizes our contractual obligations as of December 31, 2022 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:

Payments Due by Period
TotalLess Than 1 Year1 to 3 Years4 to 5 YearsMore Than 5 Years
(in thousands)
Operating lease commitments (1)$1,100$1,100$—$—$—
Total$1,100$1,100$—$—$—
(1)Amounts in table reflect payments due for our leases of office and laboratory space in Cambridge, Massachusetts under an operating lease agreement terminated in December 2022 with an effective date in January 2023.
36
As of December 31, 2022, we were party to contracts in the normal course of business with third parties for various services. These contracts generally do not contain minimum purchase commitments and are cancelable by us upon prior written notice; many such contracts have been cancelled since December 31, 2022. Payments due upon cancellation typically consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the table above.
We have also entered into a license agreement with the Whitehead Institute for Biomedical Research, or WIBR, as amended, under which we have been granted an exclusive, sublicensable, nontransferable license under certain patent families related to the development of our RCTs, or the WIBR License. Under the terms of the WIBR License, we are obligated to pay to WIBR low single-digit royalties based on any annual net sales by us, our affiliates and our sublicensees of licensed products and licensed services that are covered by a valid claim of the licensed patent rights at the time and in the country of sale. The terms of the agreement require us to make aggregate milestone payments of up to $1.6 million upon the achievement of specified preclinical, clinical and regulatory milestones. In addition, the license requires us to pay to WIBR a percentage of the non-royalty payments that we receive from sublicensees of the patent rights licensed by WIBR. This percentage varies from low single-digit to low double-digit percentages and is based upon the clinical stage of the product that is the subject of the sublicense. The WIBR License provides that royalties shall be paid by us on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country.
We have the right to terminate the WIBR License in its entirety, on a patent-by-patent or country-by-country basis, at will upon three months’ notice to WIBR. WIBR may terminate the agreement upon breach of contract or in the event of bankruptcy, liquidation, insolvency or cessation of business related to the license. For additional information, see “Business—Licenses.”
Loan and Security Agreements
In December 2018, or the Closing Date, we entered into a Loan and Security Agreement with SLR Investment Corp., or SLR (formerly Solar Capital Ltd.), as collateral agent for the lenders party thereto for an aggregate principal amount of $75.0 million. The aggregate principal amount was funded in three tranches of term loans of $25.0 million each, on the Closing Date, in June 2019, and in June 2020. On October 13, 2022, we entered into a payoff letter with SLR, under which we voluntarily prepaid SLR approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under the Loan Agreement. The payoff letter also provided for the termination of all commitments and obligations under the Loan Agreement and release of all liens held by SLR on our assets.

Common Stock Sales Agreement

On August 1, 2019, we entered into a Distribution Agreement, or the Distribution Agreement, with multiple sales agents, pursuant to which the Company was entitled to offer and sell to or through the agents, from time to time, shares of the Company's common stock, par value $0.001 per share, having an aggregate gross sales price of up to $100.0 million. No shares of the Company's common stock were sold under the Distribution Agreement, which expired in accordance with its terms on August 21, 2022, and the applicable registration statement is no longer effective.

Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Significant Judgments and Estimates
Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
37
While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.
Accrued Research and Development Expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:
•vendors in connection with preclinical and assay development activities;
•CMOs in connection with raw material acquisition; and
•CROs in connection with clinical trials.
We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply materials and conduct services. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.
Stock-based Compensation
We measure stock-based awards with service-based and performance-based vesting conditions granted to employees, directors and non-employees based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of our common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. We use the straight-line method to record the expense of awards with service-based vesting conditions. We use the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing when achievement of the performance condition becomes probable.
The Black-Scholes option-pricing model uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our common stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options, and our expected dividend yield.
We measure the fair value of stock-based awards with market-based vesting conditions on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, we recognize stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, we recognize stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. We begin recording stock-based compensation expense for this type of award when the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.


38
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows are disclosed in Note 2 to our consolidated financial statements.

Item 7A. Quantitative and Qualitative Disclosure about Market Risk
As of December 31, 2022, we had cash and cash equivalents of $14.9 million, which consisted of cash, money market accounts and U.S. government money market funds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio.
We are not currently exposed to significant market risk related to changes in foreign currency exchange rates.
Inflation generally affects us by increasing our cost of labor and materials. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December 31, 2022.

39
Item 8. Consolidated Financial Statements and Supplementary Data
RUBIUS THERAPEUTICS, INC.
Index to Consolidated Financial Statements



40
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Rubius Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Rubius Therapeutics, Inc. and its subsidiary (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, of stockholders’ equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses from operations and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Restructuring and Impairment Charges
As described in Notes 1 and 13 to the consolidated financial statements, the Company’s Board of Directors approved a strategic reorganization plan on September 13, 2022 to discontinue the RTX-240 and RTX-224 clinical trials and reduce the Company’s overall workforce (the “Reorganization Plan”). On November 2, 2022, the Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of the Company’s assets and to significantly and immediately reduce its operations and workforce except for a core team of individuals to
41
lead the strategic review process (the “Strategic Plan”). The Reorganization Plan and the Strategic Plan required management to evaluate matters related to involuntary termination benefits provided pursuant to a one-time benefit arrangement, contract termination costs, and the impairment of long-lived assets in accordance with generally accepted accounting principles. The recognition of the Company’s liability for one-time termination benefits is based on contractual agreements and whether employees are required to render service until they are terminated in order to receive the termination benefits and, if so, whether the employee will be retained to render service beyond a minimum retention period. The Company’s contract termination costs represent costs to terminate a contract before the end of its term or costs that will continue to be incurred under a contract for its remaining term without economic benefit to the Company and is recognized at fair value when the contract is terminated or the Company ceases using the right conveyed by the contract. The impairment of long-lived assets is based on the fair value of the Company’s long-lived asset group as determined by actual sale transactions. Management recorded restructuring and impairment charges of $51.2 million for the year ended December 31, 2022.

The principal considerations for our determination that performing procedures relating to the Company’s restructuring and impairment charges is a critical audit matter are a high degree of auditor effort in performing procedures and evaluating audit evidence related to management’s recognition of restructuring and impairment charges related to (i) liabilities for one-time termination benefits and contract termination costs; and (ii) long-lived asset impairment.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing contractual agreements related to the liabilities for one-time termination benefits and contract termination costs, (ii) evaluating management’s accounting conclusions, (iii) evaluating, on a sample basis, the recognition of the restructuring and impairment charges for one-time termination benefits, contract termination costs and long-lived asset impairment, and (iv) evaluating actual sale transactions occurring before or after the measurement date related to the Company’s long-lived asset group.

/s/PricewaterhouseCoopers LLP
Boston, Massachusetts
February 27, 2023

We have served as the Company’s auditor since 2016.

42
RUBIUS THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)

December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$14,865 $225,848 
Assets held for sale4,070 — 
Prepaid expenses and other current assets1,260 3,975 
Total current assets20,195 229,823 
Operating lease, right-of-use-asset2,679 35,095 
Property, plant and equipment, net146 51,530 
Restricted cash50 1,573 
Total assets$23,070 $318,021 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,232 $11,572 
Accrued expenses and other current liabilities5,607 14,072 
Operating lease liabilities1,100 9,015 
Total current liabilities7,939 34,659 
Long-term debt, net of discount— 76,154 
Other long-term liabilities— 135 
Operating lease liabilities, net of current portion— 28,291 
Total liabilities7,939 139,239 
Commitments and contingencies (see Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued or outstanding at December 31, 2022 and December 31, 2021
— — 
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,387,732 and 90,063,770 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively
90 90 
Additional paid-in capital871,725 855,710 
Accumulated deficit(856,684)(677,018)
Total stockholders' equity15,131 178,782 
Total liabilities and stockholders' equity $23,070 $318,021 
The accompanying notes are an integral part of these consolidated financial statements.
43
RUBIUS THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
Year Ended December 31,
202220212020
Revenue$— $— $— 
Operating expenses:
Research and development96,414 141,587 116,107 
General and administrative30,835 53,029 50,341 
Restructuring and impairment charges51,197 — — 
Total operating expenses178,446 194,616 166,448 
Loss from operations(178,446)(194,616)(166,448)
Other income (expense):   
Interest income819 91 1,760 
Interest expense(3,863)(6,434)(4,185)
Other income, net1,824 4,412 1,142 
Total other income (expense), net(1,220)(1,931)(1,283)
Net loss(179,666)(196,547)(167,731)
Net loss per share, basic and diluted$(1.99)$(2.23)$(2.08)
Weighted average common shares outstanding, basic and diluted90,305,46387,950,44080,624,608
   
Comprehensive loss:   
Net loss$(179,666)$(196,547)$(167,731)
Other comprehensive income (loss):
Unrealized losses on investments, net of tax of $0
— (4)(71)
Comprehensive loss$(179,666)$(196,551)$(167,802)

The accompanying notes are an integral part of these consolidated financial statements.


44
RUBIUS THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
Common stockAdditional paid-in capitalAccumulated other comprehensive income (loss)Accumulated deficitTotal stockholders' equity
SharesAmount
Balances at December 31, 201980,016,245$80 $586,798 $75 $(312,740)$274,213 
Issuance of common stock
 upon exercise of stock options
1,037,4061 1,483 — — 1,484 
Stock-based compensation expense
—— 33,665 — — 33,665 
Unrealized losses on investments
—— — (71)— (71)
Net loss—— — — (167,731)(167,731)
Balances at December 31, 202081,053,651$81 $621,946 $4 $(480,471)$141,560 
Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs of $800
6,896,5527 187,193 — — 187,200 
Issuance of common stock
 upon exercise of stock options
1,933,5232 10,683 — — 10,685 
Issuance of common stock under
 employee stock purchase plan
26,444— 278 — — 278 
Vesting of restricted stock units153,600— — — — — 
Stock-based compensation expense
—— 35,610 — — 35,610 
Unrealized losses on investments
—— — (4)— (4)
Net loss—— — — (196,547)(196,547)
Balances at December 31, 202190,063,770$90 $855,710 $— $(677,018)$178,782 
Issuance of common stock
 upon exercise of stock options
42,228— 98 — — 98 
Issuance of common stock under
 employee stock purchase plan		143,906— 134 — — 134 
Vesting of restricted stock units137,828— — — — — 
Stock-based compensation expense
—— 15,783 — — 15,783 
Net loss—— — — (179,666)(179,666)
Balances at December 31, 202290,387,732$90 $871,725 $— $(856,684)$15,131 

The accompanying notes are an integral part of these consolidated financial statements.
45
RUBIUS THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

Year ended December 31,
202220212020
Cash flows from operating activities:
Net loss$(179,666)$(196,547)$(167,731)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense15,783 35,610 33,665 
Depreciation and amortization expense6,254 7,723 5,691 
Amortization (accretion) of premium (discount) on investments(305)118 266 
Non-cash interest expense604 1,280 349 
Impairment charges25,841 — — 
Gain on debt extinguishment(1,128)— — 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets2,738 1,249 992 
Operating lease, right-of-use-asset7,002 5,352 5,539 
Other assets— 5 46 
Accounts payable(9,811)5,858 (1,369)
Accrued expenses and other current liabilities(6,615)(816)(96)
Other long-term liabilities(135)(553)283 
Operating lease liabilities(10,704)(4,401)(5,283)
Net cash used in operating activities(150,142)(145,122)(127,648)
Cash flows from investing activities:
Purchases of property, plant and equipment(5,304)(3,649)(5,497)
Proceeds from sale of property, plant and equipment17,943 — — 
Purchases of investments(83,626)— (122,671)
Sales and maturities of investments83,931 85,000 228,600 
Net cash provided by investing activities12,944 81,351 100,432 
Cash flows from financing activities:
Proceeds from underwritten public offering of common stock, net of commissions and underwriting discounts— 188,000 — 
Payments of offering costs— (360)— 
Payments of debt issuance costs— (150)— 
Proceeds from borrowings under loan and security agreement— — 25,000 
Payment of long-term debt(75,702)— — 
Proceeds from issuance of common stock upon exercise of stock options and under employee stock purchase plan232 10,963 1,484 
Net cash provided by (used in) financing activities(75,470)198,453 26,484 
Net increase (decrease) in cash, cash equivalents and restricted cash(212,668)134,682 (732)
Cash, cash equivalents and restricted cash at beginning of period227,583 92,901 93,633 
Cash, cash equivalents and restricted cash at end of period$14,915 $227,583 $92,901 
Supplemental cash flow information:
Cash paid for interest$4,387 $5,092 $3,822 
Cash paid for leases$11,565 $7,364 $8,486 
Supplemental disclosure of non-cash investing and financing information:
Purchases of property, plant and equipment included in accounts payable or accrued expenses$— $1,989 $317 
Offering costs included in accounts payable and accrued expenses$— $35 $— 
Lease assets obtained in exchange for new operating lease liabilities$— $— $496 
Lease asset derecognized upon lease cancellation$78 $— $982 
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification$25,502 $— $— 

The accompanying notes are an integral part of these consolidated financial statements.
46
RUBIUS THERAPEUTICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Nature of the Business and Basis of Presentation
Rubius Therapeutics, Inc. (“Rubius” or the “Company”) is a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines, called Red Cell Therapeutics, for the treatment of cancer and autoimmune diseases. Rubius was incorporated in April 2013 as VL26, Inc. under the laws of the State of Delaware. In January 2015, the Company changed its name to Rubius Therapeutics, Inc.
On July 27, 2022, the Company received a deficiency letter from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price for its common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. In February 2023, the Company was notified by the Staff that it would be delisted at the opening of business on February 15, 2023 unless the Company were to timely request a hearing before a Nasdaq Hearings Panel, or the Panel, to address the deficiencies and present a plan to regain compliance. On February 13, 2023, the Company timely requested a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel, unless the Company determine to withdraw its hearing request. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process.
On September 13, 2022, the Company's Board of Directors approved certain operational and organizational steps that the Company undertook in connection with a new strategic reorganization plan and related cost-saving measures (collectively, the “Reorganization Plan”). The Company discontinued its ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructured the organization to support advancing drug candidates based on its next generation platform. Under the Reorganization Plan, the Company reduced its overall workforce by approximately 75%, primarily consisting of employees who were focused on clinical development of RTX-240 and RTX-224, with the remainder coming from its manufacturing and general and administrative functions.
On November 2, 2022, in light of the Company’s financial condition, including the repayment and termination of its $75.0 million credit facility with SLR Investment Corp., and the early stage of its programs, its Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of its assets, and to significantly and immediately reduce its operations (the “Strategic Plan”). In connection with the Strategic Plan, the Company terminated 42 of its employees (representing 82% of its then-current employee base), leaving a core team of individuals to lead the strategic review process.
On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. In addition, the Company is subject to uncertainty regarding the performance and safety of its product candidates in humans. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. It is uncertain when, if ever, the Company will realize significant revenue from product sales.
Under Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued.
As of December 31, 2022, the Company had an accumulated deficit of $856.7 million, and cash and cash equivalents of $14.9 million. For the year ended December 31, 2022, the Company incurred a net loss of $179.7 million and used $150.1 million of cash in operations. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company’s accumulated deficit, history of losses and future expected
47
losses met the ASC 205-40 standard for raising substantial doubt about the Company’s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least twelve months from the filing of its Annual Report on Form 10-K.

Through the implementation of its Strategic Plan, the Company’s primary goal was to successfully complete a review of strategic alternatives and consummate a transaction or series of transactions to realize value for the Company’s platform and programs. On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company. As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Concentrations of Credit Risk and of Significant Suppliers
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalents as of December 31, 2022 consisted of cash, money market accounts and U.S. government money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
Deferred Offering Costs
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
Deferred Financing Costs
The Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term.
48
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Restricted Cash
As of December 31, 2021, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2021.
Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $14.9 million, $227.6 million and $92.9 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $0.1 million, $1.7 million and $1.7 million was restricted cash for each year, respectively.
Property, Plant and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
Estimated useful life
Computer equipment3 years
Laboratory equipment5 years
Furniture and fixtures7 years
Manufacturing equipment10 years
Manufacturing facility30 years
Leasehold improvements
Shorter of life of lease or 10 years
Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.
Impairment of Long-Lived Assets
Long-lived assets consist of property, plant and equipment and operating lease, right-of-use asset. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.
Fair Value Measurements
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial
49
assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1—Quoted prices in active markets for identical assets or liabilities.
•Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
Investments
The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.
The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.
Assets Held for Sale
The Company classifies its long-lived assets to be sold as held for sale in the period (i) the Company has approved and committed to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value, less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset until the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale.
Leases
At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option.

For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain
50
adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.

Segment Information
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company’s tangible assets are held in the United States.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.
Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.
Research and Manufacturing Contract Costs and Accruals
The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent Costs
All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-Based Compensation
The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited.
51
For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.
The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Comprehensive Loss
Comprehensive loss includes net loss, as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2020, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments. For the year ended December 31, 2022 there was no difference between the Company’s net loss and comprehensive loss.

Net Income (Loss) per Share
Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.

Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.



52
Recently Adopted Accounting Pronouncements
ASU No. 2016-13, Financial Instruments—Credit Losses
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.
ASU No. 2019-12, Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company adopted this standard as of January 1, 2021 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.

3. Investments and Fair Value of Financial Assets and Liabilities
The Company had no investments as of December 31, 2022 or December 31, 2021.
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$1,010 $— $— $1,010 
$1,010 $— $— $1,010 

December 31, 2021
Level 1 Level 2 Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$217,009 $— $— $217,009 
 $217,009 $— $— $217,009 

U.S. government money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no changes to the valuation methods during the year ended December 31, 2022. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level 1, Level 2 or Level 3 during the year ended December 31, 2022 and 2021, respectively.


53
4. Property, Plant and Equipment, Net and Assets Held for Sale
Property, plant and equipment, net and assets held for sale consisted of the following, after the effects of impairment charges and held-for-sale reclassifications (in thousands):
December 31,
20222021
Land$— $1,300 
Manufacturing facility— 33,203 
Manufacturing equipment— 8,831 
Laboratory equipment— 17,501 
Computer equipment— 2,645 
Furniture and fixtures— 1,281 
Leasehold improvements570 444 
Construction-in-progress— 4,181 
570 69,386 
Less: Accumulated depreciation and amortization(424)(17,856)
$146 $51,530 
Assets held for sale$4,070 $— 
During the year ended December 31, 2022, the Company recorded impairment charges of $25.8 million due to its Reorganization Plan (Note 13). Depreciation and amortization expense was $6.3 million, $7.7 million and $5.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.

5. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
December 31,
20222021
Accrued employee termination benefits$1,401 $— 
Accrued contract termination costs1,387 — 
Accrued general and administrative expenses521 889 
Accrued employee compensation and benefits— 7,451 
Accrued external research and development expenses— 2,713 
Accrued manufacturing facility expenses— 2,349 
Deposit received for assets held for sale2,125 — 
Other173 670 
$5,607 $14,072 





54

6. Debt
Long-term debt consisted of the following (in thousands):
December 31, 2022December 31, 2021
Principal amount of long‑term debt$— $75,000 
Less: Current portion of long‑term debt— — 
Long‑term debt, net of current portion— 75,000 
Accrued final interest payment— 1,654 
Debt discount— (500)
Long‑term debt, net of discount and current portion$— $76,154 

Loan Agreement
On December 21, 2018 (the “Closing Date”), the Company entered into a loan and security agreement(the "Original Loan Agreement," and, as amended, the “Loan Agreement”) with Solar Capital Ltd., now SLR Investment Corp. ("SLR"), as collateral agent for the lenders party thereto for an aggregate principal amount of $75.0 million. The aggregate principal amount will be funded in three tranches of term loans of $25.0 million each. On the Closing Date, the Company made an initial borrowing of $25.0 million. In June 2019, the Company made a second borrowing of $25.0 million and in June 2020, the Company made a third and final borrowing of $25.0 million.
On June 22, 2021 (the “Amendment Closing Date”), the Company entered into an amendment (the “Amendment”) to the Original Loan Agreement. Pursuant to the Amendment, the Company and its lenders agreed to extend the interest-only period applicable to borrowings under the Loan Agreement from December 21, 2021 until July 1, 2024 and the final maturity date from December 21, 2023 until June 1, 2026. An additional tranche in the amount of $35.0 million is available at the request of the Company prior to the final maturity date, to be provided at the sole discretion of the lenders. The Amendment increases the LIBOR interest rate floor from 0.00% to 2.10%. Interest on the outstanding loan balance will accrue at a rate of 5.50%, plus the greater of 2.10% or the one-month U.S. LIBOR rate. Certain back-end fees are due to the lender at the time of final repayment based on the total funded term loans. The Company accrues the back-end fees that will be due at final repayment to outstanding debt by charges to interest expense over the term of the loans using the effective interest method. The term loans are subject to a prepayment fee of 1.00% if prepayment occurs within the first year subsequent to the Amendment Closing Date, 0.50% in the second year and 0.25% in the third year through final maturity date.
As the terms of the Amendment were not substantially different than the terms of the Original Loan Agreement, the Amendment was accounted for as a debt modification. In conjunction with the Amendment, the Company incurred issuance costs of $0.2 million payable to the lenders, which were recorded as an additional debt discount and will be amortized to interest expense over the remaining term, together with unamortized original issuance costs as of the Amendment Closing Date, using the effective interest method.
On October 13, 2022, the Company entered into a payoff letter with SLR, under which the Company voluntarily prepaid SLR approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under the Loan Agreement. The payoff letter also provided for the termination of all commitments and obligations under the Loan Agreement and release of all liens held by SLR on the Company’s assets. The Loan Agreement was extinguished and accounted for as a troubled debt restructuring as the Company was experiencing financial difficulty and SLR granted the Company a concession by forgiving certain contractually owed amounts. The Company recognized a gain on the extinguishment of the Loan Agreement of $1.1 million, which is recorded in interest expense on the consolidated statements of operations and comprehensive loss. As of December 31, 2022, the Company does not have any debt outstanding.

7. Equity
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.
55
On July 20, 2018, the Company filed a restated certificate of incorporation in the State of Delaware, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 160,000,000 shares, consisting of (i) 150,000,000 shares of common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon issuance. The shares of preferred stock are currently undesignated.
On August 1, 2019, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and SVB Leerink LLC (the “Sales Agents”), pursuant to which the Company was able to issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agents. As of December 31, 2022, no shares of common stock have been issued and sold pursuant to the Distribution Agreement, which expired in accordance with its terms on August 21, 2022, and the applicable registration statement is no longer effective.
On March 18, 2021, the Company completed the March 2021 Offering, pursuant to which it issued and sold 6,896,552 shares of common stock. The aggregate net proceeds received by the Company from the March 2021 Offering were $187.2 million, after deducting underwriting discounts and commissions and other offering costs.
On July 7, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which increased the number of shares of common stock that the Company has authority to issue from 150,000,000 to 300,000,000 shares. The number of shares of preferred stock authorized for issuance was not impacted by this amendment.

8. Stock-Based Compensation
2018 Equity Incentive Plan
On July 6, 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Plan, which became effective on July 16, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2018 Plan is 5,708,931, which shall be cumulatively increased on January 1, 2019 and each January 1 thereafter by 4% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s board of directors or compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Plan. As of December 31, 2022, 9,666,433 shares remained available for issuance under the 2018 Plan. The number of authorized shares reserved for issuance under the 2018 Plan was increased by 3,615,509 shares effective as of January 1, 2023.
2018 Employee Stock Purchase Plan
On July 6, 2018, the Company’s board of directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”), which became effective on July 16, 2018. On December 15, 2022, the Company's board of directors voted to terminate the ESPP effective immediately.
The Company issued 143,906 and 26,444 shares of common stock under the ESPP during the years ended December 31, 2022 and December 31, 2021, respectively. The Company recorded $0.1 million and $0.1 million of stock-based compensation expense as a result of the ESPP for the year ended December 31, 2022 and December 31, 2021, respectively. There were no shares of common stock issued and no stock-based compensation expense recorded under the ESPP for the year ended December 31, 2020. Due to the plan termination, no further shares will be issued under to the ESPP.
Stock Option Valuation
Service-Based and Performance-Based Stock Options
The fair value of stock option grants with service-based and performance-based vesting conditions is estimated using the Black-Scholes option-pricing model. The Company estimates expected volatility based on the historical volatility of publicly traded peer companies. For options with service-based vesting conditions, the expected term of the Company’s
56
stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock-based awards granted to employees, directors, and non-employees:
Year ended December 31,
202220212020
Risk-free interest rate2.37 %0.81 %1.10 %
Expected volatility78.4 %77.4 %69.4 %
Expected dividend yield———
Expected term (in years)5.876.086.05

The following table summarizes the Company’s service-based and performance-based option activity since December 31, 2022:

Number of
shares		Weighted average exercise
price		Weighted average contractual termAggregate intrinsic
value
(in years)(in thousands)
Outstanding as of December 31, 202117,138,772$12.047.22$23,511
Granted4,104,4034.37  
Exercised(42,228)2.32  
Forfeited(7,105,039)10.31  
Outstanding as of December 31, 202214,095,908$10.713.55$6
Vested and expected to vest as of December 31, 202214,095,908$10.713.55$6
Options exercisable as of December 31, 202212,061,182$11.292.82$6
The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $0.1 million, $34.6 million and $5.7 million, respectively.
The weighted average grant-date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was $2.98 per share, $10.55 per share and $4.51 per share, respectively.
Market-Based Stock Options
The fair value of stock option grants with market-based vesting conditions is estimated using a Monte Carlo simulation model.

In October 2018, the Company granted to an executive officer an option to purchase 164,400 shares of common stock (“Option A”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the satisfaction of service-based vesting conditions, and an option to purchase 193,400 shares of common stock (“Option B”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the achievement of certain other performance-based vesting conditions. The Company used a Monte Carlo simulation model to estimate the grant-date fair value of the awards. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility based on a combination of the Company’s historical stock volatility since its July 2018 IPO and the historical volatility of a publicly traded set of peer companies and the estimated period to achievement of the market condition. Stock-based compensation expense for Option A is being recognized using the graded-vesting method over the longer of the derived service period from the market condition or the explicit service period required to be completed for each vesting tranche. Stock-based compensation expense for Option B is being recognized using the graded-vesting method over the longer of
57
the derived service period from the market condition or the estimated achievement of performance-based conditions. For Option B, stock-based compensation expense is recognized when the achievement of each performance-based vesting condition becomes probable regardless of whether the market condition has been achieved. The aggregate grant date fair value of these options was $4.3 million. During the years ended December 31, 2022, 2021 and 2020 the Company recorded stock-based compensation expense on Option A of $0.1 million, $0.2 million and $0.6 million, respectively. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense on Option B of $1.1 million and $1.1 million, respectively, as a performance-based vesting condition was determined to be probable during each year. No stock-based compensation expense on Option B was recorded during the year ended December 31, 2022.
The Company did not grant market-based stock options during the years ended December 31, 2022, 2021 and 2020. During the years ended December 31, 2022, 2021 and 2020, none of the outstanding stock options with market-based vesting conditions were exercised, forfeited or vested and they had no intrinsic value at December 31, 2022.
Restricted Stock Units
The Company has also granted restricted stock units to its employees. During the years ended December 31, 2022 and 2021, the Company granted restricted stock units to employees that were subject to time-based vesting conditions that lapse over four years and three years from the date of grant. No restricted stock units were granted during the year ended December 31, 2020. Restricted stock units with time-based vesting conditions are valued on the grant date using the grant date market price of the underlying shares. The following table summarizes the Company’s restricted stock unit activity since December 31, 2022:

SharesWeighted average
grant-date
fair value
Unvested restricted common stock as of December 31, 2021794,244$15.346
Issued906,8154.880
Vested(137,828)12.522
Forfeited(1,130,028)9.446
Unvested restricted common stock as of December 31, 2022433,203$9.728

Stock-Based Compensation
The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):
Year ended December 31,
202220212020
Research and development expenses$6,863 $12,338 $8,023 
General and administrative expenses8,920 23,272 25,642 
$15,783 $35,610 $33,665 

As of December 31, 2022, total unrecognized compensation cost related to unvested stock-based awards was $6.8 million, which is expected to be recognized over a weighted average period of 2.2 years.

9. Income Taxes
During the years ended December 31, 2022, 2021 and 2020, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.
All of the Company’s operating losses since inception have been generated in the United States.
58
A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:
Year ended
December 31,
20222021
Federal statutory income tax rate(21.0)%(21.0)%
State taxes, net of federal benefit(6.0)(6.2)
Federal and state research and development tax credits(5.3)(6.4)
Stock‑based compensation expense0.5 (1.6)
Section 162(m) compensation deduction limitation0.1 1.6 
Other0.1 (0.4)
Increase in deferred tax asset valuation allowance31.6 34.0 
Effective income tax rate— %— %

Net deferred tax assets consisted of the following (in thousands):

December 31,
20222021
Deferred tax assets:
Net operating loss carryforwards$159,691 $145,990 
Research and development tax credit carryforwards45,478 36,161 
Accrued expenses105 2,137 
Capitalized intellectual property costs2,051 1,746 
Capitalized research and development expense32,007 86 
Operating lease liabilities301 10,194 
Stock‑based compensation expense24,454 21,483 
Depreciation74 — 
Total deferred tax assets264,161 217,797 
Deferred tax liabilities:
Operating lease assets(732)(9,590)
Depreciation and other— (1,500)
Total deferred tax liabilities(732)(11,090)
Valuation allowance263,429 206,707 
Net deferred tax assets$— $— 
As of December 31, 2022, the Company had U.S. federal and state net operating loss (“NOL”) carryforwards of $584.8 million and $583.6 million, respectively, which may be available to offset future taxable income. The federal NOLs include $37.2 million which expire at various dates through 2037 and $547.6 million which carryforward indefinitely. The state NOLs expire at various dates through 2042. As of December 31, 2022, the Company also had U.S. federal and state research and development tax credit carryforwards of $29.5 million and $19.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2026, respectively. During the year ended December 31, 2022, deferred tax assets, before valuation allowance, increased by approximately $46.4 million mainly due to the operating loss incurred by the Company during that period and the capitalization of research and development expenses.
Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred
59
or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.
The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period.
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022, 2021 and 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):
Year ended December 31,
202220212020
Valuation allowance as of beginning of year$206,707$139,877$85,884
Decreases recorded as benefit to income tax provision———
Increases recorded to income tax provision56,72266,83053,993
Valuation allowance as of end of year$263,429$206,707$139,877

As of December 31, 2022 and 2021, the Company had no recorded amounts for unrecognized tax benefits. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations and comprehensive loss. The Company files income tax returns in the U.S., Massachusetts and Rhode Island, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present; however, carryforward attributes that were generated prior to January 1, 2016 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.

10. Commitments and Contingencies
License Agreement with the Whitehead Institute for Biomedical Research
The Company has a license agreement with the Whitehead Institute for Biomedical Research (“WIBR”), as amended, under which the Company has been granted an exclusive, sublicensable, nontransferable license under certain patent families related to the development of the Company’s red blood cell therapies (as amended, the “WIBR License”). The Company is obligated to pay WIBR annual license maintenance fees of less than $0.1 million, as well as patent-related costs, including legal fees, and low single-digit royalties based on annual net sales of licensed products and licensed services by the Company and its sublicensees. Based on the progress the Company makes in the advancement of products covered by the licensed patent rights, the Company is required to make aggregate milestone payments of up to $1.6 million upon the achievement of specified preclinical, clinical and regulatory milestones. In addition, the Company is required to pay to WIBR a percentage of the non-royalty payments that it receives from sublicensees of the patent rights licensed by WIBR. This percentage varies from low single-digit to low double-digit percentages and will be based upon the clinical stage of the product that is the subject of the sublicense. Royalties shall be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country.
The Company has the right to terminate the WIBR License in its entirety, on a patent-by-patent or country-by-country basis, at will upon three months’ notice to WIBR. WIBR may terminate the agreement upon breach of contract or in the event of the Company’s bankruptcy, liquidation, insolvency or cessation of business related to the license.
60
401(k) Plan
In January 2018, the Company established a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company makes matching contributions at a rate of 50% of each employee’s contribution up to a maximum employee contribution of 6% of eligible plan compensation. For the years ended December 31, 2022, 2021 and 2020, the Company made matching contributions of $0.9 million, $0.9 million and $0.8 million, respectively. In January 2023, the Company terminated the 401(k) Plan effective December 30, 2022.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.
Legal Proceedings
The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

11. Leases
Operating Leases
During the year ended December 31, 2022, the Company leased office and laboratory facilities in Cambridge, Massachusetts under one noncancelable operating lease, which is subject to two expiration dates based on two distinct leased spaces, expiring in January 2027 and August 2028.
In January 2018, the Company entered into a lease for office and laboratory space in Cambridge, Massachusetts (the “Initial Space”). The lease term commenced on January 28, 2019 and was scheduled to expire eight years from the commencement date. The initial annual base rent is approximately $3.8 million, and such amounts increased during the initial term by 3% annually on the anniversary of the commencement date.
In November 2018, the Company entered into a lease amendment for office and laboratory space in the same building (the “Expansion Space”). The lease term for the Expansion Space commenced on August 8, 2019 and was scheduled to expire approximately nine years from the commencement date. The initial annual base rent for the Expansion Space was approximately $2.5 million and such amount increased by 3% annually on the anniversary of the commencement date. The Company was obligated to pay its portion of real estate taxes and costs related to the Expansion Space, including costs of operations, maintenance, repair, replacement and property management.
In December 2022, the Company entered into an Agreement for Termination of Lease (the “Lease Termination Agreement”) relating to its two distinct leased spaces for office and laboratory space in Cambridge, Massachusetts (the “Cambridge Facility”). Under the Lease Termination Agreement, the Company’s lease for the Cambridge Facility terminated on January 31, 2023. Under the terms of the Lease Termination Agreement, the Company paid the landlord a lease termination payment, inclusive of the full amount of a letter of credit that the landlord held under the lease and rent previously paid by the Company to the landlord for the month of December 2022, of approximately $5.9 million in the fourth quarter of the year ended December 31, 2022, and the Company paid the landlord a subsequent payment of $1.1 million in the first quarter of the year ending December 31, 2023.

61
The Lease Termination Agreement terminated the lease on January 31, 2023. As the lease termination was effective at a future date, the Company accounted for the change as a lease modification that shortened the lease term. Upon the modification, the Company decreased its operating lease, right-of-use asset by an amount equal to the adjustment of its operating lease liabilities.

The Company evaluated its vendor contracts to identify embedded leases, if any, and noted that an agreement with a contract manufacturing supplier constituted a lease under ASC 842 as the Company has the right to substantially all the economic benefits from the use of the asset and can direct the use of the asset. The Company entered into the agreement during the first quarter of 2019. The lease commenced during March 2019 and was scheduled to expire 22 months from commencement date with no stated option to extend the term. The lease was cancelled prior to expiration during the first quarter of 2020, resulting in derecognition of the lease assets and operating lease liabilities.

As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate based on information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and, therefore, has allocated all the contract consideration across lease components only. This may result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability for leases being greater than if the policy election was not applied. Assets under operating lease at December 31, 2022 were $2.7 million. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance.

As of December 31, 2022, minimum lease payments under the Company’s operating leases are as follows (in thousands):
Year ending December 31,
2023$1,100
2024—
2025—
2026—
2027—
Thereafter—
1,100
Less: imputed interest— 
$1,100
The Company has not entered any material financing leases as of December 31, 2022.
Lease Portfolio
The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):
62

Year ended December 31,
202220212020
Lease cost:
Operating lease cost$12,655 $8,173 $9,240 
Short-term lease cost— 41 24 
Variable lease cost3,058 3,723 1,916 
Sublease income— (719)(1,017)
Total lease cost$15,713 $11,218 $10,163 
Operating leases:
Operating lease, right-of-use-asset$2,679 $35,095 $40,447 
Operating lease liabilities$1,100 $9,015 $8,945 
Operating lease liabilities, net of current portion$— $28,291 $32,762 
Other information:
Weighted average remaining lease term - operating leases0.08 years5.80 years6.70 years
Weighted-average discount rate - operating leases— %7.60 %7.60 %

12. Net Loss per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Year ended December 31,
202220212020
Numerator:   
Net loss $(179,666)$(196,547)(167,731)
Denominator:
Weighted average common shares outstanding, basic and diluted90,305,46387,950,44080,624,608
Net loss per share, basic and diluted$(1.99)$(2.23)$(2.08)

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares from the periods in the table above, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Year ended December 31,
202220212020
Unvested restricted common stock433,203794,244252,000
Stock options to purchase common stock14,453,70817,496,57216,318,124
14,886,91118,290,81616,570,124

63
13. Restructuring and Impairment Charges
The Company estimates that it will incur approximately $51.9 million in costs to implement the Reorganization Plan and the Strategic Plan, as described in Note 1. The actions associated with the Reorganization Plan and the Strategic Plan commenced in September 2022 and November 2022, respectively, and are expected to be substantially completed by February 28, 2023.
The Reorganization Plan and the Strategic Plan required management to evaluate matters related to involuntary termination benefits provided pursuant to a one-time benefit arrangement, contract termination costs and the impairment of long-lived assets in accordance with generally accepted accounting principles. The recognition of the Company’s liability for one-time termination benefits is based on contractual agreements and whether employees are required to render service until they are terminated in order to receive the termination benefits and, if so, whether the employee will be retained to render service beyond a minimum retention period. The Company’s contract termination costs represent costs to terminate a contract before the end of its term or costs that will continue to be incurred under a contract for its remaining term without economic benefit to the Company and is recognized at fair value when the contract is terminated or the Company ceases using the right conveyed by the contract. The impairment of long-lived assets is based on the fair value of the Company's long-lived asset group as determined by actual sale transactions.

As a result of these events, the Company incurred the following restructuring and impairment charges, which are recorded in the consolidated statements of operations and comprehensive loss (in thousands):

Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Employee termination benefits$12,929 $— $— 
Impairment of property, plant and equipment25,841 — — 
Contract termination costs12,427 — — 
$51,197 $— $— 

Employee Termination Benefits

Employees affected by the reduction in workforce under the Company's Reorganization Plan and Strategic Plan received involuntary termination benefits that are provided pursuant to a one-time benefit arrangement. For employees who were notified of their termination and have no requirements to provide future service, the Company recognized the liability for the termination benefits in full at fair value in the period in which they were incurred. For employees who are required to render services beyond a minimum retention period to receive their one-time termination benefits, the Company is recognizing the termination benefits ratably over their future service periods. The service periods for the Reorganization Plan began in September 2022 and ended at various dates through December 31, 2022. The service periods for the Strategic Plan began in November 2022 and ended at various dates through January 31, 2023. The Company will incur approximately $13.6 million of employee termination benefits expense to implement the Reorganization Plan and the Strategic Plan of which $12.9 million has been incurred in the year ended December 31, 2022.

The following table shows the liability related to employee termination benefits as of December 31, 2022:

Employee Termination Benefits
Accrued employee termination benefits beginning balance$— 
Employee termination benefits charges incurred during the period12,929 
Amounts paid or otherwise settled during the period(11,528)
Accrued employee termination benefits as of December 31, 2022$1,401 

Impairment of Property, Plant and Equipment

As a result of the Reorganization Plan, the Company determined that sufficient indicators existed to trigger the performance of an interim long-lived asset impairment analysis as of September 30, 2022. In the third quarter of 2022, the Company tested the recoverability of its asset group using entity-specific undiscounted cash flows. Based on these undiscounted cash flows, the Company concluded the undiscounted future cash flows expected to result from the use and eventual disposition of its long-lived assets were less than the carrying value of the asset group. Therefore, the Company measured the long-lived asset impairment as the amount by which the carrying value of the asset group exceeds its fair
64
value and recorded an impairment of $17.8 million. The loss was allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the loss allocated to an individual long-lived asset of the group did not reduce the carrying value of that asset below its fair value. The fair value of the asset group was determined from a third-party commercial real estate appraisal which represents a Level 3 fair value measurement.

Additionally, in conjunction with its Reorganization Plan, the Company committed to a plan to actively sell specific assets within its asset group, primarily its laboratory equipment and furniture and fixtures. The laboratory equipment and furniture and fixtures met all of the prescribed criteria required to classify it as held for sale. At December 31, 2022, $4.1 million of laboratory equipment and furniture and fixtures was classified as held for sale as current assets on the consolidated balance sheet as the disposal was expected to be consummated within one year of the balance sheet date and the Company does not expect to use the sale proceeds to reduce any long-term borrowings. The sale was completed by January 31, 2023.

In December 2022, the Company entered into a purchase and sale agreement for the sale of its manufacturing facility and certain related fixtures and personal property for an aggregate purchase price of $18.5 million. The purchase price was less than the carrying amount of the assets sold and the resulting impairment of $8.0 million was recorded within restructuring and impairment charges in the consolidated statements of operations and comprehensive loss.

For the year ended December 31, 2022, the Company recorded long-lived impairment charges of $25.8 million, which were recorded within restructuring and impairment charges on the consolidated statements of operations and comprehensive loss.

Contract Termination Costs

The discontinuation of the RTX-240 and RTX-224 clinical trials as part of the Reorganization Plan and of discovery activities and platform development as part of the Strategic Plan resulted in the termination of vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company. The Company recognized these contract termination costs in full in the period in which they no longer held an economic benefit to the Company. During the year ended December 31, 2022, the Company incurred $12.4 million of contract termination costs, which it estimates to be the full amount of such costs to be incurred related to the Reorganization Plan.

The following table shows the liability related to contract termination costs as of December 31, 2022:

Contract Termination Costs
Accrued contract termination costs beginning balance$— 
Contract termination costs incurred during the period12,427 
Amounts paid or otherwise settled during the period(11,040)
Accrued contract termination costs as of December 31, 2022$1,387 

14. Subsequent Events
On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.

65
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (our principal executive officer and principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Internal Control Over Financial Reporting

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our management conducted an assessment of the effectiveness of our internal control over financial reporting, as of December 31, 2022, based on the criteria described in “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We engaged Verdolino & Lowey, P.C. during the quarter ended December 31, 2022 to provide certain services, including accounting services, to the Company. Although the underlying internal controls did not significantly change with this move, the responsibility to perform certain internal controls has transferred to an outsourced service provider.

Item 9B. Other Information
None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
66
PART III

Item 10. Directors, Executive Officers and Corporate Governance

Incorporated by reference from the information in our Proxy Statement to the extent filed with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.

Item 11. Executive Compensation

Incorporated by reference from the information in our Proxy Statement to the extent filed with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Incorporated by reference from the information in our Proxy Statement to the extent filed with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Incorporated by reference from the information in our Proxy Statement to the extent filed with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.

Item 14. Principal Accounting Fees and Services

Incorporated by reference from the information in our Proxy Statement to the extent filed with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates.

67
PART IV

Item 15. Exhibits and Financial Statement Schedules

(a) 1. Financial Statements

For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page 142 of this Annual Report on Form 10-K, incorporated into this Item by reference.

2. Financial Statement Schedules

Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.

3. Exhibits

The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.
(b) Exhibit Index
3.1
3.2
3.3
4.1
4.2
4.3
10.1#
10.2#
10.3#
10.4#
68
10.5#
10.6#
10.7#
10.8
10.9
10.10˄
10.11˄
10.12˄˄
10.13#
21.1*
24.1*Power of Attorney (included on signature page to this Annual Report on Form 10-K)
31.1*
31.2*
32.1*†
101.INS*Inline XBRL Instance Document.
69
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

*Filed herewith.
#Indicates a management contract or any compensatory plan, contract or arrangement.
˄Confidential treatment has been granted with respect to redacted portions of this exhibit. Redacted portions of this exhibit (indicated by asterisks) have been filed separately with the Securities and Exchange Commission.
˄˄Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.
†This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

Item 16. Form 10-K Summary
The company has elected not to include summary information.


70
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RUBIUS THERAPEUTICS, INC.
February 27, 2023 By:/s/ Dannielle Appelhans
 Dannielle Appelhans
 Chief Executive Officer

POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Dannielle Appelhans with full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agent or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Dannielle AppelhansChief Executive OfficerFebruary 27, 2023
Dannielle Appelhans(Principal Executive Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer)
/s/ Pablo J. CagnoniChairman of the Board of DirectorsFebruary 27, 2023
Pablo J. Cagnoni, M.D.
/s/ Catherine A. SohnDirectorFebruary 27, 2023
Catherine A. Sohn, Pharm.D.
/s/ Jonathan R. SymondsDirectorFebruary 27, 2023
Jonathan R. Symonds, CBE

71
 EX-101.SCH 2 ruby-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Restructuring and Impairment Charges link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Restructuring and Impairment Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Nature of the Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Debt - Current and Non current (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Stock-Based Compensation - Granted to non-employees (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Stock-Based Compensation - Option activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Stock-Based Compensation - Compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Income Taxes - U S federal statutory income tax rate (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Income Taxes - Net deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Income Taxes - Valuation allowance for deferred tax assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Commitments and Contingencies - Defined Contribution Plan (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Leases - Minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Leases - Lease Portfolio (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Net Loss per Share - Weighted Average Shares (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Net Loss per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Restructuring and Impairment Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Restructuring and Impairment Charges - Summary of Charges (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Restructuring and Impairment Charges - Restructuring Reserve Activity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 ruby-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 ruby-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 ruby-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Payments due Lessee, Operating Lease, Liability, to be Paid Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Principal amount of long‑term debt Long-Term Debt, Gross Accrued employee termination benefits Accrued Employee Termination Benefits, Current Accrued Employee Termination Benefits, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Annual increase of shares reserved for awards (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase Percentage Annual increase of the shares (or other type of equity) for awards under the equity-based compensation plan as as a proportion of outstanding capital stock. Income tax benefits - operating losses incurred Income Tax Benefits For Net Operating Losses Incurred The amount of income tax benefits for the net operating losses incurred. Assets held for sale Assets Held-for-sale, Not Part of Disposal Group Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Debt Instrument [Axis] Debt Instrument [Axis] Property, plant and equipment, gross Property, Plant and Equipment, Gross Maximum amount outstanding Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Balance at beginning of period Balance at end of period Restructuring Reserve Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Variable interest rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Borrowing Proceeds from Issuance of Debt Issuance of common stock upon exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Net deferred tax assets Deferred Tax Assets, Net Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Market-Based Stock Options Market-Based Stock Options Stock options awarded to employees for meeting certain closing prices of its common stock. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Domestic Tax Authority Domestic Tax Authority [Member] Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Audit Information [Abstract] Audit Information Diluted net loss per share attributable to common stockholders Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of of diluted weighted average shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Minimum lease payments Lessee, Operating Lease, Liability, to be Paid [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Scenario [Axis] Scenario [Axis] Prepayment fee in first year Debt Instrument, Prepayment Rate One Represents the prepayment rate if prepayment occurs in first year. Assets Assets, Fair Value Disclosure Restructuring Plan [Axis] Restructuring Plan [Axis] Leases Lessee, Operating Leases [Text Block] Leases Lessee, Lease, Description [Line Items] Related Party [Domain] Related Party [Domain] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Plan Name [Axis] Plan Name [Axis] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Executive Officer Executive Officer [Member] One-month LIBOR Debt Instrument, Description of Variable Rate Basis Plan Name [Domain] Plan Name [Domain] State operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, State and Local Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Outstanding at the beginning (in years) Outstanding at the end (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Non-cash interest expense Other Noncash Expense Operating lease liabilities Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Lease cost: Lease, Cost [Abstract] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increases recorded to income tax provision Valuation Allowance, Deferred Tax Asset, Increase in Income Tax Provision Amount of increase in the valuation allowance for a specified deferred tax asset. Performance-based vesting Performance-based vesting Represents a share based compensation award with vesting based on achievement of performance conditions. Document Annual Report Document Annual Report Long-term debt, net of discount Long‑term debt, net of discount and current portion Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Accrued Expenses and Other Current Liabilities The increase (decrease) during the reporting period in the amounts of accrued expenses and other current liabilities. Weighted average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Share-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization (accretion) of premium (discount) on investments Investment Income, Net, Amortization of Discount and Premium Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs of $800 Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Restructuring and impairment charges Restructuring Costs and Asset Impairment Charges Schedule of property, plant and equipment, Net Property, Plant and Equipment [Table Text Block] Investments Debt Securities, Available-for-Sale, Current Restructuring and related cost, number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Decreases recorded as benefit to income tax provision Valuation Allowance, Deferred Tax Asset, Decreases Recorded As Benefit To Income Tax Provision Valuation Allowance, Deferred Tax Asset, Decreases Recorded As Benefit To Income Tax Provision Estimated useful life Property, Plant and Equipment, Useful Life Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Laboratory equipment Laboratory equipment Tangible personal property used in laboratory. Assets: Assets, Fair Value Disclosure [Abstract] Restructuring Type [Axis] Restructuring Type [Axis] Weighted average grant date fair value - beginning of the period (in dollars per share) Weighted average grant date fair value - end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Financial Instrument [Axis] Financial Instrument [Axis] Embedded lease contracts Embedded lease contracts Represents information relating to embedded lease contracts. Document Period End Date Document Period End Date Restructuring and Impairment Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Net of commissions, underwriting discounts and offering costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Manufacturing equipment Manufacturing equipment Represents the information pertaining to manufacturing equipment. Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Contract termination costs Contract Termination [Member] Less: Current portion of long‑term debt Long-Term Debt, Current Maturities Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Options exercise price (in dollars per share) Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Principal amount of each tranche of term loans Debt Instrument, Unused Borrowing Capacity, Amount Accrued employee compensation and benefits Employee-related Liabilities, Current Variable lease cost Variable Lease, Cost Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Net Loss per Share Earnings Per Share [Text Block] Schedule of assumptions used to determine the fair value of stock awards granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Unrealized gains (losses) on investments, tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Increase in deferred tax asset valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Unrecognized compensation cost expected to be recognized over a weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gain on debt extinguishment Gain on debt extinguishment Gain (Loss) on Extinguishment of Debt Options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring Plan [Domain] Restructuring Plan [Domain] Computer equipment Computer Equipment [Member] Entity Registrant Name Entity Registrant Name Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs (in shares) Shares issued (in shares) Stock Issued During Period, Shares, New Issues Subsequent Events Subsequent Events [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Proceeds from borrowings under loan and security agreement Proceeds from Issuance of Secured Debt Market based and service based vesting Market based and service based vesting Share-based payment arrangement granting right, subject to common stock closing prices and service based vesting requirements, to purchase or sell certain number of shares at predetermined price for specified period of time. Issuance costs Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Auditor Name Auditor Name Investments and Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Capitalized research and development expense Deferred Tax Assets, Capitalized Research and Development Expense Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences, capitalized research and development expense. Federal and state research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Accrued final interest payment Interest Payable, Current Research and development Research and Development Expense Disposal Group Classification [Axis] Disposal Group Classification [Axis] Restricted stock units issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 2018 ESPP 2018 ESPP [Member] 2018 ESPP Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Equity Option Equity Option [Member] Accounts payable Increase (Decrease) in Accounts Payable One-month U.S. LIBOR London Interbank Offered Rate (LIBOR) [Member] Subsequent Events [Abstract] Revenue Revenues Increase in number of authorized shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Restructuring and related cost, cost incurred to date Restructuring and Related Cost, Cost Incurred to Date Income Taxes Income Tax Disclosure [Text Block] Manufacturing facility Manufacturing Facility [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Accrued general and administrative expenses Accrued General And Administrative Expenses Current The amount of current portion of accrued general and administrative expenses as at the end of the reporting period. 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' equity Balances at beginning of period Balances at end of period Stockholders' Equity Attributable to Parent Weighted average grant date fair value- forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] U.S. government money market funds Money Market Funds [Member] Accumulated deficit Retained Earnings [Member] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Total lease cost Lease, Cost Common stock Common Stock [Member] Prepayment fee in third year Debt Instrument, Prepayment Rate Three Represents the prepayment rate if prepayment occurs in third year. Schedule of lease cost and lease liabilities for the Company's lease portfolio Lease, Cost [Table Text Block] Payment of long-term debt Payments for Repurchase of Common Stock Number of shares remained available for future issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule of restricted stock unit activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Statement [Table] Statement [Table] Weighted average grant date fair value- vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Research and development tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Prepayment fee in second year Debt Instrument, Prepayment Rate Two Represents the prepayment rate if prepayment occurs in second year. Company matching contribution Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Disposal Group Name [Axis] Disposal Group Name [Axis] Accrued contract termination costs Accrued Contract Termination Costs, Current Accrued Contract Termination Costs, Current Restricted cash for the benefit of its leased properties Restricted Cash For The Benefit Of Landlord a Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Recurring Fair Value, Recurring [Member] Options exercisable (in dollars per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Vesting of restricted stock units APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Disposal group, including discontinued operation, consideration Disposal Group, Including Discontinued Operation, Consideration Unvested restricted common stock beginning of period (in shares) Unvested restricted common stock end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Deferred Offering Costs Deferred Charges, Policy [Policy Text Block] Total other income (expense), net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease, right-of-use-asset Operating Lease, Right-of-Use Asset Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Impairment of Long-Lived Assets, Assets Held for Sale Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Initial annual base rent Operating Lease, Expense Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Offering Offering Represents information related to an unwritten public offering. Section 162(m) compensation deduction limitation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent 2022 Strategic Restructuring Plan 2022 Strategic Restructuring Plan [Member] 2022 Strategic Restructuring Plan Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) License costs Other Cost and Expense, Operating Federal operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Domestic Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Offering costs included in accounts payable and accrued expenses Offering Costs And Issuance Costs Included In Accounts Payable And Accrued Expenses The amount represents the offering costs and issuance costs included in accounts payable and accrued expenses Stock‑based compensation expense Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Number of leases Number of Operating Leases Number of non cancellable operating lease contracts. Summary of property plant and equipment Public Utility Property, Plant, and Equipment [Table Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities State and Local Jurisdiction State and Local Jurisdiction [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Aggregate offering price Maximum Aggregate Offering Price Of Stock Maximum amount of aggregate offering price of the Company's common stock sold through Sales Agents under distribution agreement. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Valuation allowance Valuation allowance as of beginning of year Valuation allowance as of end of year Deferred Tax Assets, Valuation Allowance Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Number of votes per share Number of Votes Per Share Number of vote entitled to common stock holders per share. Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Number of options granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional paid-in capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash Restricted cash (non-current) Restricted Cash, Noncurrent Aggregate intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average number of shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Long‑term debt, net of current portion Long Term Debt Net Of Current Amount of debt prior to reduction for unamortized (discount) or premium and debt issuance costs classified as noncurrent. Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Prepaid expenses and other current assets Prepaid Expense And Other, Current Amount of asset related to consideration paid in advance and other for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Deferred Tax Asset, Valuation Allowance Activity [Roll Forward] Deferred Tax Asset, Valuation Allowance Activity Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,387,732 and 90,063,770 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] At the market offering At the market offering Sale of stock by company under the distribution agreement through the Sales Agents, deemed to be an at the market offering. Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Weighted average grant date fair value- issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term lease cost Short-Term Lease, Cost Property, Plant and Equipment, Net [Abstract] Property, Plant and Equipment, Net [Abstract] Preferred stock, share authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Proceeds from issuance of common stock upon exercise of stock options and under employee stock purchase plan Proceeds from Stock Options Exercised Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Number of tranche Debt Instrument, Number Of Tranche Represents the number of tranche. 2018 Equity Incentive Plan 2018 Equity Incentive Plan The information pertaining to 2018 Equity Incentive Plan. Purchases of property, plant and equipment included in accounts payable or accrued expenses Capital Expenditures Incurred but Not yet Paid Percentage of employee's gross pay match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Summary of changes in the valuation allowance for deferred tax assets Summary of Valuation Allowance [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Principal amount Debt Instrument, Face Amount Investments Investment, Policy [Policy Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Operating lease liabilities Increase Decrease, Operating Lease Liabilities The increase (decrease) during the reporting period in the value of operating lease liabilities. Capitalized intellectual property costs Deferred Tax Assets, Capitalized Intellectual Property Costs Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences, Capitalized Intellectual Property Costs. Impairment charges Impairment charges Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Federal operating loss carryforwards subject to expiration indefinitely Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Amounts paid or otherwise settled during the period Payments for Restructuring Weighted average contractual term and aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization expense Depreciation, Depletion and Amortization Employee termination benefits Employee Severance [Member] Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Lease term Lessee, Operating Lease, Term of Contract Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Debt discount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Stock‑based compensation expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Collaborative Arrangements and Non-collaborative Arrangement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] WIBR WIBR Represents the information pertaining to Whitehead Institute for Biomedical Research. Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Cash paid for leases Operating Lease, Payments Repayments of long-term debt Repayments of Long-Term Debt Operating leases: Assets and Liabilities, Lessee [Abstract] Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] License and Maintenance License and Maintenance [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Excluding Current Operating Lease Liabilities Carrying value as of the balance sheet date of obligations incurred and payable, excluding current operating lease liabilities, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Loss on disposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Restricted stock units forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income, net Other Nonoperating Income (Expense) Number of distinct leased spaces Number of Distinct Leased Spaces Number of Distinct Leased Spaces Common stock, share authorized (in shares) Common stock, authorized (in shares) Common Stock, Shares Authorized Shares authorized Aggregate Stock, Shares Authorized The maximum number of shares permitted to be issued by an entity's charter and bylaws. Total operating expenses Operating Expenses Maximum Maximum [Member] Depreciation and other Deferred Tax Liabilities Depreciation and Other The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Entity Small Business Entity Small Business Other Commitments [Table] Other Commitments [Table] Balances at beginning of period (in shares) Balances at end of period (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Equity Stockholders' Equity Note Disclosure [Text Block] Restricted cash Restricted Cash Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Accrued external research and development expenses Accrued Research and Development, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development expenses. Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property, Plant and Equipment, Net and Assets Held for Sale Property, Plant and Equipment Disclosure [Text Block] Depreciation Deferred Tax Assets, Depreciation Deferred Tax Assets, Depreciation Sublease income Sublease Income Outstanding at the beginning (in dollars) Outstanding at the end (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Impairment of property, plant and equipment Impairment Of Property Plant And Equipment [Member] Impairment Of Property Plant And Equipment Title of 12(b) Security Title of 12(b) Security Nature of the Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Sales and maturities of investments Proceeds from Sale, Maturity and Collection of Investments Payables and Accruals [Abstract] Payables and Accruals [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Payments of debt issuance costs Payments of Debt Issuance Costs Operating lease liability Operating Lease, Liability Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Aggregate milestone payments Aggregate Milestone Payments, Achievement of Specified Milestones The aggregate milestone payments to be made on achieving of specific . Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounts payable Accounts Payable, Current Restructuring charges Restructuring Charges Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Income Tax Authority [Axis] Income Tax Authority [Axis] Other assets Increase (Decrease) in Other Operating Assets Vested and expected to vest (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Auditor Location Auditor Location Entity Filer Category Entity Filer Category Weighted average number of shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Deposit received for assets held for sale Deposit For Assets Held-For-Sale, Current Deposit For Assets Held-For-Sale, Current Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities. Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (see Note 10) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding at the beginning (in dollars per share) Outstanding at the end (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease, termination payment Operating Lease, Termination Payment Operating Lease, Termination Payment Fair value of financial assets and liabilities Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued or outstanding at December 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Restricted cash, current Restricted Cash, Current Restricted Stock Restricted Stock [Member] Marketable securities Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Property, Plant and Equipment, Net Property, Plant and Equipment [Line Items] Schedule of long term debt Schedule of Debt [Table Text Block] General and administrative expenses General and Administrative Expense [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Employer matching contribution (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Entity Voluntary Filers Entity Voluntary Filers Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Restructuring and Related Activities [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Schedule of allocation of share based compensation Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Forecast Forecast [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Total liabilities and stockholders' equity Liabilities and Equity Net deferred tax assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Related Party [Axis] Related Party [Axis] Land Land [Member] Stock-based compensation, fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grant Date Fair Value The amount represents the value of share-based compensation arrangement by share-based payment award, options, grant date fair value. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total deferred tax assets Deferred Tax Assets, Gross Disposal Group Name [Domain] Disposal Group Name [Domain] Stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Accrued interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Disposal group, including discontinued operation, assets Disposal Group, Including Discontinued Operation, Assets 2022 Restructuring Plan 2022 Restructuring Plan [Member] 2022 Restructuring Plan Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payments of offering costs Payments of Stock Issuance Costs Impairment charges Gain (Loss) on Disposition of Property Plant Equipment Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Number of expiration period Number of Expiration Dates Represents the number of expiration dates. Federal operating loss carryforwards subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Other income (expense): Nonoperating Income (Expense) [Abstract] Entity Address, Address Line Three Entity Address, Address Line Three Schedule of minimum lease payments under the Company's operating leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Base rent incremental (as a percentage) Operating Lease, Base Rent incremental Percentage Base rent increase during the initial term in percentage annually on the anniversary of the commencement date. Operating lease, right-of-use-asset Increase Decrease, Operating Lease, Right Of Use Asset The increase (decrease) during the reporting period in the value of operating lease, right-of-use-asset. Unrealized losses on investments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Nature of the business and basis of presentation Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Interest expense Interest Expense Research and Manufacturing Contract Costs and Accruals Research and Manufacturing Contract Costs and Accruals [Policy Text Block] Disclosure of accounting policy for research and manufacturing contract costs and accruals. Unrealized losses on investments, net of tax of $0 OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Operating lease assets Deferred Tax Liabilities, Leasing Arrangements Remeasurement of operating lease liabilities and right-of-use assets due to lease modification Proceeds From Stock Options Exercised In Other Current Assets Amount of cash inflow from exercise of option in other current assets under share-based payment arrangement. Vesting of restricted stock units (in shares) Restricted stock units vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Total number of shares of common stock authorized to issue (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Lease asset derecognized upon lease cancellation Lease Asset Derecognized Upon Lease Cancellation Amount of decrease in right-of-use asset upon cancellation of lease. Total deferred tax liabilities Deferred Tax Liabilities, Gross Schedule of reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Restructuring Reserve by Type of Cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Deferred Financing Costs Deferred Financing Costs [policy Text Block] Disclosure of accounting policy for deferred financing costs. Increase in gross deferred tax assets, before valuation allowance "Deferred Tax Asset, Increase (Decrease), Amount " The amount of increase (decrease) in gross deferred tax assets, before valuation allowance. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentrations of Credit Risk and of Significant Suppliers Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Other Accrued Liabilities, Current City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Loan Agreement Loan Agreement [Member] Loan Agreement Commitments and Contingencies Other Commitments [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Patent Costs Patent Costs [Policy Text Block] Disclosure of accounting policy for patent costs. Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from underwritten public offering of common stock, net of commissions and underwriting discounts Net proceeds after deducting underwriting discounts and commissions Proceeds from Issuance Initial Public Offering Net Income (Loss) per Share Earnings Per Share, Policy [Policy Text Block] Supplemental disclosure of non-cash investing and financing information: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted average grant-date fair value (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Other long-term liabilities Other Liabilities, Noncurrent Disposal Group Classification [Domain] Disposal Group Classification [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Construction-in-progress Asset under Construction [Member] Research and development expenses Research and Development Expense [Member] Schedule of calculation of basic and diluted net loss per share attributable to common stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Lease assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Restructuring and related cost, number of positions eliminated, period percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Accrued manufacturing facility expenses Accrued Manufacturing Facility Expenses Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing facility expenses. EX-101.PRE 6 ruby-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-21.1 7 ruby-20221231x10kex211.htm EX-21.1 Document

EXHIBIT 21.1

SUBSIDIARIES

SubsidiaryJurisdiction of Incorporation
Rubius Therapeutics Securities CorporationMassachusetts




 EX-31.1 8 ruby-20221231x10kex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO SECURITIES AND EXCHANGE ACT OF 1934
RULE 13A-14 AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

CERTIFICATION
I, Dannielle Appelhans, certify that:
1.I have reviewed this Annual Report on Form 10-K of Rubius Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 27, 2023
By:/s/ Dannielle Appelhans
  Dannielle Appelhans
  Chief Executive Officer and President
(Principal Executive Officer)


 EX-31.2 9 ruby-20221231x10kex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO SECURITIES AND EXCHANGE ACT OF 1934
RULE 13A-14 AS ADOPTED PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

CERTIFICATION
I, Dannielle Appelhans, certify that:
1.I have reviewed this Annual Report on Form 10-K of Rubius Therapeutics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: February 27, 2023
By:/s/ Dannielle Appelhans
  Dannielle Appelhans
  Chief Executive Officer and President
(Principal Financial Officer)


 EX-32.1 10 ruby-20221231x10kex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Rubius Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Dannielle Appelhans, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 27, 2023
By:/s/ Dannielle Appelhans
  Dannielle Appelhans
  Chief Executive Officer and President
(Principal Executive Officer and Principal Financial Officer)


 GRAPHIC 11 ruby-20221231_g1.jpg begin 644 ruby-20221231_g1.jpg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ⅅ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htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Jan. 31, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38586    
Entity Registrant Name RUBIUS THERAPEUTICS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 46-2688109    
Entity Address, Address Line One c/o Verdolino & Lowey, P.C.    
Entity Address, Address Line Two 124 Washington Street,    
Entity Address, Address Line Three Suite 101    
Entity Address, City or Town Foxborough,    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02035    
City Area Code (508)    
Local Phone Number 543-1720    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol RUBY    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 28.4
Entity Common Stock, Shares Outstanding   90,397,732  
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001709401    
Amendment Flag false    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Boston, Massachusetts
Auditor Firm ID 238
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 14,865 $ 225,848
Assets held for sale 4,070 0
Prepaid expenses and other current assets 1,260 3,975
Total current assets 20,195 229,823
Operating lease, right-of-use-asset 2,679 35,095
Property, plant and equipment, net 146 51,530
Restricted cash 50 1,573
Total assets 23,070 318,021
Current liabilities:    
Accounts payable 1,232 11,572
Accrued expenses and other current liabilities 5,607 14,072
Operating lease liabilities 1,100 9,015
Total current liabilities 7,939 34,659
Long-term debt, net of discount 0 76,154
Other long-term liabilities 0 135
Operating lease liabilities, net of current portion 0 28,291
Total liabilities 7,939 139,239
Commitments and contingencies (see Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued or outstanding at December 31, 2022 and December 31, 2021 0 0
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,387,732 and 90,063,770 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively 90 90
Additional paid-in capital 871,725 855,710
Accumulated deficit (856,684) (677,018)
Total stockholders' equity 15,131 178,782
Total liabilities and stockholders' equity $ 23,070 $ 318,021
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, share authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, share authorized (in shares) 300,000,000 150,000,000
Common stock, shares issued (in shares) 90,387,732 90,063,770
Common stock, shares outstanding (in shares) 90,387,732 90,063,770
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Revenue $ 0 $ 0 $ 0
Operating expenses:      
Research and development 96,414 141,587 116,107
General and administrative 30,835 53,029 50,341
Restructuring and impairment charges 51,197 0 0
Total operating expenses 178,446 194,616 166,448
Loss from operations (178,446) (194,616) (166,448)
Other income (expense):      
Interest income 819 91 1,760
Interest expense (3,863) (6,434) (4,185)
Other income, net 1,824 4,412 1,142
Total other income (expense), net (1,220) (1,931) (1,283)
Net loss $ (179,666) $ (196,547) $ (167,731)
Net loss per share, diluted (in dollars per share) $ (1.99) $ (2.23) $ (2.08)
Net loss per share, basic (in dollars per share) $ (1.99) $ (2.23) $ (2.08)
Weighted average number of shares outstanding, diluted (in shares) 90,305,463 87,950,440 80,624,608
Weighted average number of shares outstanding, basic (in shares) 90,305,463 87,950,440 80,624,608
Comprehensive loss:      
Net loss $ (179,666) $ (196,547) $ (167,731)
Other comprehensive income (loss):      
Unrealized losses on investments, net of tax of $0 0 (4) (71)
Comprehensive loss $ (179,666) $ (196,551) $ (167,802)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Unrealized gains (losses) on investments, tax $ 0 $ 0 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Balances at beginning of period (in shares) at Dec. 31, 2019   80,016,245      
Balances at beginning of period at Dec. 31, 2019 $ 274,213 $ 80 $ 586,798 $ 75 $ (312,740)
Issuance of common stock upon exercise of stock options (in shares)   1,037,406      
Issuance of common stock upon exercise of stock options 1,484 $ 1 1,483    
Stock-based compensation expense 33,665   33,665    
Unrealized losses on investments (71)     (71)  
Issuance of common stock under employee stock purchase plan (in shares)   0      
Net loss (167,731)       (167,731)
Balances at end of period (in shares) at Dec. 31, 2020   81,053,651      
Balances at end of period at Dec. 31, 2020 141,560 $ 81 621,946 4 (480,471)
Issuance of common stock upon exercise of stock options (in shares)   1,933,523      
Issuance of common stock upon exercise of stock options 10,685 $ 2 10,683    
Stock-based compensation expense 35,610   35,610    
Vesting of restricted stock units (in shares)   153,600      
Vesting of restricted stock units 0        
Unrealized losses on investments (4)     (4)  
Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs (in shares)   6,896,552      
Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs of $800 187,200 $ 7 187,193    
Issuance of common stock under employee stock purchase plan (in shares)   26,444      
Issuance of common stock under employee stock purchase plan 278   278    
Net loss (196,547)       (196,547)
Balances at end of period (in shares) at Dec. 31, 2021   90,063,770      
Balances at end of period at Dec. 31, 2021 178,782 $ 90 855,710 0 (677,018)
Issuance of common stock upon exercise of stock options (in shares)   42,228      
Issuance of common stock upon exercise of stock options 98   98    
Stock-based compensation expense 15,783   15,783    
Vesting of restricted stock units (in shares)   137,828      
Vesting of restricted stock units 0        
Issuance of common stock under employee stock purchase plan (in shares)   143,906      
Issuance of common stock under employee stock purchase plan 134   134    
Net loss (179,666)       (179,666)
Balances at end of period (in shares) at Dec. 31, 2022   90,387,732      
Balances at end of period at Dec. 31, 2022 $ 15,131 $ 90 $ 871,725 $ 0 $ (856,684)
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Statement of Stockholders' Equity [Abstract]  
Net of commissions, underwriting discounts and offering costs $ 800
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (179,666) $ (196,547) $ (167,731)
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation expense 15,783 35,610 33,665
Depreciation and amortization expense 6,254 7,723 5,691
Amortization (accretion) of premium (discount) on investments (305) 118 266
Non-cash interest expense 604 1,280 349
Impairment charges 25,841 0 0
Gain on debt extinguishment (1,128) 0 0
Changes in operating assets and liabilities:      
Prepaid expenses and other current assets 2,738 1,249 992
Operating lease, right-of-use-asset 7,002 5,352 5,539
Other assets 0 5 46
Accounts payable (9,811) 5,858 (1,369)
Accrued expenses and other current liabilities (6,615) (816) (96)
Other long-term liabilities (135) (553) 283
Operating lease liabilities (10,704) (4,401) (5,283)
Net cash used in operating activities (150,142) (145,122) (127,648)
Cash flows from investing activities:      
Purchases of property, plant and equipment (5,304) (3,649) (5,497)
Proceeds from sale of property, plant and equipment 17,943 0 0
Purchases of investments (83,626) 0 (122,671)
Sales and maturities of investments 83,931 85,000 228,600
Net cash provided by investing activities 12,944 81,351 100,432
Cash flows from financing activities:      
Proceeds from underwritten public offering of common stock, net of commissions and underwriting discounts 0 188,000 0
Payments of offering costs 0 (360) 0
Payments of debt issuance costs 0 (150) 0
Proceeds from borrowings under loan and security agreement 0 0 25,000
Payment of long-term debt (75,702) 0 0
Proceeds from issuance of common stock upon exercise of stock options and under employee stock purchase plan 232 10,963 1,484
Net cash provided by (used in) financing activities (75,470) 198,453 26,484
Net increase (decrease) in cash, cash equivalents and restricted cash (212,668) 134,682 (732)
Cash, cash equivalents and restricted cash at beginning of period 227,583 92,901 93,633
Cash, cash equivalents and restricted cash at end of period 14,915 227,583 92,901
Supplemental cash flow information:      
Cash paid for interest 4,387 5,092 3,822
Cash paid for leases 11,565 7,364 8,486
Supplemental disclosure of non-cash investing and financing information:      
Purchases of property, plant and equipment included in accounts payable or accrued expenses 0 1,989 317
Offering costs included in accounts payable and accrued expenses 0 35 0
Lease assets obtained in exchange for new operating lease liabilities 0 0 496
Lease asset derecognized upon lease cancellation 78 0 982
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification $ 25,502 $ 0 $ 0
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of the Business and Basis of Presentation
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation Nature of the Business and Basis of Presentation
Rubius Therapeutics, Inc. (“Rubius” or the “Company”) is a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines, called Red Cell Therapeutics, for the treatment of cancer and autoimmune diseases. Rubius was incorporated in April 2013 as VL26, Inc. under the laws of the State of Delaware. In January 2015, the Company changed its name to Rubius Therapeutics, Inc.
On July 27, 2022, the Company received a deficiency letter from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price for its common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. In February 2023, the Company was notified by the Staff that it would be delisted at the opening of business on February 15, 2023 unless the Company were to timely request a hearing before a Nasdaq Hearings Panel, or the Panel, to address the deficiencies and present a plan to regain compliance. On February 13, 2023, the Company timely requested a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel, unless the Company determine to withdraw its hearing request. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process.
On September 13, 2022, the Company's Board of Directors approved certain operational and organizational steps that the Company undertook in connection with a new strategic reorganization plan and related cost-saving measures (collectively, the “Reorganization Plan”). The Company discontinued its ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructured the organization to support advancing drug candidates based on its next generation platform. Under the Reorganization Plan, the Company reduced its overall workforce by approximately 75%, primarily consisting of employees who were focused on clinical development of RTX-240 and RTX-224, with the remainder coming from its manufacturing and general and administrative functions.
On November 2, 2022, in light of the Company’s financial condition, including the repayment and termination of its $75.0 million credit facility with SLR Investment Corp., and the early stage of its programs, its Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of its assets, and to significantly and immediately reduce its operations (the “Strategic Plan”). In connection with the Strategic Plan, the Company terminated 42 of its employees (representing 82% of its then-current employee base), leaving a core team of individuals to lead the strategic review process.
On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. In addition, the Company is subject to uncertainty regarding the performance and safety of its product candidates in humans. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. It is uncertain when, if ever, the Company will realize significant revenue from product sales.
Under Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued.
As of December 31, 2022, the Company had an accumulated deficit of $856.7 million, and cash and cash equivalents of $14.9 million. For the year ended December 31, 2022, the Company incurred a net loss of $179.7 million and used $150.1 million of cash in operations. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company’s accumulated deficit, history of losses and future expected
losses met the ASC 205-40 standard for raising substantial doubt about the Company’s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least twelve months from the filing of its Annual Report on Form 10-K.

Through the implementation of its Strategic Plan, the Company’s primary goal was to successfully complete a review of strategic alternatives and consummate a transaction or series of transactions to realize value for the Company’s platform and programs. On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company. As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Concentrations of Credit Risk and of Significant Suppliers
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalents as of December 31, 2022 consisted of cash, money market accounts and U.S. government money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
Deferred Offering Costs
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
Deferred Financing Costs
The Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term.
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Restricted Cash
As of December 31, 2021, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2021.
Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $14.9 million, $227.6 million and $92.9 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $0.1 million, $1.7 million and $1.7 million was restricted cash for each year, respectively.
Property, Plant and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
Estimated useful life
Computer equipment3 years
Laboratory equipment5 years
Furniture and fixtures7 years
Manufacturing equipment10 years
Manufacturing facility30 years
Leasehold improvements
Shorter of life of lease or 10 years
Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.
Impairment of Long-Lived Assets
Long-lived assets consist of property, plant and equipment and operating lease, right-of-use asset. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.
Fair Value Measurements
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial
assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1—Quoted prices in active markets for identical assets or liabilities.
•Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
Investments
The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.
The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.
Assets Held for Sale
The Company classifies its long-lived assets to be sold as held for sale in the period (i) the Company has approved and committed to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value, less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset until the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale.
Leases
At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option.

For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain
adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.

Segment Information
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company’s tangible assets are held in the United States.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.
Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.
Research and Manufacturing Contract Costs and Accruals
The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent Costs
All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-Based Compensation
The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited.
For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.
The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Comprehensive Loss
Comprehensive loss includes net loss, as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2020, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments. For the year ended December 31, 2022 there was no difference between the Company’s net loss and comprehensive loss.

Net Income (Loss) per Share
Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.

Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.
Recently Adopted Accounting Pronouncements
ASU No. 2016-13, Financial Instruments—Credit Losses
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.
ASU No. 2019-12, Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company adopted this standard as of January 1, 2021 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Investments and Fair Value of Financial Assets and Liabilities
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Investments and Fair Value of Financial Assets and Liabilities Investments and Fair Value of Financial Assets and Liabilities
The Company had no investments as of December 31, 2022 or December 31, 2021.
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$1,010 $— $— $1,010 
$1,010 $— $— $1,010 

December 31, 2021
Level 1 Level 2 Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$217,009 $— $— $217,009 
 $217,009 $— $— $217,009 

U.S. government money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no changes to the valuation methods during the year ended December 31, 2022. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level 1, Level 2 or Level 3 during the year ended December 31, 2022 and 2021, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Property, Plant and Equipment, Net
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]  
Property, Plant and Equipment, Net and Assets Held for Sale Property, Plant and Equipment, Net and Assets Held for Sale
Property, plant and equipment, net and assets held for sale consisted of the following, after the effects of impairment charges and held-for-sale reclassifications (in thousands):
December 31,
20222021
Land$— $1,300 
Manufacturing facility— 33,203 
Manufacturing equipment— 8,831 
Laboratory equipment— 17,501 
Computer equipment— 2,645 
Furniture and fixtures— 1,281 
Leasehold improvements570 444 
Construction-in-progress— 4,181 
570 69,386 
Less: Accumulated depreciation and amortization(424)(17,856)
$146 $51,530 
Assets held for sale$4,070 $— 
During the year ended December 31, 2022, the Company recorded impairment charges of $25.8 million due to its Reorganization Plan (Note 13). Depreciation and amortization expense was $6.3 million, $7.7 million and $5.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
December 31,
20222021
Accrued employee termination benefits$1,401 $— 
Accrued contract termination costs1,387 — 
Accrued general and administrative expenses521 889 
Accrued employee compensation and benefits— 7,451 
Accrued external research and development expenses— 2,713 
Accrued manufacturing facility expenses— 2,349 
Deposit received for assets held for sale2,125 — 
Other173 670 
$5,607 $14,072 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Debt
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Debt Debt
Long-term debt consisted of the following (in thousands):
December 31, 2022December 31, 2021
Principal amount of long‑term debt$— $75,000 
Less: Current portion of long‑term debt— — 
Long‑term debt, net of current portion— 75,000 
Accrued final interest payment— 1,654 
Debt discount— (500)
Long‑term debt, net of discount and current portion$— $76,154 

Loan Agreement
On December 21, 2018 (the “Closing Date”), the Company entered into a loan and security agreement(the "Original Loan Agreement," and, as amended, the “Loan Agreement”) with Solar Capital Ltd., now SLR Investment Corp. ("SLR"), as collateral agent for the lenders party thereto for an aggregate principal amount of $75.0 million. The aggregate principal amount will be funded in three tranches of term loans of $25.0 million each. On the Closing Date, the Company made an initial borrowing of $25.0 million. In June 2019, the Company made a second borrowing of $25.0 million and in June 2020, the Company made a third and final borrowing of $25.0 million.
On June 22, 2021 (the “Amendment Closing Date”), the Company entered into an amendment (the “Amendment”) to the Original Loan Agreement. Pursuant to the Amendment, the Company and its lenders agreed to extend the interest-only period applicable to borrowings under the Loan Agreement from December 21, 2021 until July 1, 2024 and the final maturity date from December 21, 2023 until June 1, 2026. An additional tranche in the amount of $35.0 million is available at the request of the Company prior to the final maturity date, to be provided at the sole discretion of the lenders. The Amendment increases the LIBOR interest rate floor from 0.00% to 2.10%. Interest on the outstanding loan balance will accrue at a rate of 5.50%, plus the greater of 2.10% or the one-month U.S. LIBOR rate. Certain back-end fees are due to the lender at the time of final repayment based on the total funded term loans. The Company accrues the back-end fees that will be due at final repayment to outstanding debt by charges to interest expense over the term of the loans using the effective interest method. The term loans are subject to a prepayment fee of 1.00% if prepayment occurs within the first year subsequent to the Amendment Closing Date, 0.50% in the second year and 0.25% in the third year through final maturity date.
As the terms of the Amendment were not substantially different than the terms of the Original Loan Agreement, the Amendment was accounted for as a debt modification. In conjunction with the Amendment, the Company incurred issuance costs of $0.2 million payable to the lenders, which were recorded as an additional debt discount and will be amortized to interest expense over the remaining term, together with unamortized original issuance costs as of the Amendment Closing Date, using the effective interest method.
On October 13, 2022, the Company entered into a payoff letter with SLR, under which the Company voluntarily prepaid SLR approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under the Loan Agreement. The payoff letter also provided for the termination of all commitments and obligations under the Loan Agreement and release of all liens held by SLR on the Company’s assets. The Loan Agreement was extinguished and accounted for as a troubled debt restructuring as the Company was experiencing financial difficulty and SLR granted the Company a concession by forgiving certain contractually owed amounts. The Company recognized a gain on the extinguishment of the Loan Agreement of $1.1 million, which is recorded in interest expense on the consolidated statements of operations and comprehensive loss. As of December 31, 2022, the Company does not have any debt outstanding.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Equity
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Equity EquityEach share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.
On July 20, 2018, the Company filed a restated certificate of incorporation in the State of Delaware, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 160,000,000 shares, consisting of (i) 150,000,000 shares of common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon issuance. The shares of preferred stock are currently undesignated.
On August 1, 2019, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and SVB Leerink LLC (the “Sales Agents”), pursuant to which the Company was able to issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agents. As of December 31, 2022, no shares of common stock have been issued and sold pursuant to the Distribution Agreement, which expired in accordance with its terms on August 21, 2022, and the applicable registration statement is no longer effective.
On March 18, 2021, the Company completed the March 2021 Offering, pursuant to which it issued and sold 6,896,552 shares of common stock. The aggregate net proceeds received by the Company from the March 2021 Offering were $187.2 million, after deducting underwriting discounts and commissions and other offering costs.
On July 7, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which increased the number of shares of common stock that the Company has authority to issue from 150,000,000 to 300,000,000 shares. The number of shares of preferred stock authorized for issuance was not impacted by this amendment.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2018 Equity Incentive Plan
On July 6, 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Plan, which became effective on July 16, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2018 Plan is 5,708,931, which shall be cumulatively increased on January 1, 2019 and each January 1 thereafter by 4% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s board of directors or compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Plan. As of December 31, 2022, 9,666,433 shares remained available for issuance under the 2018 Plan. The number of authorized shares reserved for issuance under the 2018 Plan was increased by 3,615,509 shares effective as of January 1, 2023.
2018 Employee Stock Purchase Plan
On July 6, 2018, the Company’s board of directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”), which became effective on July 16, 2018. On December 15, 2022, the Company's board of directors voted to terminate the ESPP effective immediately.
The Company issued 143,906 and 26,444 shares of common stock under the ESPP during the years ended December 31, 2022 and December 31, 2021, respectively. The Company recorded $0.1 million and $0.1 million of stock-based compensation expense as a result of the ESPP for the year ended December 31, 2022 and December 31, 2021, respectively. There were no shares of common stock issued and no stock-based compensation expense recorded under the ESPP for the year ended December 31, 2020. Due to the plan termination, no further shares will be issued under to the ESPP.
Stock Option Valuation
Service-Based and Performance-Based Stock Options
The fair value of stock option grants with service-based and performance-based vesting conditions is estimated using the Black-Scholes option-pricing model. The Company estimates expected volatility based on the historical volatility of publicly traded peer companies. For options with service-based vesting conditions, the expected term of the Company’s
stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock-based awards granted to employees, directors, and non-employees:
Year ended December 31,
202220212020
Risk-free interest rate2.37 %0.81 %1.10 %
Expected volatility78.4 %77.4 %69.4 %
Expected dividend yield———
Expected term (in years)5.876.086.05

The following table summarizes the Company’s service-based and performance-based option activity since December 31, 2022:

Number of
shares		Weighted average exercise
price		Weighted average contractual termAggregate intrinsic
value
(in years)(in thousands)
Outstanding as of December 31, 202117,138,772$12.047.22$23,511
Granted4,104,4034.37  
Exercised(42,228)2.32  
Forfeited(7,105,039)10.31  
Outstanding as of December 31, 202214,095,908$10.713.55$6
Vested and expected to vest as of December 31, 202214,095,908$10.713.55$6
Options exercisable as of December 31, 202212,061,182$11.292.82$6
The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $0.1 million, $34.6 million and $5.7 million, respectively.
The weighted average grant-date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was $2.98 per share, $10.55 per share and $4.51 per share, respectively.
Market-Based Stock Options
The fair value of stock option grants with market-based vesting conditions is estimated using a Monte Carlo simulation model.

In October 2018, the Company granted to an executive officer an option to purchase 164,400 shares of common stock (“Option A”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the satisfaction of service-based vesting conditions, and an option to purchase 193,400 shares of common stock (“Option B”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the achievement of certain other performance-based vesting conditions. The Company used a Monte Carlo simulation model to estimate the grant-date fair value of the awards. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility based on a combination of the Company’s historical stock volatility since its July 2018 IPO and the historical volatility of a publicly traded set of peer companies and the estimated period to achievement of the market condition. Stock-based compensation expense for Option A is being recognized using the graded-vesting method over the longer of the derived service period from the market condition or the explicit service period required to be completed for each vesting tranche. Stock-based compensation expense for Option B is being recognized using the graded-vesting method over the longer of
the derived service period from the market condition or the estimated achievement of performance-based conditions. For Option B, stock-based compensation expense is recognized when the achievement of each performance-based vesting condition becomes probable regardless of whether the market condition has been achieved. The aggregate grant date fair value of these options was $4.3 million. During the years ended December 31, 2022, 2021 and 2020 the Company recorded stock-based compensation expense on Option A of $0.1 million, $0.2 million and $0.6 million, respectively. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense on Option B of $1.1 million and $1.1 million, respectively, as a performance-based vesting condition was determined to be probable during each year. No stock-based compensation expense on Option B was recorded during the year ended December 31, 2022.
The Company did not grant market-based stock options during the years ended December 31, 2022, 2021 and 2020. During the years ended December 31, 2022, 2021 and 2020, none of the outstanding stock options with market-based vesting conditions were exercised, forfeited or vested and they had no intrinsic value at December 31, 2022.
Restricted Stock Units
The Company has also granted restricted stock units to its employees. During the years ended December 31, 2022 and 2021, the Company granted restricted stock units to employees that were subject to time-based vesting conditions that lapse over four years and three years from the date of grant. No restricted stock units were granted during the year ended December 31, 2020. Restricted stock units with time-based vesting conditions are valued on the grant date using the grant date market price of the underlying shares. The following table summarizes the Company’s restricted stock unit activity since December 31, 2022:

SharesWeighted average
grant-date
fair value
Unvested restricted common stock as of December 31, 2021794,244$15.346
Issued906,8154.880
Vested(137,828)12.522
Forfeited(1,130,028)9.446
Unvested restricted common stock as of December 31, 2022433,203$9.728

Stock-Based Compensation
The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):
Year ended December 31,
202220212020
Research and development expenses$6,863 $12,338 $8,023 
General and administrative expenses8,920 23,272 25,642 
$15,783 $35,610 $33,665 

As of December 31, 2022, total unrecognized compensation cost related to unvested stock-based awards was $6.8 million, which is expected to be recognized over a weighted average period of 2.2 years.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
During the years ended December 31, 2022, 2021 and 2020, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.
All of the Company’s operating losses since inception have been generated in the United States.
A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:
Year ended
December 31,
20222021
Federal statutory income tax rate(21.0)%(21.0)%
State taxes, net of federal benefit(6.0)(6.2)
Federal and state research and development tax credits(5.3)(6.4)
Stock‑based compensation expense0.5 (1.6)
Section 162(m) compensation deduction limitation0.1 1.6 
Other0.1 (0.4)
Increase in deferred tax asset valuation allowance31.6 34.0 
Effective income tax rate— %— %

Net deferred tax assets consisted of the following (in thousands):

December 31,
20222021
Deferred tax assets:
Net operating loss carryforwards$159,691 $145,990 
Research and development tax credit carryforwards45,478 36,161 
Accrued expenses105 2,137 
Capitalized intellectual property costs2,051 1,746 
Capitalized research and development expense32,007 86 
Operating lease liabilities301 10,194 
Stock‑based compensation expense24,454 21,483 
Depreciation74 — 
Total deferred tax assets264,161 217,797 
Deferred tax liabilities:
Operating lease assets(732)(9,590)
Depreciation and other— (1,500)
Total deferred tax liabilities(732)(11,090)
Valuation allowance263,429 206,707 
Net deferred tax assets$— $— 
As of December 31, 2022, the Company had U.S. federal and state net operating loss (“NOL”) carryforwards of $584.8 million and $583.6 million, respectively, which may be available to offset future taxable income. The federal NOLs include $37.2 million which expire at various dates through 2037 and $547.6 million which carryforward indefinitely. The state NOLs expire at various dates through 2042. As of December 31, 2022, the Company also had U.S. federal and state research and development tax credit carryforwards of $29.5 million and $19.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2026, respectively. During the year ended December 31, 2022, deferred tax assets, before valuation allowance, increased by approximately $46.4 million mainly due to the operating loss incurred by the Company during that period and the capitalization of research and development expenses.
Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred
or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.
The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period.
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022, 2021 and 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):
Year ended December 31,
202220212020
Valuation allowance as of beginning of year$206,707$139,877$85,884
Decreases recorded as benefit to income tax provision———
Increases recorded to income tax provision56,72266,83053,993
Valuation allowance as of end of year$263,429$206,707$139,877

As of December 31, 2022 and 2021, the Company had no recorded amounts for unrecognized tax benefits. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations and comprehensive loss. The Company files income tax returns in the U.S., Massachusetts and Rhode Island, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present; however, carryforward attributes that were generated prior to January 1, 2016 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
License Agreement with the Whitehead Institute for Biomedical Research
The Company has a license agreement with the Whitehead Institute for Biomedical Research (“WIBR”), as amended, under which the Company has been granted an exclusive, sublicensable, nontransferable license under certain patent families related to the development of the Company’s red blood cell therapies (as amended, the “WIBR License”). The Company is obligated to pay WIBR annual license maintenance fees of less than $0.1 million, as well as patent-related costs, including legal fees, and low single-digit royalties based on annual net sales of licensed products and licensed services by the Company and its sublicensees. Based on the progress the Company makes in the advancement of products covered by the licensed patent rights, the Company is required to make aggregate milestone payments of up to $1.6 million upon the achievement of specified preclinical, clinical and regulatory milestones. In addition, the Company is required to pay to WIBR a percentage of the non-royalty payments that it receives from sublicensees of the patent rights licensed by WIBR. This percentage varies from low single-digit to low double-digit percentages and will be based upon the clinical stage of the product that is the subject of the sublicense. Royalties shall be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country.
The Company has the right to terminate the WIBR License in its entirety, on a patent-by-patent or country-by-country basis, at will upon three months’ notice to WIBR. WIBR may terminate the agreement upon breach of contract or in the event of the Company’s bankruptcy, liquidation, insolvency or cessation of business related to the license.
401(k) Plan
In January 2018, the Company established a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company makes matching contributions at a rate of 50% of each employee’s contribution up to a maximum employee contribution of 6% of eligible plan compensation. For the years ended December 31, 2022, 2021 and 2020, the Company made matching contributions of $0.9 million, $0.9 million and $0.8 million, respectively. In January 2023, the Company terminated the 401(k) Plan effective December 30, 2022.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.
Legal Proceedings
The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Leases
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Leases Leases
Operating Leases
During the year ended December 31, 2022, the Company leased office and laboratory facilities in Cambridge, Massachusetts under one noncancelable operating lease, which is subject to two expiration dates based on two distinct leased spaces, expiring in January 2027 and August 2028.
In January 2018, the Company entered into a lease for office and laboratory space in Cambridge, Massachusetts (the “Initial Space”). The lease term commenced on January 28, 2019 and was scheduled to expire eight years from the commencement date. The initial annual base rent is approximately $3.8 million, and such amounts increased during the initial term by 3% annually on the anniversary of the commencement date.
In November 2018, the Company entered into a lease amendment for office and laboratory space in the same building (the “Expansion Space”). The lease term for the Expansion Space commenced on August 8, 2019 and was scheduled to expire approximately nine years from the commencement date. The initial annual base rent for the Expansion Space was approximately $2.5 million and such amount increased by 3% annually on the anniversary of the commencement date. The Company was obligated to pay its portion of real estate taxes and costs related to the Expansion Space, including costs of operations, maintenance, repair, replacement and property management.
In December 2022, the Company entered into an Agreement for Termination of Lease (the “Lease Termination Agreement”) relating to its two distinct leased spaces for office and laboratory space in Cambridge, Massachusetts (the “Cambridge Facility”). Under the Lease Termination Agreement, the Company’s lease for the Cambridge Facility terminated on January 31, 2023. Under the terms of the Lease Termination Agreement, the Company paid the landlord a lease termination payment, inclusive of the full amount of a letter of credit that the landlord held under the lease and rent previously paid by the Company to the landlord for the month of December 2022, of approximately $5.9 million in the fourth quarter of the year ended December 31, 2022, and the Company paid the landlord a subsequent payment of $1.1 million in the first quarter of the year ending December 31, 2023.
The Lease Termination Agreement terminated the lease on January 31, 2023. As the lease termination was effective at a future date, the Company accounted for the change as a lease modification that shortened the lease term. Upon the modification, the Company decreased its operating lease, right-of-use asset by an amount equal to the adjustment of its operating lease liabilities.

The Company evaluated its vendor contracts to identify embedded leases, if any, and noted that an agreement with a contract manufacturing supplier constituted a lease under ASC 842 as the Company has the right to substantially all the economic benefits from the use of the asset and can direct the use of the asset. The Company entered into the agreement during the first quarter of 2019. The lease commenced during March 2019 and was scheduled to expire 22 months from commencement date with no stated option to extend the term. The lease was cancelled prior to expiration during the first quarter of 2020, resulting in derecognition of the lease assets and operating lease liabilities.

As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate based on information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and, therefore, has allocated all the contract consideration across lease components only. This may result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability for leases being greater than if the policy election was not applied. Assets under operating lease at December 31, 2022 were $2.7 million. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance.

As of December 31, 2022, minimum lease payments under the Company’s operating leases are as follows (in thousands):
Year ending December 31,
2023$1,100
2024—
2025—
2026—
2027—
Thereafter—
1,100
Less: imputed interest— 
$1,100
The Company has not entered any material financing leases as of December 31, 2022.
Lease Portfolio
The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):
Year ended December 31,
202220212020
Lease cost:
Operating lease cost$12,655 $8,173 $9,240 
Short-term lease cost— 41 24 
Variable lease cost3,058 3,723 1,916 
Sublease income— (719)(1,017)
Total lease cost$15,713 $11,218 $10,163 
Operating leases:
Operating lease, right-of-use-asset$2,679 $35,095 $40,447 
Operating lease liabilities$1,100 $9,015 $8,945 
Operating lease liabilities, net of current portion$— $28,291 $32,762 
Other information:
Weighted average remaining lease term - operating leases0.08 years5.80 years6.70 years
Weighted-average discount rate - operating leases— %7.60 %7.60 %
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss per Share
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Year ended December 31,
202220212020
Numerator:   
Net loss $(179,666)$(196,547)(167,731)
Denominator:
Weighted average common shares outstanding, basic and diluted90,305,46387,950,44080,624,608
Net loss per share, basic and diluted$(1.99)$(2.23)$(2.08)

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares from the periods in the table above, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Year ended December 31,
202220212020
Unvested restricted common stock433,203794,244252,000
Stock options to purchase common stock14,453,70817,496,57216,318,124
14,886,91118,290,81616,570,124
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Impairment Charges
 12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Restructuring and Impairment Charges Restructuring and Impairment Charges
The Company estimates that it will incur approximately $51.9 million in costs to implement the Reorganization Plan and the Strategic Plan, as described in Note 1. The actions associated with the Reorganization Plan and the Strategic Plan commenced in September 2022 and November 2022, respectively, and are expected to be substantially completed by February 28, 2023.
The Reorganization Plan and the Strategic Plan required management to evaluate matters related to involuntary termination benefits provided pursuant to a one-time benefit arrangement, contract termination costs and the impairment of long-lived assets in accordance with generally accepted accounting principles. The recognition of the Company’s liability for one-time termination benefits is based on contractual agreements and whether employees are required to render service until they are terminated in order to receive the termination benefits and, if so, whether the employee will be retained to render service beyond a minimum retention period. The Company’s contract termination costs represent costs to terminate a contract before the end of its term or costs that will continue to be incurred under a contract for its remaining term without economic benefit to the Company and is recognized at fair value when the contract is terminated or the Company ceases using the right conveyed by the contract. The impairment of long-lived assets is based on the fair value of the Company's long-lived asset group as determined by actual sale transactions.

As a result of these events, the Company incurred the following restructuring and impairment charges, which are recorded in the consolidated statements of operations and comprehensive loss (in thousands):

Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Employee termination benefits$12,929 $— $— 
Impairment of property, plant and equipment25,841 — — 
Contract termination costs12,427 — — 
$51,197 $— $— 

Employee Termination Benefits

Employees affected by the reduction in workforce under the Company's Reorganization Plan and Strategic Plan received involuntary termination benefits that are provided pursuant to a one-time benefit arrangement. For employees who were notified of their termination and have no requirements to provide future service, the Company recognized the liability for the termination benefits in full at fair value in the period in which they were incurred. For employees who are required to render services beyond a minimum retention period to receive their one-time termination benefits, the Company is recognizing the termination benefits ratably over their future service periods. The service periods for the Reorganization Plan began in September 2022 and ended at various dates through December 31, 2022. The service periods for the Strategic Plan began in November 2022 and ended at various dates through January 31, 2023. The Company will incur approximately $13.6 million of employee termination benefits expense to implement the Reorganization Plan and the Strategic Plan of which $12.9 million has been incurred in the year ended December 31, 2022.

The following table shows the liability related to employee termination benefits as of December 31, 2022:

Employee Termination Benefits
Accrued employee termination benefits beginning balance$— 
Employee termination benefits charges incurred during the period12,929 
Amounts paid or otherwise settled during the period(11,528)
Accrued employee termination benefits as of December 31, 2022$1,401 

Impairment of Property, Plant and Equipment

As a result of the Reorganization Plan, the Company determined that sufficient indicators existed to trigger the performance of an interim long-lived asset impairment analysis as of September 30, 2022. In the third quarter of 2022, the Company tested the recoverability of its asset group using entity-specific undiscounted cash flows. Based on these undiscounted cash flows, the Company concluded the undiscounted future cash flows expected to result from the use and eventual disposition of its long-lived assets were less than the carrying value of the asset group. Therefore, the Company measured the long-lived asset impairment as the amount by which the carrying value of the asset group exceeds its fair
value and recorded an impairment of $17.8 million. The loss was allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the loss allocated to an individual long-lived asset of the group did not reduce the carrying value of that asset below its fair value. The fair value of the asset group was determined from a third-party commercial real estate appraisal which represents a Level 3 fair value measurement.

Additionally, in conjunction with its Reorganization Plan, the Company committed to a plan to actively sell specific assets within its asset group, primarily its laboratory equipment and furniture and fixtures. The laboratory equipment and furniture and fixtures met all of the prescribed criteria required to classify it as held for sale. At December 31, 2022, $4.1 million of laboratory equipment and furniture and fixtures was classified as held for sale as current assets on the consolidated balance sheet as the disposal was expected to be consummated within one year of the balance sheet date and the Company does not expect to use the sale proceeds to reduce any long-term borrowings. The sale was completed by January 31, 2023.

In December 2022, the Company entered into a purchase and sale agreement for the sale of its manufacturing facility and certain related fixtures and personal property for an aggregate purchase price of $18.5 million. The purchase price was less than the carrying amount of the assets sold and the resulting impairment of $8.0 million was recorded within restructuring and impairment charges in the consolidated statements of operations and comprehensive loss.

For the year ended December 31, 2022, the Company recorded long-lived impairment charges of $25.8 million, which were recorded within restructuring and impairment charges on the consolidated statements of operations and comprehensive loss.

Contract Termination Costs

The discontinuation of the RTX-240 and RTX-224 clinical trials as part of the Reorganization Plan and of discovery activities and platform development as part of the Strategic Plan resulted in the termination of vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company. The Company recognized these contract termination costs in full in the period in which they no longer held an economic benefit to the Company. During the year ended December 31, 2022, the Company incurred $12.4 million of contract termination costs, which it estimates to be the full amount of such costs to be incurred related to the Reorganization Plan.

The following table shows the liability related to contract termination costs as of December 31, 2022:

Contract Termination Costs
Accrued contract termination costs beginning balance$— 
Contract termination costs incurred during the period12,427 
Amounts paid or otherwise settled during the period(11,040)
Accrued contract termination costs as of December 31, 2022$1,387 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events
14. Subsequent Events
On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Concentrations of Credit Risk and of Significant Suppliers
Concentrations of Credit Risk and of Significant Suppliers
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalents as of December 31, 2022 consisted of cash, money market accounts and U.S. government money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
Deferred Offering Costs Deferred Offering CostsThe Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
Deferred Financing Costs Deferred Financing CostsThe Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term.
Cash Equivalents
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Restricted Cash
Restricted Cash
As of December 31, 2021, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2021.
Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $14.9 million, $227.6 million and $92.9 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $0.1 million, $1.7 million and $1.7 million was restricted cash for each year, respectively.
Property, Plant and Equipment
Property, Plant and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
Estimated useful life
Computer equipment3 years
Laboratory equipment5 years
Furniture and fixtures7 years
Manufacturing equipment10 years
Manufacturing facility30 years
Leasehold improvements
Shorter of life of lease or 10 years
Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.
Impairment of Long-Lived Assets, Assets Held for Sale
Impairment of Long-Lived Assets
Long-lived assets consist of property, plant and equipment and operating lease, right-of-use asset. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows.
Assets Held for SaleThe Company classifies its long-lived assets to be sold as held for sale in the period (i) the Company has approved and committed to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value, less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset until the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale.
Fair Value Measurements
Fair Value Measurements
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial
assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1—Quoted prices in active markets for identical assets or liabilities.
•Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
Investments
Investments
The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.
The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.
Leases
Leases
At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option.

For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain
adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.
Segment Information
Segment Information
The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company’s tangible assets are held in the United States.
Research and Development Costs
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.
Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.
Research and Manufacturing Contract Costs and Accruals
Research and Manufacturing Contract Costs and Accruals
The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent Costs
Patent Costs
All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-Based Compensation
Stock-Based Compensation
The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited.
For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.
The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Comprehensive Loss Comprehensive LossComprehensive loss includes net loss, as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2020, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments. For the year ended December 31, 2022 there was no difference between the Company’s net loss and comprehensive loss.
Net Income (Loss) per Share
Net Income (Loss) per Share
Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2016-13, Financial Instruments—Credit Losses
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.
ASU No. 2019-12, Simplifying the Accounting for Income Taxes
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (ASC 740). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company adopted this standard as of January 1, 2021 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of property plant and equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:
Estimated useful life
Computer equipment3 years
Laboratory equipment5 years
Furniture and fixtures7 years
Manufacturing equipment10 years
Manufacturing facility30 years
Leasehold improvements
Shorter of life of lease or 10 years
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Investments and Fair Value of Financial Assets and Liabilities (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities measured at fair value on a recurring basis
The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):
December 31, 2022
Level 1Level 2Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$1,010 $— $— $1,010 
$1,010 $— $— $1,010 

December 31, 2021
Level 1 Level 2 Level 3Total
Assets:    
Cash equivalents:    
U.S. government money market funds$217,009 $— $— $217,009 
 $217,009 $— $— $217,009 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Property, Plant and Equipment, Net and Assets Held for Sale (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]  
Schedule of property, plant and equipment, Net
Property, plant and equipment, net and assets held for sale consisted of the following, after the effects of impairment charges and held-for-sale reclassifications (in thousands):
December 31,
20222021
Land$— $1,300 
Manufacturing facility— 33,203 
Manufacturing equipment— 8,831 
Laboratory equipment— 17,501 
Computer equipment— 2,645 
Furniture and fixtures— 1,281 
Leasehold improvements570 444 
Construction-in-progress— 4,181 
570 69,386 
Less: Accumulated depreciation and amortization(424)(17,856)
$146 $51,530 
Assets held for sale$4,070 $— 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Schedule of accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
December 31,
20222021
Accrued employee termination benefits$1,401 $— 
Accrued contract termination costs1,387 — 
Accrued general and administrative expenses521 889 
Accrued employee compensation and benefits— 7,451 
Accrued external research and development expenses— 2,713 
Accrued manufacturing facility expenses— 2,349 
Deposit received for assets held for sale2,125 — 
Other173 670 
$5,607 $14,072 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Debt (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of long term debt
Long-term debt consisted of the following (in thousands):
December 31, 2022December 31, 2021
Principal amount of long‑term debt$— $75,000 
Less: Current portion of long‑term debt— — 
Long‑term debt, net of current portion— 75,000 
Accrued final interest payment— 1,654 
Debt discount— (500)
Long‑term debt, net of discount and current portion$— $76,154 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of assumptions used to determine the fair value of stock awards granted
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock-based awards granted to employees, directors, and non-employees:
Year ended December 31,
202220212020
Risk-free interest rate2.37 %0.81 %1.10 %
Expected volatility78.4 %77.4 %69.4 %
Expected dividend yield———
Expected term (in years)5.876.086.05
Schedule of stock option activity
The following table summarizes the Company’s service-based and performance-based option activity since December 31, 2022:

Number of
shares		Weighted average exercise
price		Weighted average contractual termAggregate intrinsic
value
(in years)(in thousands)
Outstanding as of December 31, 202117,138,772$12.047.22$23,511
Granted4,104,4034.37  
Exercised(42,228)2.32  
Forfeited(7,105,039)10.31  
Outstanding as of December 31, 202214,095,908$10.713.55$6
Vested and expected to vest as of December 31, 202214,095,908$10.713.55$6
Options exercisable as of December 31, 202212,061,182$11.292.82$6
Schedule of restricted stock unit activity The following table summarizes the Company’s restricted stock unit activity since December 31, 2022:
SharesWeighted average
grant-date
fair value
Unvested restricted common stock as of December 31, 2021794,244$15.346
Issued906,8154.880
Vested(137,828)12.522
Forfeited(1,130,028)9.446
Unvested restricted common stock as of December 31, 2022433,203$9.728
Schedule of allocation of share based compensation
The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):
Year ended December 31,
202220212020
Research and development expenses$6,863 $12,338 $8,023 
General and administrative expenses8,920 23,272 25,642 
$15,783 $35,610 $33,665 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax
A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:
Year ended
December 31,
20222021
Federal statutory income tax rate(21.0)%(21.0)%
State taxes, net of federal benefit(6.0)(6.2)
Federal and state research and development tax credits(5.3)(6.4)
Stock‑based compensation expense0.5 (1.6)
Section 162(m) compensation deduction limitation0.1 1.6 
Other0.1 (0.4)
Increase in deferred tax asset valuation allowance31.6 34.0 
Effective income tax rate— %— %
Net deferred tax assets
Net deferred tax assets consisted of the following (in thousands):

December 31,
20222021
Deferred tax assets:
Net operating loss carryforwards$159,691 $145,990 
Research and development tax credit carryforwards45,478 36,161 
Accrued expenses105 2,137 
Capitalized intellectual property costs2,051 1,746 
Capitalized research and development expense32,007 86 
Operating lease liabilities301 10,194 
Stock‑based compensation expense24,454 21,483 
Depreciation74 — 
Total deferred tax assets264,161 217,797 
Deferred tax liabilities:
Operating lease assets(732)(9,590)
Depreciation and other— (1,500)
Total deferred tax liabilities(732)(11,090)
Valuation allowance263,429 206,707 
Net deferred tax assets$— $— 
Summary of changes in the valuation allowance for deferred tax assets
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022, 2021 and 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):
Year ended December 31,
202220212020
Valuation allowance as of beginning of year$206,707$139,877$85,884
Decreases recorded as benefit to income tax provision———
Increases recorded to income tax provision56,72266,83053,993
Valuation allowance as of end of year$263,429$206,707$139,877
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Schedule of minimum lease payments under the Company's operating leases
As of December 31, 2022, minimum lease payments under the Company’s operating leases are as follows (in thousands):
Year ending December 31,
2023$1,100
2024—
2025—
2026—
2027—
Thereafter—
1,100
Less: imputed interest— 
$1,100
Schedule of lease cost and lease liabilities for the Company's lease portfolio The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):
Year ended December 31,
202220212020
Lease cost:
Operating lease cost$12,655 $8,173 $9,240 
Short-term lease cost— 41 24 
Variable lease cost3,058 3,723 1,916 
Sublease income— (719)(1,017)
Total lease cost$15,713 $11,218 $10,163 
Operating leases:
Operating lease, right-of-use-asset$2,679 $35,095 $40,447 
Operating lease liabilities$1,100 $9,015 $8,945 
Operating lease liabilities, net of current portion$— $28,291 $32,762 
Other information:
Weighted average remaining lease term - operating leases0.08 years5.80 years6.70 years
Weighted-average discount rate - operating leases— %7.60 %7.60 %
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Schedule of calculation of basic and diluted net loss per share attributable to common stockholders
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Year ended December 31,
202220212020
Numerator:   
Net loss $(179,666)$(196,547)(167,731)
Denominator:
Weighted average common shares outstanding, basic and diluted90,305,46387,950,44080,624,608
Net loss per share, basic and diluted$(1.99)$(2.23)$(2.08)
Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding The Company excluded the following potential common shares from the periods in the table above, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Year ended December 31,
202220212020
Unvested restricted common stock433,203794,244252,000
Stock options to purchase common stock14,453,70817,496,57216,318,124
14,886,91118,290,81616,570,124
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Impairment Charges (Tables)
 12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
As a result of these events, the Company incurred the following restructuring and impairment charges, which are recorded in the consolidated statements of operations and comprehensive loss (in thousands):

Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Employee termination benefits$12,929 $— $— 
Impairment of property, plant and equipment25,841 — — 
Contract termination costs12,427 — — 
$51,197 $— $— 
Schedule of Restructuring Reserve by Type of Cost
The following table shows the liability related to employee termination benefits as of December 31, 2022:

Employee Termination Benefits
Accrued employee termination benefits beginning balance$— 
Employee termination benefits charges incurred during the period12,929 
Amounts paid or otherwise settled during the period(11,528)
Accrued employee termination benefits as of December 31, 2022$1,401 
The following table shows the liability related to contract termination costs as of December 31, 2022:

Contract Termination Costs
Accrued contract termination costs beginning balance$— 
Contract termination costs incurred during the period12,427 
Amounts paid or otherwise settled during the period(11,040)
Accrued contract termination costs as of December 31, 2022$1,387 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of the Business and Basis of Presentation (Details)
$ in Thousands
 12 Months Ended
Nov. 02, 2022
employee
Sep. 13, 2022
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 21, 2018
USD ($)
Nature of the business and basis of presentation            
Accumulated deficit     $ 856,684 $ 677,018    
Cash and cash equivalents     14,865 225,848    
Net loss     179,666 196,547 $ 167,731  
Net cash provided by (used in) operating activities     $ (150,142) $ (145,122) $ (127,648)  
2022 Strategic Restructuring Plan            
Nature of the business and basis of presentation            
Restructuring and related cost, number of positions eliminated, period percent 82.00% 75.00%        
Restructuring and related cost, number of positions eliminated | employee 42          
Loan Agreement            
Nature of the business and basis of presentation            
Maximum amount outstanding           $ 75,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]        
Restricted cash for the benefit of its leased properties   $ 1,700    
Restricted cash (non-current) $ 50 1,573    
Restricted cash, current   100    
Cash, cash equivalents and restricted cash 14,915 227,583 $ 92,901 $ 93,633
Restricted cash $ 100 $ 1,700 $ 1,700  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Estimated useful life (Details)
 12 Months Ended
Dec. 31, 2022
Computer equipment  
Property, Plant and Equipment, Net  
Estimated useful life 3 years
Laboratory equipment  
Property, Plant and Equipment, Net  
Estimated useful life 5 years
Furniture and fixtures  
Property, Plant and Equipment, Net  
Estimated useful life 7 years
Manufacturing equipment  
Property, Plant and Equipment, Net  
Estimated useful life 10 years
Manufacturing facility  
Property, Plant and Equipment, Net  
Estimated useful life 30 years
Leasehold improvements  
Property, Plant and Equipment, Net  
Estimated useful life 10 years
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Investments and Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Marketable securities    
Investments $ 0  
Recurring    
Assets:    
Assets 1,010 $ 217,009
Recurring | U.S. government money market funds    
Assets:    
Cash equivalents 1,010 217,009
Recurring | Level 1    
Assets:    
Assets 1,010 217,009
Recurring | Level 1 | U.S. government money market funds    
Assets:    
Cash equivalents 1,010 217,009
Recurring | Level 2    
Assets:    
Assets 0 0
Recurring | Level 2 | U.S. government money market funds    
Assets:    
Cash equivalents 0 0
Recurring | Level 3    
Assets:    
Assets 0 0
Recurring | Level 3 | U.S. government money market funds    
Assets:    
Cash equivalents $ 0 $ 0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Property, Plant and Equipment, Net and Assets Held for Sale (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   $ 570 $ 69,386  
Less: Accumulated depreciation and amortization   (424) (17,856)  
Property, plant and equipment, net   146 51,530  
Assets held for sale   4,070 0  
Depreciation and amortization expense   6,300 7,700 $ 5,700
2022 Restructuring Plan        
Property, Plant and Equipment, Net        
Impairment charges $ 17,800      
Impairment of property, plant and equipment | 2022 Restructuring Plan        
Property, Plant and Equipment, Net        
Impairment charges   25,800    
Land        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 1,300  
Manufacturing facility        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 33,203  
Manufacturing equipment        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 8,831  
Laboratory equipment        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 17,501  
Computer equipment        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 2,645  
Furniture and fixtures        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   0 1,281  
Leasehold improvements        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   570 444  
Construction-in-progress        
Property, Plant and Equipment, Net        
Property, plant and equipment, gross   $ 0 $ 4,181  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued employee termination benefits $ 1,401 $ 0
Accrued contract termination costs 1,387 0
Accrued general and administrative expenses 521 889
Accrued employee compensation and benefits 0 7,451
Accrued external research and development expenses 0 2,713
Accrued manufacturing facility expenses 0 2,349
Deposit received for assets held for sale 2,125 0
Other 173 670
Accrued expenses and other current liabilities $ 5,607 $ 14,072
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Debt - Current and Non current (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Principal amount of long‑term debt $ 0 $ 75,000
Less: Current portion of long‑term debt 0 0
Long‑term debt, net of current portion 0 75,000
Accrued final interest payment 0 1,654
Debt discount 0 (500)
Long‑term debt, net of discount and current portion $ 0 $ 76,154
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Debt - Narrative (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 13, 2022
USD ($)
Jun. 22, 2021
USD ($)
Dec. 21, 2018
USD ($)
tranche
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]                
Gain on debt extinguishment           $ 1,128 $ 0 $ 0
Loan Agreement                
Debt Instrument [Line Items]                
Maximum amount outstanding     $ 75,000          
Number of tranche | tranche     3          
Principal amount of each tranche of term loans     $ 25,000          
Borrowing     $ 25,000 $ 25,000 $ 25,000      
Principal amount   $ 35,000            
Interest rate (as a percent)   5.50%            
One-month LIBOR   one-month            
Prepayment fee in first year   1.00%            
Prepayment fee in second year   0.50%            
Prepayment fee in third year   0.25%            
Issuance costs   $ 200            
Repayments of long-term debt $ 75,700              
Gain on debt extinguishment           $ 1,100    
Minimum | Loan Agreement                
Debt Instrument [Line Items]                
Variable interest rate   2.10%            
One-month U.S. LIBOR | Loan Agreement                
Debt Instrument [Line Items]                
Variable interest rate   0.00%            
One-month U.S. LIBOR | Maximum | Loan Agreement                
Debt Instrument [Line Items]                
Variable interest rate   2.10%            
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Equity (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Mar. 18, 2021
USD ($)
shares
Dec. 31, 2022
USD ($)
vote
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
Jul. 07, 2022
shares
Jul. 06, 2022
shares
Aug. 01, 2019
USD ($)
Jul. 20, 2018
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]                
Number of votes per share | vote   1            
Shares authorized               160,000,000
Common stock, authorized (in shares)   300,000,000 150,000,000   300,000,000 150,000,000   150,000,000
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001         $ 0.001
Preferred stock, share authorized (in shares)   10,000,000 10,000,000         10,000,000
Preferred stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001         $ 0.001
Net proceeds after deducting underwriting discounts and commissions | $   $ 0 $ 188,000 $ 0        
At the market offering                
Subsidiary, Sale of Stock [Line Items]                
Aggregate offering price | $             $ 100,000  
Shares issued (in shares)   0            
Offering                
Subsidiary, Sale of Stock [Line Items]                
Shares issued (in shares) 6,896,552              
Net proceeds after deducting underwriting discounts and commissions | $ $ 187,200              
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Jan. 01, 2022
Oct. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jul. 06, 2018
Share-Based Compensation            
Stock-based compensation expense     $ 15,783 $ 35,610 $ 33,665  
Common stock            
Share-Based Compensation            
Issuance of common stock under employee stock purchase plan (in shares)     143,906 26,444 0  
Issuance of common stock upon exercise of stock options (in shares)     42,228 1,933,523 1,037,406  
Executive Officer            
Share-Based Compensation            
Number of options granted (in shares)   193,400        
Options exercise price (in dollars per share)   $ 16.43        
Stock-based compensation, fair value     $ 4,300      
Share-based Payment Arrangement, Option            
Share-Based Compensation            
Aggregate intrinsic value of stock options exercised     $ 100 $ 34,600 $ 5,700  
Weighted average grant-date fair value (per share)     $ 2.98 $ 10.55 $ 4.51  
Number of options granted (in shares)     4,104,403      
Options exercise price (in dollars per share)     $ 2.32      
Issuance of common stock upon exercise of stock options (in shares)     42,228      
Unrecognized compensation cost     $ 6,800      
Unrecognized compensation cost expected to be recognized over a weighted average period     2 years 2 months 12 days      
Market-Based Stock Options            
Share-Based Compensation            
Aggregate intrinsic value of stock options exercised     $ 0      
Number of options granted (in shares)     0 0 0  
Issuance of common stock upon exercise of stock options (in shares)     0 0 0  
Market based and service based vesting            
Share-Based Compensation            
Stock-based compensation expense     $ 100 $ 200 $ 600  
Number of options granted (in shares)   164,400        
Options exercise price (in dollars per share)   $ 16.43        
Performance-based vesting            
Share-Based Compensation            
Stock-based compensation expense     $ 1,100 1,100 $ 0  
Restricted Stock Units (RSUs)            
Share-Based Compensation            
Number of options granted (in shares)         0  
Minimum | Restricted Stock Units (RSUs)            
Share-Based Compensation            
Vesting period     3 years      
Maximum | Restricted Stock Units (RSUs)            
Share-Based Compensation            
Vesting period     4 years      
2018 Equity Incentive Plan            
Share-Based Compensation            
Total number of shares of common stock authorized to issue (in shares)           5,708,931
Annual increase of shares reserved for awards (as a percent)           4.00%
Number of shares remained available for future issuance (in shares)     9,666,433      
Increase in number of authorized shares reserved for issuance (in shares) 3,615,509          
2018 ESPP            
Share-Based Compensation            
Stock-based compensation expense     $ 100 $ 100 $ 0  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Granted to non-employees (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Risk-free interest rate 2.37% 0.81% 1.10%
Expected volatility 78.40% 77.40% 69.40%
Expected dividend yield 0.00% 0.00% 0.00%
Expected term (in years) 5 years 10 months 13 days 6 years 29 days 6 years 18 days
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Option activity (Details) - Share-based Payment Arrangement, Option - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Number of shares    
Outstanding at beginning of period (in shares) 17,138,772  
Granted (in shares) 4,104,403  
Exercised (in shares) (42,228)  
Forfeited (in shares) (7,105,039)  
Outstanding at end of period (in shares) 14,095,908 17,138,772
Vested and expected to vest (in shares) 14,095,908  
Options exercisable (in shares) 12,061,182  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Outstanding at the beginning (in dollars per share) $ 12.04  
Granted (in dollars per share) 4.37  
Exercised (in dollars per share) 2.32  
Forfeited (in dollars per share) 10.31  
Outstanding at the end (in dollars per share) 10.71 $ 12.04
Vested and expected to vest (in dollars per share) 10.71  
Options exercisable (in dollars per share $ 11.29  
Weighted average contractual term and aggregate intrinsic value    
Outstanding at the beginning (in years) 3 years 6 months 18 days 7 years 2 months 19 days
Outstanding at the end (in years) 3 years 6 months 18 days 7 years 2 months 19 days
Vested and expected to vest (in years) 3 years 6 months 18 days  
Options exercisable (in years) 2 years 9 months 25 days  
Outstanding at the beginning (in dollars) $ 23,511  
Outstanding at the end (in dollars) 6 $ 23,511
Vested and expected to vest (in dollars) 6  
Options exercisable (in dollars) $ 6  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Restricted Common Stock (Details) - Restricted Stock Units (RSUs)
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Number of shares  
Unvested restricted common stock beginning of period (in shares) | shares 794,244
Restricted stock units issued (in shares) | shares 906,815
Restricted stock units vested (in shares) | shares (137,828)
Restricted stock units forfeited (in shares) | shares (1,130,028)
Unvested restricted common stock end of period (in shares) | shares 433,203
Weighted Average Grant Date Fair Value  
Weighted average grant date fair value - beginning of the period (in dollars per share) | $ / shares $ 15.346
Weighted average grant date fair value- issued (in dollars per share) | $ / shares 4.880
Weighted average grant date fair value- vested (in dollars per share) | $ / shares 12.522
Weighted average grant date fair value- forfeited (in dollars per share) | $ / shares 9.446
Weighted average grant date fair value - end of the period (in dollars per share) | $ / shares $ 9.728
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Compensation expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Stock-based compensation expense      
Stock-based compensation expense $ 15,783 $ 35,610 $ 33,665
Research and development expenses      
Stock-based compensation expense      
Stock-based compensation expense 6,863 12,338 8,023
General and administrative expenses      
Stock-based compensation expense      
Stock-based compensation expense $ 8,920 $ 23,272 $ 25,642
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]      
Income tax benefits - operating losses incurred $ 0 $ 0 $ 0
Federal operating loss carryforwards 584,800    
State operating loss carryforwards 583,600    
Federal operating loss carryforwards subject to expiration 37,200    
Federal operating loss carryforwards subject to expiration indefinitely 547,600    
Research and development tax credit carryforwards 45,478 36,161  
Increase in gross deferred tax assets, before valuation allowance 46,400    
Uncertain tax positions 0 0  
Accrued interest or penalties 0 $ 0  
Domestic Tax Authority      
Operating Loss Carryforwards [Line Items]      
Research and development tax credit carryforwards 29,500    
State and Local Jurisdiction      
Operating Loss Carryforwards [Line Items]      
Research and development tax credit carryforwards $ 19,900    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - U S federal statutory income tax rate (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate (21.00%) (21.00%)
State taxes, net of federal benefit (6.00%) (6.20%)
Federal and state research and development tax credits (5.30%) (6.40%)
Stock‑based compensation expense 0.50% (1.60%)
Section 162(m) compensation deduction limitation 0.10% 1.60%
Other 0.10% (0.40%)
Increase in deferred tax asset valuation allowance 31.60% 34.00%
Effective income tax rate 0.00% 0.00%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Net deferred tax assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:        
Net operating loss carryforwards $ 159,691 $ 145,990    
Research and development tax credit carryforwards 45,478 36,161    
Accrued expenses 105 2,137    
Capitalized intellectual property costs 2,051 1,746    
Capitalized research and development expense 32,007 86    
Operating lease liabilities 301 10,194    
Stock‑based compensation expense 24,454 21,483    
Depreciation 74 0    
Total deferred tax assets 264,161 217,797    
Deferred tax liabilities:        
Operating lease assets (732) (9,590)    
Depreciation and other 0 (1,500)    
Total deferred tax liabilities (732) (11,090)    
Valuation allowance (263,429) (206,707) $ (139,877) $ (85,884)
Net deferred tax assets $ 0 $ 0    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Valuation allowance for deferred tax assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred Tax Asset, Valuation Allowance Activity [Roll Forward]      
Valuation allowance as of beginning of year $ 206,707 $ 139,877 $ 85,884
Decreases recorded as benefit to income tax provision 0 0 0
Increases recorded to income tax provision 56,722 66,830 53,993
Valuation allowance as of end of year $ 263,429 $ 206,707 $ 139,877
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details) - WIBR
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement  
Aggregate milestone payments $ 1.6
Maximum | License and Maintenance  
Collaborative Arrangements and Non-collaborative Arrangement  
License costs $ 0.1
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Defined Contribution Plan (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Jan. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies        
Employer matching contribution (as a percent) 50.00%      
Company matching contribution   $ 0.9 $ 0.9 $ 0.8
Maximum        
Commitments and Contingencies        
Percentage of employee's gross pay match 6.00%      
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2018
USD ($)
Jan. 31, 2018
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
lease
Dec. 31, 2022
USD ($)
date
property
lease
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Leases              
Number of leases | lease       1 1    
Number of expiration period | date         2    
Number of distinct leased spaces | property         2    
Lease term 9 years 8 years          
Initial annual base rent $ 2,500 $ 3,800          
Base rent incremental (as a percentage) 3.00% 3.00%          
Operating lease, termination payment       $ 5,900      
Operating lease, right-of-use-asset       $ 2,679 $ 2,679 $ 35,095 $ 40,447
Forecast              
Leases              
Operating lease, termination payment     $ 1,100        
Embedded lease contracts              
Leases              
Lease term       22 months 22 months    
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Minimum lease payments (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Minimum lease payments  
2023 $ 1,100
2024 0
2025 0
2026 0
2027 0
Thereafter 0
Payments due 1,100
Less: imputed interest 0
Operating lease liability $ 1,100
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Lease Portfolio (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Lease cost:      
Operating lease cost $ 12,655 $ 8,173 $ 9,240
Short-term lease cost 0 41 24
Variable lease cost 3,058 3,723 1,916
Sublease income 0 (719) (1,017)
Total lease cost 15,713 11,218 10,163
Operating leases:      
Operating lease, right-of-use-asset 2,679 35,095 40,447
Operating lease liabilities 1,100 9,015 8,945
Operating lease liabilities, net of current portion $ 0 $ 28,291 $ 32,762
Weighted average remaining lease term - operating leases 29 days 5 years 9 months 18 days 6 years 8 months 12 days
Weighted-average discount rate - operating leases 0.00% 7.60% 7.60%
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss per Share - Weighted Average Shares (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Numerator:      
Net loss $ (179,666) $ (196,547) $ (167,731)
Denominator:      
Weighted average number of shares outstanding, basic (in shares) 90,305,463 87,950,440 80,624,608
Weighted average number of shares outstanding, diluted (in shares) 90,305,463 87,950,440 80,624,608
Net loss per share, diluted (in dollars per share) $ (1.99) $ (2.23) $ (2.08)
Net loss per share, basic (in dollars per share) $ (1.99) $ (2.23) $ (2.08)
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Net Loss per Share - Antidilutive Securities (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Diluted net loss per share attributable to common stockholders      
Antidilutive securities excluded from computation of of diluted weighted average shares outstanding 14,886,911 18,290,816 16,570,124
Restricted Stock      
Diluted net loss per share attributable to common stockholders      
Antidilutive securities excluded from computation of of diluted weighted average shares outstanding 433,203 794,244 252,000
Equity Option      
Diluted net loss per share attributable to common stockholders      
Antidilutive securities excluded from computation of of diluted weighted average shares outstanding 14,453,708 17,496,572 16,318,124
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Impairment Charges - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]        
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring and impairment charges    
2022 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected cost   $ 51,900    
Disposal group, including discontinued operation, assets   4,100    
Impairment charges $ (17,800)      
Restructuring charges   51,197 $ 0 $ 0
2022 Restructuring Plan | Manufacturing facility | Disposal Group, Disposed of by Sale, Not Discontinued Operations        
Restructuring Cost and Reserve [Line Items]        
Disposal group, including discontinued operation, consideration   18,500    
Loss on disposal   8,000    
Employee termination benefits | 2022 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, cost incurred to date   13,600    
Restructuring charges   12,929 0 0
Impairment of property, plant and equipment | 2022 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Impairment charges   (25,800)    
Restructuring charges   25,841 0 0
Contract termination costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   12,400    
Contract termination costs | 2022 Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges   $ 12,427 $ 0 $ 0
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Impairment Charges - Summary of Charges (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
2022 Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges $ 51,197 $ 0 $ 0
Employee termination benefits | 2022 Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 12,929 0 0
Impairment of property, plant and equipment | 2022 Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 25,841 0 0
Contract termination costs      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges 12,400    
Contract termination costs | 2022 Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges $ 12,427 $ 0 $ 0
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring and Impairment Charges - Restructuring Reserve Activity (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Reserve [Roll Forward]      
Balance at end of period $ 1,387    
Contract termination costs      
Restructuring Reserve [Roll Forward]      
Restructuring charges 12,400    
2022 Restructuring Plan      
Restructuring Reserve [Roll Forward]      
Restructuring charges 51,197 $ 0 $ 0
2022 Restructuring Plan | Employee termination benefits      
Restructuring Reserve [Roll Forward]      
Balance at beginning of period 0    
Restructuring charges 12,929 0 0
Amounts paid or otherwise settled during the period (11,528)    
Balance at end of period 1,401 0  
2022 Restructuring Plan | Contract termination costs      
Restructuring Reserve [Roll Forward]      
Balance at beginning of period 0    
Restructuring charges 12,427 0 $ 0
Amounts paid or otherwise settled during the period $ (11,040)    
Balance at end of period   $ 0  
XML 74 ruby-20221231_htm.xml IDEA: XBRL DOCUMENT 0001709401 2022-01-01 2022-12-31 0001709401 2022-06-30 0001709401 2023-01-31 0001709401 2022-12-31 0001709401 us-gaap:DomesticCountryMember 2022-12-31 0001709401 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001709401 2021-12-31 0001709401 2021-01-01 2021-12-31 0001709401 2020-01-01 2020-12-31 0001709401 us-gaap:CommonStockMember 2019-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001709401 us-gaap:RetainedEarningsMember 2019-12-31 0001709401 2019-12-31 0001709401 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001709401 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001709401 us-gaap:CommonStockMember 2020-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001709401 us-gaap:RetainedEarningsMember 2020-12-31 0001709401 2020-12-31 0001709401 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001709401 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001709401 us-gaap:CommonStockMember 2021-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001709401 us-gaap:RetainedEarningsMember 2021-12-31 0001709401 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001709401 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001709401 us-gaap:CommonStockMember 2022-12-31 0001709401 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001709401 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001709401 us-gaap:RetainedEarningsMember 2022-12-31 0001709401 ruby:A2022StrategicRestructuringPlanMember 2022-09-13 2022-09-13 0001709401 ruby:LoanAgreementMember 2018-12-21 0001709401 ruby:A2022StrategicRestructuringPlanMember 2022-11-02 2022-11-02 0001709401 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001709401 ruby:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001709401 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001709401 ruby:ManufacturingEquipmentMember 2022-01-01 2022-12-31 0001709401 us-gaap:ManufacturingFacilityMember 2022-01-01 2022-12-31 0001709401 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001709401 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001709401 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001709401 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001709401 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001709401 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001709401 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001709401 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001709401 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001709401 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001709401 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001709401 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001709401 us-gaap:LandMember 2022-12-31 0001709401 us-gaap:LandMember 2021-12-31 0001709401 us-gaap:ManufacturingFacilityMember 2022-12-31 0001709401 us-gaap:ManufacturingFacilityMember 2021-12-31 0001709401 ruby:ManufacturingEquipmentMember 2022-12-31 0001709401 ruby:ManufacturingEquipmentMember 2021-12-31 0001709401 ruby:LaboratoryEquipmentMember 2022-12-31 0001709401 ruby:LaboratoryEquipmentMember 2021-12-31 0001709401 us-gaap:ComputerEquipmentMember 2022-12-31 0001709401 us-gaap:ComputerEquipmentMember 2021-12-31 0001709401 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001709401 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001709401 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001709401 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001709401 us-gaap:AssetUnderConstructionMember 2022-12-31 0001709401 us-gaap:AssetUnderConstructionMember 2021-12-31 0001709401 ruby:ImpairmentOfPropertyPlantAndEquipmentMember ruby:A2022RestructuringPlanMember 2022-01-01 2022-12-31 0001709401 ruby:LoanAgreementMember 2018-12-21 2018-12-21 0001709401 ruby:LoanAgreementMember 2019-06-01 2019-06-30 0001709401 ruby:LoanAgreementMember 2020-06-01 2020-06-30 0001709401 ruby:LoanAgreementMember 2021-06-22 0001709401 ruby:LoanAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-06-22 2021-06-22 0001709401 srt:MaximumMember ruby:LoanAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-06-22 2021-06-22 0001709401 srt:MinimumMember ruby:LoanAgreementMember 2021-06-22 2021-06-22 0001709401 ruby:LoanAgreementMember 2021-06-22 2021-06-22 0001709401 ruby:LoanAgreementMember 2022-10-13 2022-10-13 0001709401 ruby:LoanAgreementMember 2022-01-01 2022-12-31 0001709401 2018-07-20 0001709401 ruby:AtMarketOfferingMember 2019-08-01 0001709401 ruby:AtMarketOfferingMember 2022-01-01 2022-12-31 0001709401 ruby:OfferingMember 2021-03-18 2021-03-18 0001709401 2022-07-06 0001709401 2022-07-07 0001709401 ruby:EquityIncentivePlan2018Member 2018-07-06 0001709401 ruby:EquityIncentivePlan2018Member 2022-12-31 0001709401 ruby:EquityIncentivePlan2018Member 2022-01-01 2022-01-01 0001709401 ruby:A2018ESPPMember 2022-01-01 2022-12-31 0001709401 ruby:A2018ESPPMember 2021-01-01 2021-12-31 0001709401 ruby:A2018ESPPMember 2020-01-01 2020-12-31 0001709401 us-gaap:EmployeeStockOptionMember 2021-12-31 0001709401 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001709401 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001709401 us-gaap:EmployeeStockOptionMember 2022-12-31 0001709401 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001709401 ruby:MarketBasedAndServiceBasedVestingMember 2018-10-01 2018-10-31 0001709401 srt:ExecutiveOfficerMember 2018-10-01 2018-10-31 0001709401 srt:ExecutiveOfficerMember 2022-12-31 0001709401 ruby:MarketBasedAndServiceBasedVestingMember 2022-01-01 2022-12-31 0001709401 ruby:MarketBasedAndServiceBasedVestingMember 2021-01-01 2021-12-31 0001709401 ruby:MarketBasedAndServiceBasedVestingMember 2020-01-01 2020-12-31 0001709401 ruby:VestingBasedOnPerformanceMember 2022-01-01 2022-12-31 0001709401 ruby:VestingBasedOnPerformanceMember 2021-01-01 2021-12-31 0001709401 ruby:VestingBasedOnPerformanceMember 2020-01-01 2020-12-31 0001709401 ruby:MarketBasedStockOptionsMember 2021-01-01 2021-12-31 0001709401 ruby:MarketBasedStockOptionsMember 2020-01-01 2020-12-31 0001709401 ruby:MarketBasedStockOptionsMember 2022-01-01 2022-12-31 0001709401 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001709401 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001709401 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001709401 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001709401 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001709401 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001709401 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001709401 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001709401 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001709401 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001709401 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001709401 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001709401 ruby:WhiteheadInstituteForBiomedicalResearchMember us-gaap:LicenseAndMaintenanceMember srt:MaximumMember 2022-01-01 2022-12-31 0001709401 ruby:WhiteheadInstituteForBiomedicalResearchMember 2022-01-01 2022-12-31 0001709401 2018-01-01 2018-01-31 0001709401 srt:MaximumMember 2018-01-01 2018-01-31 0001709401 2018-01-31 0001709401 2018-11-30 0001709401 2018-11-01 2018-11-30 0001709401 2022-10-01 2022-12-31 0001709401 srt:ScenarioForecastMember 2023-01-01 2023-03-31 0001709401 ruby:EmbeddedLeaseContractsMember 2022-12-31 0001709401 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001709401 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001709401 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001709401 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001709401 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001709401 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001709401 ruby:A2022RestructuringPlanMember 2022-12-31 0001709401 us-gaap:EmployeeSeveranceMember ruby:A2022RestructuringPlanMember 2022-01-01 2022-12-31 0001709401 us-gaap:EmployeeSeveranceMember ruby:A2022RestructuringPlanMember 2021-01-01 2021-12-31 0001709401 us-gaap:EmployeeSeveranceMember ruby:A2022RestructuringPlanMember 2020-01-01 2020-12-31 0001709401 ruby:ImpairmentOfPropertyPlantAndEquipmentMember ruby:A2022RestructuringPlanMember 2021-01-01 2021-12-31 0001709401 ruby:ImpairmentOfPropertyPlantAndEquipmentMember ruby:A2022RestructuringPlanMember 2020-01-01 2020-12-31 0001709401 us-gaap:ContractTerminationMember ruby:A2022RestructuringPlanMember 2022-01-01 2022-12-31 0001709401 us-gaap:ContractTerminationMember ruby:A2022RestructuringPlanMember 2021-01-01 2021-12-31 0001709401 us-gaap:ContractTerminationMember ruby:A2022RestructuringPlanMember 2020-01-01 2020-12-31 0001709401 ruby:A2022RestructuringPlanMember 2022-01-01 2022-12-31 0001709401 ruby:A2022RestructuringPlanMember 2021-01-01 2021-12-31 0001709401 ruby:A2022RestructuringPlanMember 2020-01-01 2020-12-31 0001709401 us-gaap:EmployeeSeveranceMember ruby:A2022RestructuringPlanMember 2022-12-31 0001709401 us-gaap:EmployeeSeveranceMember ruby:A2022RestructuringPlanMember 2021-12-31 0001709401 ruby:A2022RestructuringPlanMember 2022-07-01 2022-09-30 0001709401 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember us-gaap:ManufacturingFacilityMember ruby:A2022RestructuringPlanMember 2022-12-31 0001709401 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember us-gaap:ManufacturingFacilityMember ruby:A2022RestructuringPlanMember 2022-01-01 2022-12-31 0001709401 us-gaap:ContractTerminationMember 2022-01-01 2022-12-31 0001709401 us-gaap:ContractTerminationMember ruby:A2022RestructuringPlanMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure ruby:employee ruby:tranche ruby:vote ruby:lease ruby:date ruby:property 2022 FY 0001709401 false http://fasb.org/us-gaap/2022#RestructuringCostsAndAssetImpairmentCharges 10-K true 2022-12-31 --12-31 false 001-38586 RUBIUS THERAPEUTICS, INC. DE 46-2688109 c/o Verdolino & Lowey, P.C. 124 Washington Street, Suite 101 Foxborough, MA 02035 (508) 543-1720 Common Stock, par value $0.001 per share RUBY NASDAQ No No Yes Yes Non-accelerated Filer true false false 28400000 90397732 584800000 583600000 37200000 547600000 29500000 19900000 238 PricewaterhouseCoopers LLP Boston, Massachusetts 14865000 225848000 4070000 0 1260000 3975000 20195000 229823000 2679000 35095000 146000 51530000 50000 1573000 23070000 318021000 1232000 11572000 5607000 14072000 1100000 9015000 7939000 34659000 0 76154000 0 135000 0 28291000 7939000 139239000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 300000000 150000000 90387732 90387732 90063770 90063770 90000 90000 871725000 855710000 -856684000 -677018000 15131000 178782000 23070000 318021000 0 0 0 96414000 141587000 116107000 30835000 53029000 50341000 51197000 0 0 178446000 194616000 166448000 -178446000 -194616000 -166448000 819000 91000 1760000 3863000 6434000 4185000 1824000 4412000 1142000 -1220000 -1931000 -1283000 -179666000 -196547000 -167731000 -1.99 -1.99 -2.23 -2.23 -2.08 -2.08 90305463 90305463 87950440 87950440 80624608 80624608 -179666000 -196547000 -167731000 0 0 0 0 -4000 -71000 -179666000 -196551000 -167802000 80016245 80000 586798000 75000 -312740000 274213000 1037406 1000 1483000 1484000 33665000 33665000 -71000 -71000 -167731000 -167731000 81053651 81000 621946000 4000 -480471000 141560000 800000 6896552 7000 187193000 187200000 1933523 2000 10683000 10685000 26444 278000 278000 153600 0 35610000 35610000 -4000 -4000 -196547000 -196547000 90063770 90000 855710000 0 -677018000 178782000 42228 98000 98000 143906 134000 134000 137828 0 15783000 15783000 -179666000 -179666000 90387732 90000 871725000 0 -856684000 15131000 -179666000 -196547000 -167731000 15783000 35610000 33665000 6254000 7723000 5691000 305000 -118000 -266000 604000 1280000 349000 -25841000 0 0 1128000 0 0 -2738000 -1249000 -992000 -7002000 -5352000 -5539000 0 -5000 -46000 -9811000 5858000 -1369000 -6615000 -816000 -96000 -135000 -553000 283000 -10704000 -4401000 -5283000 -150142000 -145122000 -127648000 5304000 3649000 5497000 17943000 0 0 83626000 0 122671000 83931000 85000000 228600000 12944000 81351000 100432000 0 188000000 0 0 360000 0 0 150000 0 0 0 25000000 75702000 0 0 232000 10963000 1484000 -75470000 198453000 26484000 -212668000 134682000 -732000 227583000 92901000 93633000 14915000 227583000 92901000 4387000 5092000 3822000 11565000 7364000 8486000 0 1989000 317000 0 35000 0 0 0 496000 78000 0 982000 25502000 0 0 Nature of the Business and Basis of Presentation<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rubius Therapeutics, Inc. (“Rubius” or the “Company”) is a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines, called Red Cell Therapeutics, for the treatment of cancer and autoimmune diseases. Rubius was incorporated in April 2013 as VL26, Inc. under the laws of the State of Delaware. In January 2015, the Company changed its name to Rubius Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2022, the Company received a deficiency letter from the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price for its common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. In February 2023, the Company was notified by the Staff that it would be delisted at the opening of business on February 15, 2023 unless the Company were to timely request a hearing before a Nasdaq Hearings Panel, or the Panel, to address the deficiencies and present a plan to regain compliance. On February 13, 2023, the Company timely requested a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel, unless the Company determine to withdraw its hearing request. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 13, 2022, the Company's Board of Directors approved certain operational and organizational steps that the Company undertook in connection with a new strategic reorganization plan and related cost-saving measures (collectively, the “Reorganization Plan”). The Company discontinued its ongoing Phase 1 clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructured the organization to support advancing drug candidates based on its next generation platform. Under the Reorganization Plan, the Company reduced its overall workforce by approximately 75%, primarily consisting of employees who were focused on clinical development of RTX-240 and RTX-224, with the remainder coming from its manufacturing and general and administrative functions. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 2, 2022, in light of the Company’s financial condition, including the repayment and termination of its $75.0 million credit facility with SLR Investment Corp., and the early stage of its programs, its Board of Directors approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of its assets, and to significantly and immediately reduce its operations (the “Strategic Plan”). In connection with the Strategic Plan, the Company terminated 42 of its employees (representing 82% of its then-current employee base), leaving a core team of individuals to lead the strategic review process. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. In addition, the Company is subject to uncertainty regarding the performance and safety of its product candidates in humans. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. It is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2022, the Company had an accumulated deficit of $856.7 million, and cash and cash equivalents of $14.9 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the year ended December 31, 2022, the Company incurred a net loss of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$179.7 million </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and used </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$150.1 million </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of cash in operations. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40 and determined that the Company’s accumulated deficit, history of losses and future expected </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">losses met the ASC 205-40 standard for raising substantial doubt about the Company’s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least twelve months from the filing of its Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through the implementation of its Strategic Plan, the Company’s primary goal was to successfully complete a review of strategic alternatives and consummate a transaction or series of transactions to realize value for the Company’s platform and programs. On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></div>The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. 0.75 75000000 42 0.82 -856700000 14900000 -179700000 -150100000 Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk and of Significant Suppliers</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalents as of December 31, 2022 consisted of cash, money market accounts and U.S. government money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Deferred Offering Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Deferred Financing Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Cash</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $14.9 million, $227.6 million and $92.9 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $0.1 million, $1.7 million and $1.7 million was restricted cash for each year, respectively. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property, Plant and Equipment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.87pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of life of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-lived assets consist of property, plant and equipment and operating lease, right-of-use asset. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value Measurements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Assets Held for Sale</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company classifies its long-lived assets to be sold as held for sale in the period (i) the Company has approved and committed to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value, less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset until the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company’s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Manufacturing Contract Costs and Accruals</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Comprehensive loss includes net loss, as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2020, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments. For the year ended December 31, 2022 there was no difference between the Company’s net loss and comprehensive loss. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Income (Loss) per Share</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ASU No. 2016-13, Financial Instruments—Credit Losses</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ASU No. 2019-12, Simplifying the Accounting for Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Simplifying the Accounting for Income Taxes (ASC 740).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company adopted this standard as of January 1, 2021 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.</span></div> <div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk and of Significant Suppliers</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalents as of December 31, 2022 consisted of cash, money market accounts and U.S. government money market funds. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div> Deferred Offering CostsThe Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. Deferred Financing CostsThe Company capitalizes certain legal and other third-party fees that are directly associated with obtaining access to capital under credit facilities. Deferred financing costs incurred in connection with obtaining access to capital are recorded in other assets and are amortized over the term of the credit facility. Deferred financing costs related to a recognized debt liability are recorded as a reduction of the carrying amount of the debt liability and amortized to interest expense using the effective interest method over the repayment term. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Cash</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company maintained letters of credit totaling $1.7 million for the benefit of the landlords of its leased properties. The Company was required to maintain separate cash balances of these amounts to secure the letters of credit. Related to these separate cash balances, the Company included $0.1 million in prepaid expenses and other current assets and $1.6 million in restricted cash (non-current) in its consolidated balance sheet as of December 31, 2021. </span></div>Cash, cash equivalents and restricted cash presented in the accompanying consolidated statement of cash flows was $14.9 million, $227.6 million and $92.9 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $0.1 million, $1.7 million and $1.7 million was restricted cash for each year, respectively. 1700000 100000 1600000 14900000 227600000 92900000 100000 1700000 1700000 <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property, Plant and Equipment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.87pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of life of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for major renewals and improvements which extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Estimated useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.87pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shorter of life of lease or 10 years</span></div></td></tr></table></div> P3Y P5Y P7Y P10Y P30Y P10Y <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-lived assets consist of property, plant and equipment and operating lease, right-of-use asset. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. </span></div>Assets Held for SaleThe Company classifies its long-lived assets to be sold as held for sale in the period (i) the Company has approved and committed to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value, less any costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset until the date of sale. Upon designation as an asset held for sale, the Company stops recording depreciation and amortization expense on long-lived assets. The Company assesses the fair value of a long-lived asset, less any costs to sell, at each reporting period and until the asset is no longer classified as held for sale. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value Measurements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1—Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div>The Company’s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s investments are classified as available-for-sale and are carried at fair value. Realized gains and losses and declines in value are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such investments are available for current operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. No such credit losses were recorded during the periods presented.</span></div> <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of an arrangement as lessee or lessor, the Company determines whether the arrangement is or contains a lease. Operating lease cost is recognized over the lease term on a straight-line basis. Variable lease cost and short-term leases (lease terms less than 12 months) are recognized as incurred. For both lessee and lessor arrangements, variable lease payments are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are expensed when incurred. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For lessee arrangements, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has elected the following lease policies at the inception of a lease: (1) for lessee and lessor arrangements within all asset classes, combine lease and non-lease components as a single component, with the lease expense recognized over the expected term on a straight-line basis and (2) for lessee arrangements, apply short-term lease exemption for all leases that qualify, where a right-of-use asset or lease liability will not be recognized for leases with terms of one year or less.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. All of the Company’s tangible assets are held in the United States.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials, as well as the cost of licensing technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Manufacturing Contract Costs and Accruals</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various research and development and manufacturing contracts with research institutions and other companies both inside and outside of the U.S. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end with those third parties to record accruals for estimated ongoing research and development costs. Any accrual estimates are based on a number of factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Costs</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company’s common stock. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company measures restricted stock units with service-based vesting as the market value of the Company’s stock on the date of grant. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company accounts for forfeitures as they occur and records compensation cost assuming all option holders will complete the requisite service period. If an award is forfeited, the Company reverses compensation expense previously recognized in the period the award is forfeited. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For stock-based awards with market-based vesting conditions, the Company measures the fair value on the date of grant using a Monte Carlo simulation model. When service-based vesting conditions also exist, the Company recognizes stock-based compensation expense using the graded-vesting method over the longer of the derived service period from the market condition or the required service period. In accordance with accounting guidance for awards with market conditions, the stock-based compensation expense will be recognized over the appropriate period regardless of whether the award achieves the market condition and will only be adjusted to the extent the service condition is not met. When an award contains a market-based vesting condition and a performance-based vesting condition where both must be achieved to earn the award, the Company recognizes stock-based compensation expense over the longer of the derived service period from the market condition or the period estimated for the performance-based vesting condition to be achieved. The Company begins recording stock-based compensation expense for this type of award once the achievement of the performance-based vesting condition becomes probable regardless of whether the market condition has been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.</span></div> Comprehensive LossComprehensive loss includes net loss, as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2021 and 2020, the Company’s only element of other comprehensive loss was unrealized gains (losses) on investments. For the year ended December 31, 2022 there was no difference between the Company’s net loss and comprehensive loss. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Income (Loss) per Share</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding common stock equivalents. Accordingly, in periods in which the Company reported a net loss, dilutive common shares were not assumed to have been issued as their effect was anti-dilutive, and as a result, diluted net loss per common share was the same as basic net loss per common share.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ASU No. 2016-13, Financial Instruments—Credit Losses</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company early adopted this standard as of January 1, 2020 on a prospective basis. The adoption did not have a material impact on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ASU No. 2019-12, Simplifying the Accounting for Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Simplifying the Accounting for Income Taxes (ASC 740).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance is effective for the Company for annual and interim periods beginning after December 31, 2020; however, early adoption is permitted. The Company adopted this standard as of January 1, 2021 on a prospective basis. The adoption did not have an impact on the Company’s consolidated financial statements.</span></div> Investments and Fair Value of Financial Assets and Liabilities<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company had no investments as of December 31, 2022 or December 31, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash equivalents:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1 </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2 </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash equivalents:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. government money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no changes to the valuation methods during the year ended December 31, 2022. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level 1, Level 2 or Level 3 during the year ended December 31, 2022 and 2021, respectively.</span></div> 0 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables present the Company’s fair value hierarchy for its assets and liabilities, which are measured at fair value on a recurring basis (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash equivalents:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,010 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1 </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2 </span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash equivalents:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">U.S. government money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%"> </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,009 </span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1010000 0 0 1010000 1010000 0 0 1010000 217009000 0 0 217009000 217009000 0 0 217009000 Property, Plant and Equipment, Net and Assets Held for Sale<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment, net and assets held for sale consisted of the following, after the effects of impairment charges and held-for-sale reclassifications (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">570 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,386 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,530 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the year ended December 31, 2022, the Company recorded impairment charges of $25.8 million due to its Reorganization Plan (Note 13). Depreciation and amortization expense was $6.3 million, $7.7 million and $5.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment, net and assets held for sale consisted of the following, after the effects of impairment charges and held-for-sale reclassifications (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">570 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,386 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,530 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 1300000 0 33203000 0 8831000 0 17501000 0 2645000 0 1281000 570000 444000 0 4181000 570000 69386000 424000 17856000 146000 51530000 4070000 0 25800000 6300000 7700000 5700000 Accrued Expenses and Other Current Liabilities<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,401 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deposit received for assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,072 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,401 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">889 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deposit received for assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,072 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1401000 0 1387000 0 521000 889000 0 7451000 0 2713000 0 2349000 2125000 0 173000 670000 5607000 14072000 Debt<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-term debt consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Principal amount of long‑term debt</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,000 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Current portion of long‑term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long‑term debt, net of current portion</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,000 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued final interest payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Debt discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long‑term debt, net of discount and current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,154 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Loan Agreement </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 21, 2018 (the “Closing Date”), the Company entered into a loan and security agreement(the "Original Loan Agreement," and, as amended, the “Loan Agreement”) with Solar Capital Ltd., now SLR Investment Corp. ("SLR"), as collateral agent for the lenders party thereto for an aggregate principal amount of $75.0 million. The aggregate principal amount will be funded in three tranches of term loans of $25.0 million each. On the Closing Date, the Company made an initial borrowing of $25.0 million. In June 2019, the Company made a second borrowing of $25.0 million and in June 2020, the Company made a third and final borrowing of $25.0 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 22, 2021 (the “Amendment Closing Date”), the Company entered into an amendment (the “Amendment”) to the Original Loan Agreement. Pursuant to the Amendment, the Company and its lenders agreed to extend the interest-only period applicable to borrowings under the Loan Agreement from December 21, 2021 until July 1, 2024 and the final maturity date from December 21, 2023 until June 1, 2026. An additional tranche in the amount of $35.0 million is available at the request of the Company prior to the final maturity date, to be provided at the sole discretion of the lenders. The Amendment increases the LIBOR interest rate floor from 0.00% to 2.10%. Interest on the outstanding loan balance will accrue at a rate of 5.50%, plus the greater of 2.10% or the one-month U.S. LIBOR rate. Certain back-end fees are due to the lender at the time of final repayment based on the total funded term loans. The Company accrues the back-end fees that will be due at final repayment to outstanding debt by charges to interest expense over the term of the loans using the effective interest method. The term loans are subject to a prepayment fee of 1.00% if prepayment occurs within the first year subsequent to the Amendment Closing Date, 0.50% in the second year and 0.25% in the third year through final maturity date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the terms of the Amendment were not substantially different than the terms of the Original Loan Agreement, the Amendment was accounted for as a debt modification. In conjunction with the Amendment, the Company incurred issuance costs of $0.2 million payable to the lenders, which were recorded as an additional debt discount and will be amortized to interest expense over the remaining term, together with unamortized original issuance costs as of the Amendment Closing Date, using the effective interest method.</span></div>On October 13, 2022, the Company entered into a payoff letter with SLR, under which the Company voluntarily prepaid SLR approximately $75.7 million, in full satisfaction of all obligations, including all outstanding principal, accrued interest, fees, costs, expenses and other amounts chargeable, under the Loan Agreement. The payoff letter also provided for the termination of all commitments and obligations under the Loan Agreement and release of all liens held by SLR on the Company’s assets. The Loan Agreement was extinguished and accounted for as a troubled debt restructuring as the Company was experiencing financial difficulty and SLR granted the Company a concession by forgiving certain contractually owed amounts. The Company recognized a gain on the extinguishment of the Loan Agreement of $1.1 million, which is recorded in interest expense on the consolidated statements of operations and comprehensive loss. As of December 31, 2022, the Company does not have any debt outstanding. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-term debt consisted of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Principal amount of long‑term debt</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,000 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Current portion of long‑term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long‑term debt, net of current portion</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,000 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued final interest payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Debt discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long‑term debt, net of discount and current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,154 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 75000000 0 0 0 75000000 0 1654000 0 500000 0 76154000 75000000 3 25000000 25000000 25000000 25000000 35000000 0.0000 0.0210 0.0550 0.0210 one-month 0.0100 0.0050 0.0025 200000 75700000 1100000 EquityEach share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 20, 2018, the Company filed a restated certificate of incorporation in the State of Delaware, which, among other things, restated the number of shares of all classes of stock that the Company has authority to issue to 160,000,000 shares, consisting of (i) 150,000,000 shares of common stock, $0.001 par value per share, and (ii) 10,000,000 shares of preferred stock, $0.001 par value per share. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon issuance. The shares of preferred stock are currently undesignated. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 1, 2019, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and SVB Leerink LLC (the “Sales Agents”), pursuant to which the Company was able to issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $100.0 million through the Sales Agents. As of December 31, 2022, no shares of common stock have been issued and sold pursuant to the Distribution Agreement, which expired in accordance with its terms on August 21, 2022, and the applicable registration statement is no longer effective. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 18, 2021, the Company completed the March 2021 Offering, pursuant to which it issued and sold 6,896,552 shares of common stock. The aggregate net proceeds received by the Company from the March 2021 Offering were $187.2 million, after deducting underwriting discounts and commissions and other offering costs.</span></div>On July 7, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which increased the number of shares of common stock that the Company has authority to issue from 150,000,000 to 300,000,000 shares. The number of shares of preferred stock authorized for issuance was not impacted by this amendment. 1 160000000 150000000 0.001 10000000 0.001 100000000 0 6896552 187200000 150000000 300000000 Stock-Based Compensation<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2018 Equity Incentive Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 6, 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Plan, which became effective on July 16, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2018 Plan is 5,708,931, which shall be cumulatively increased on January 1, 2019 and each January 1 thereafter by 4% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s board of directors or compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Plan. As of December 31, 2022, 9,666,433 shares remained available for issuance under the 2018 Plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The number of authorized shares reserved for issuance under the 2018 Plan was increased by 3,615,509 shares effective as of January 1, 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2018 Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 6, 2018, the Company’s board of directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”), which became effective on July 16, 2018. On December 15, 2022, the Company's board of directors voted to terminate the ESPP effective immediately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company issued 143,906 and 26,444 shares of common stock under the ESPP during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$0.1 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of stock-based compensation expense as a result of the ESPP for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2022 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021, respectively. There were no shares of common stock issued and no stock-based compensation expense recorded under the ESPP for the year ended December 31, 2020. Due to the plan termination, no further shares will be issued under to the ESPP. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Option Valuation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Service-Based and Performance-Based Stock Options</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of stock option grants with service-based and performance-based vesting conditions is estimated using the Black-Scholes option-pricing model. The Company estimates expected volatility based on the historical volatility of publicly traded peer companies. For options with service-based vesting conditions, the expected term of the Company’s </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock-based awards granted to employees, directors, and non-employees:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.37 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.81 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.10 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">77.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.05</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company’s service-based and performance-based option activity since December 31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise <br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic <br/>value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,138,772</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,511</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,104,403</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,228)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,105,039)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,095,908</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,095,908</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.55</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,061,182</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $0.1 million, $34.6 million and $5.7 million, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average grant-date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was $2.98 per share, $10.55 per share and $4.51 per share, respectively. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Market-Based Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of stock option grants with market-based vesting conditions is estimated using a Monte Carlo simulation model. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, the Company granted to an executive officer an option to purchase 164,400 shares of common stock (“Option A”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the satisfaction of service-based vesting conditions, and an option to purchase 193,400 shares of common stock (“Option B”) at an exercise price of $16.43 per share, vesting upon the achievement of a specified thirty-day average closing price of its common stock and the achievement of certain other performance-based vesting conditions. The Company used a Monte Carlo simulation model to estimate the grant-date fair value of the awards. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility based on a combination of the Company’s historical stock volatility since its July 2018 IPO and the historical volatility of a publicly traded set of peer companies and the estimated period to achievement of the market condition. Stock-based compensation expense for Option A is being recognized using the graded-vesting method over the longer of the derived service period from the market condition or the explicit service period required to be completed for each vesting tranche. Stock-based compensation expense for Option B is being recognized using the graded-vesting method over the longer of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the derived service period from the market condition or the estimated achievement of performance-based conditions. For Option B, stock-based compensation expense is recognized when the achievement of each performance-based vesting condition becomes probable regardless of whether the market condition has been achieved. The aggregate grant date fair value of these options was $4.3 million. During the years ended December 31, 2022, 2021 and 2020 the Company recorded stock-based compensation expense on Option A of $0.1 million, $0.2 million and $0.6 million, respectively. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense on Option B of $1.1 million and $1.1 million, respectively, as a performance-based vesting condition was determined to be probable during each year. No stock-based compensation expense on Option B was recorded during the year ended December 31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company did not grant market-based stock options during the years ended December 31, 2022, 2021 and 2020. During the years ended December 31, 2022, 2021 and 2020, none of the outstanding stock options with market-based vesting conditions were exercised, forfeited or vested and they had no intrinsic value at December 31, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has also granted restricted stock units to its employees. During the years ended December 31, 2022 and 2021, the Company granted restricted stock units to employees that were subject to time-based vesting conditions that lapse over four years and three years from the date of grant. No restricted stock units were granted during the year ended December 31, 2020. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Restricted stock units with time-based vesting conditions are valued on the grant date using the grant date market price of the underlying shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The following table summarizes the Company’s restricted stock unit activity since December 31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average <br/>grant-date <br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794,244</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.346</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">906,815</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.880</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137,828)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.522</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,130,028)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.446</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.728</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,863 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,338 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,023 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,920 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,783 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, total unrecognized compensation cost related to unvested stock-based awards was $6.8 million, which is expected to be recognized over a weighted average period of 2.2 years.</span></div> 5708931 0.04 9666433 3615509 143906 26444 100000 100000 0 0 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock-based awards granted to employees, directors, and non-employees:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.37 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.81 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.10 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">77.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.05</span></td></tr></table></div> 0.0237 0.0081 0.0110 0.784 0.774 0.694 0 0 0 P5Y10M13D P6Y29D P6Y18D <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company’s service-based and performance-based option activity since December 31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of <br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average exercise <br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Aggregate intrinsic <br/>value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,138,772</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,511</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,104,403</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,228)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,105,039)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,095,908</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and expected to vest as of December 31, 2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,095,908</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.55</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,061,182</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.82</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6</span></td></tr></table></div> 17138772 12.04 P7Y2M19D 23511000 4104403 4.37 42228 2.32 7105039 10.31 14095908 10.71 P3Y6M18D 6000 14095908 10.71 P3Y6M18D 6000 12061182 11.29 P2Y9M25D 6000 100000 34600000 5700000 2.98 10.55 4.51 164400 16.43 193400 16.43 4300000 100000 200000 600000 1100000 1100000 0 0 0 0 0 0 0 0 P4Y P3Y 0 The following table summarizes the Company’s restricted stock unit activity since December 31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Weighted average <br/>grant-date <br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794,244</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.346</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Issued</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">906,815</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.880</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137,828)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.522</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,130,028)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.446</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.728</span></td></tr></table> 794244 15.346 906815 4.880 137828 12.522 1130028 9.446 433203 9.728 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,863 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,338 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,023 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,920 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,272 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,783 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33,665 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6863000 12338000 8023000 8920000 23272000 25642000 15783000 35610000 33665000 6800000 P2Y2M12D Income Taxes<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the years ended December 31, 2022, 2021 and 2020, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the Company’s operating losses since inception have been generated in the United States.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21.0)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21.0)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal and state research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock‑based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Section 162(m) compensation deduction limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net deferred tax assets consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized intellectual property costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock‑based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">264,161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(732)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,090)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263,429 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, the Company had U.S. federal and state net operating loss (“NOL”) carryforwards of $584.8 million and $583.6 million, respectively, which may be available to offset future taxable income. The federal NOLs include $37.2 million which expire at various dates through 2037 and $547.6 million which carryforward indefinitely. The state NOLs expire at various dates through 2042. As of December 31, 2022, the Company also had U.S. federal and state research and development tax credit carryforwards of $29.5 million and $19.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2034 and 2026, respectively. During the year ended December 31, 2022, deferred tax assets, before valuation allowance, increased by approximately $46.4 million mainly due to the operating loss incurred by the Company during that period and the capitalization of research and development expenses. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2022 and 2021. Management reevaluates the positive and negative evidence at each reporting period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022, 2021 and 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance as of beginning of year</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,877</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">85,884</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Decreases recorded as benefit to income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,722</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,830</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,993</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance as of end of year</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263,429</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,877</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022 and 2021, the Company had no recorded amounts for unrecognized tax benefits. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations and comprehensive loss. The Company files income tax returns in the U.S., Massachusetts and Rhode Island, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present; however, carryforward attributes that were generated prior to January 1, 2016 may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</span></div> 0 0 0 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21.0)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21.0)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal and state research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock‑based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Section 162(m) compensation deduction limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increase in deferred tax asset valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div> 0.210 0.210 -0.060 -0.062 -0.053 -0.064 0.005 -0.016 0.001 0.016 0.001 -0.004 0.316 0.340 0 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net deferred tax assets consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized intellectual property costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Capitalized research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock‑based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">264,161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">217,797 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(732)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,090)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263,429 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 159691000 145990000 45478000 36161000 105000 2137000 2051000 1746000 32007000 86000 301000 10194000 24454000 21483000 74000 0 264161000 217797000 732000 9590000 0 1500000 732000 11090000 263429000 206707000 0 0 584800000 583600000 37200000 547600000 29500000 19900000 46400000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022, 2021 and 2020 related primarily to the increase in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance as of beginning of year</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,877</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">85,884</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Decreases recorded as benefit to income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56,722</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66,830</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53,993</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance as of end of year</span></td><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263,429</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206,707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139,877</span></td></tr></table></div> 206707000 139877000 85884000 0 0 0 56722000 66830000 53993000 263429000 206707000 139877000 0 0 0 0 0 0 Commitments and Contingencies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">License Agreement with the Whitehead Institute for Biomedical Research</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a license agreement with the Whitehead Institute for Biomedical Research (“WIBR”), as amended, under which the Company has been granted an exclusive, sublicensable, nontransferable license under certain patent families related to the development of the Company’s red blood cell therapies (as amended, the “WIBR License”). The Company is obligated to pay WIBR annual license maintenance fees of less than $0.1 million, as well as patent-related costs, including legal fees, and low single-digit royalties based on annual net sales of licensed products and licensed services by the Company and its sublicensees. Based on the progress the Company makes in the advancement of products covered by the licensed patent rights, the Company is required to make aggregate milestone payments of up to $1.6 million upon the achievement of specified preclinical, clinical and regulatory milestones. In addition, the Company is required to pay to WIBR a percentage of the non-royalty payments that it receives from sublicensees of the patent rights licensed by WIBR. This percentage varies from low single-digit to low double-digit percentages and will be based upon the clinical stage of the product that is the subject of the sublicense. Royalties shall be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has the right to terminate the WIBR License in its entirety, on a patent-by-patent or country-by-country basis, at will upon three months’ notice to WIBR. WIBR may terminate the agreement upon breach of contract or in the event of the Company’s bankruptcy, liquidation, insolvency or cessation of business related to the license.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">401(k) Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2018, the Company established a defined-contribution plan under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company makes matching contributions at a rate of 50% of each employee’s contribution up to a maximum employee contribution of 6% of eligible plan compensation. For the years ended December 31, 2022, 2021 and 2020, the Company made matching contributions of $0.9 million, $0.9 million and $0.8 million, respectively. In January 2023, the Company terminated the 401(k) Plan effective December 30, 2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Indemnification Agreements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal Proceedings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div> 100000 1600000 0.50 0.06 900000 900000 800000 Leases<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2022, the Company leased office and laboratory facilities in Cambridge, Massachusetts under one noncancelable operating lease, which is subject to two expiration dates based on two distinct leased spaces, expiring in January 2027 and August 2028. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2018, the Company entered into a lease for office and laboratory space in Cambridge, Massachusetts (the “Initial Space”). The lease term commenced on January 28, 2019 and was scheduled to expire eight years from the commencement date. The initial annual base rent is approximately $3.8 million, and such amounts increased during the initial term by 3% annually on the anniversary of the commencement date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2018, the Company entered into a lease amendment for office and laboratory space in the same building (the “Expansion Space”). The lease term for the Expansion Space commenced on August 8, 2019 and was scheduled to expire approximately nine years from the commencement date. The initial annual base rent for the Expansion Space was approximately $2.5 million and such amount increased by 3% annually on the anniversary of the commencement date. The Company was obligated to pay its portion of real estate taxes and costs related to the Expansion Space, including costs of operations, maintenance, repair, replacement and property management. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2022, the Company entered into an Agreement for Termination of Lease (the “Lease Termination Agreement”) relating to its two distinct leased spaces for office and laboratory space in Cambridge, Massachusetts (the “Cambridge Facility”). Under the Lease Termination Agreement, the Company’s lease for the Cambridge Facility terminated on January 31, 2023. Under the terms of the Lease Termination Agreement, the Company paid the landlord a lease termination payment, inclusive of the full amount of a letter of credit that the landlord held under the lease and rent previously paid by the Company to the landlord for the month of December 2022, of approximately $5.9 million in the fourth quarter of the year ended December 31, 2022, and the Company paid the landlord a subsequent payment of $1.1 million in the first quarter of the year ending December 31, 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Lease Termination Agreement terminated the lease on January 31, 2023. As the lease termination was effective at a future date, the Company accounted for the change as a lease modification that shortened the lease term. Upon the modification, the Company decreased its operating lease, right-of-use asset by an amount equal to the adjustment of its operating lease liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluated its vendor contracts to identify embedded leases, if any, and noted that an agreement with a contract manufacturing supplier constituted a lease under ASC 842 as the Company has the right to substantially all the economic benefits from the use of the asset and can direct the use of the asset. The Company entered into the agreement during the first quarter of 2019. The lease commenced during March 2019 and was scheduled to expire 22 months from commencement date with no stated option to extend the term. The lease was cancelled prior to expiration during the first quarter of 2020, resulting in derecognition of the lease assets and operating lease liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate based on information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and, therefore, has allocated all the contract consideration across lease components only. This may result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability for leases being greater than if the policy election was not applied. Assets under operating lease at December 31, 2022 were $2.7 million. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, minimum lease payments under the Company’s operating leases are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ending December 31, </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has not entered any material financing leases as of December 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Lease Portfolio</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,173 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,058 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,723 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,713 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,218 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,163 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease, right-of-use-asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.08 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.80 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.70 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table> 1 2 2 P8Y 3800000 0.03 P9Y 2500000 0.03 2 5900000 1100000 P22M 2700000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, minimum lease payments under the Company’s operating leases are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ending December 31, </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.87pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100</span></td></tr></table></div> 1100000 0 0 0 0 0 1100000 0 1100000 The components of lease cost and supplemental balance sheet information for the Company’s lease portfolio were as follows (in thousands, except term and discount rate amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,655 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,173 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,058 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,723 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,916 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,713 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,218 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,163 </span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease, right-of-use-asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,015 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">28,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.08 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.80 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.70 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table> 12655000 8173000 9240000 0 41000 24000 3058000 3723000 1916000 0 719000 1017000 15713000 11218000 10163000 2679000 35095000 40447000 1100000 9015000 8945000 0 28291000 32762000 P0Y29D P5Y9M18D P6Y8M12D 0 0.0760 0.0760 Net Loss per Share<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(179,666)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(196,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(167,731)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,305,463</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,950,440</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,624,608</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.99)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.23)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.08)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares from the periods in the table above, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794,244</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock options to purchase common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,453,708</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,496,572</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,318,124</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,886,911</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,290,816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,570,124</span></td></tr></table></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(179,666)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(196,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(167,731)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90,305,463</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">87,950,440</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">80,624,608</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.99)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.23)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.08)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -179666000 -196547000 -167731000 90305463 90305463 87950440 87950440 80624608 80624608 -1.99 -1.99 -2.23 -2.23 -2.08 -2.08 The Company excluded the following potential common shares from the periods in the table above, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unvested restricted common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">433,203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">794,244</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock options to purchase common stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,453,708</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,496,572</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,318,124</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,886,911</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,290,816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,570,124</span></td></tr></table> 433203 794244 252000 14453708 17496572 16318124 14886911 18290816 16570124 Restructuring and Impairment Charges<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates that it will incur approximately $51.9 million in costs to implement the Reorganization Plan and the Strategic Plan, as described in Note 1. The actions associated with the Reorganization Plan and the Strategic Plan commenced in September 2022 and November 2022, respectively, and are expected to be substantially completed by February 28, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Reorganization Plan and the Strategic Plan required management to evaluate matters related to involuntary termination benefits provided pursuant to a one-time benefit arrangement, contract termination costs and the impairment of long-lived assets in accordance with generally accepted accounting principles. The recognition of the Company’s liability for one-time termination benefits is based on contractual agreements and whether employees are required to render service until they are terminated in order to receive the termination benefits and, if so, whether the employee will be retained to render service beyond a minimum retention period. The Company’s contract termination costs represent costs to terminate a contract before the end of its term or costs that will continue to be incurred under a contract for its remaining term without economic benefit to the Company and is recognized at fair value when the contract is terminated or the Company ceases using the right conveyed by the contract. The impairment of long-lived assets is based on the fair value of the Company's long-lived asset group as determined by actual sale transactions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of these events, the Company incurred the following restructuring and impairment charges, which are recorded in the consolidated statements of operations and comprehensive loss (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,929 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract termination costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee Termination Benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Employees affected by the reduction in workforce under the Company's Reorganization Plan and Strategic Plan received involuntary termination benefits that are provided pursuant to a one-time benefit arrangement. For employees who were notified of their termination and have no requirements to provide future service, the Company recognized the liability for the termination benefits in full at fair value in the period in which they were incurred. For employees who are required to render services beyond a minimum retention period to receive their one-time termination benefits, the Company is recognizing the termination benefits ratably over their future service periods. The service periods for the Reorganization Plan began in September 2022 and ended at various dates through December 31, 2022. The service periods for the Strategic Plan began in November 2022 and ended at various dates through January 31, 2023. The Company will incur approximately $13.6 million of employee termination benefits expense to implement the Reorganization Plan and the Strategic Plan of which $12.9 million has been incurred in the year ended December 31, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the liability related to employee termination benefits as of December 31, 2022: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"/><td style="width:82.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination benefits charges incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the Reorganization Plan, the Company determined that sufficient indicators existed to trigger the performance of an interim long-lived asset impairment analysis as of September 30, 2022. In the third quarter of 2022, the Company tested the recoverability of its asset group using entity-specific undiscounted cash flows. Based on these undiscounted cash flows, the Company concluded the undiscounted future cash flows expected to result from the use and eventual disposition of its long-lived assets were less than the carrying value of the asset group. Therefore, the Company measured the long-lived asset impairment as the amount by which the carrying value of the asset group exceeds its fair </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">value and recorded an impairment of $17.8 million. The loss was allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the loss allocated to an individual long-lived asset of the group did not reduce the carrying value of that asset below its fair value. The fair value of the asset group was determined from a third-party commercial real estate appraisal which represents a Level 3 fair value measurement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in conjunction with its Reorganization Plan, the Company committed to a plan to actively sell specific assets within its asset group, primarily its laboratory equipment and furniture and fixtures. The laboratory equipment and furniture and fixtures met all of the prescribed criteria required to classify it as held for sale. At December 31, 2022, $4.1 million of laboratory equipment and furniture and fixtures was classified as held for sale as current assets on the consolidated balance sheet as the disposal was expected to be consummated within one year of the balance sheet date and the Company does not expect to use the sale proceeds to reduce any long-term borrowings. The sale was completed by January 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2022, the Company entered into a purchase and sale agreement for the sale of its manufacturing facility and certain related fixtures and personal property for an aggregate purchase price of $18.5 million. The purchase price was less than the carrying amount of the assets sold and the resulting impairment of $8.0 million was recorded within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjMmRmNDg4NGZjOTRmNTlhZTkyYjMwNGMzNTNjY2U2L3NlYzpmYzJkZjQ4ODRmYzk0ZjU5YWU5MmIzMDRjMzUzY2NlNl81NDUvZnJhZzphZDg3YTI2NzM5OGI0OTY2YmQ1YzI1NmY1NDQ1MGExOS90ZXh0cmVnaW9uOmFkODdhMjY3Mzk4YjQ5NjZiZDVjMjU2ZjU0NDUwYTE5XzIxOTkwMjMyNzY3NjQ_82b73095-bb8f-408f-872a-d1f40fb6aaba">restructuring and impairment charges</span> in the consolidated statements of operations and comprehensive loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December 31, 2022, the Company recorded long-lived impairment charges of $25.8 million, which were recorded within restructuring and impairment charges on the consolidated statements of operations and comprehensive loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contract Termination Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The discontinuation of the RTX-240 and RTX-224 clinical trials as part of the Reorganization Plan and of discovery activities and platform development as part of the Strategic Plan resulted in the termination of vendor contracts before the end of their term, as well as costs that continue to be incurred under certain contracts with no future economic benefit to the Company. The Company recognized these contract termination costs in full in the period in which they no longer held an economic benefit to the Company. During the year ended December 31, 2022, the Company incurred $12.4 million of contract termination costs, which it estimates to be the full amount of such costs to be incurred related to the Reorganization Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the liability related to contract termination costs as of December 31, 2022: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Contract Termination Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract termination costs incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 51900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of these events, the Company incurred the following restructuring and impairment charges, which are recorded in the consolidated statements of operations and comprehensive loss (in thousands): </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.962%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination benefits</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,929 </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Impairment of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract termination costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51,197 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12929000 0 0 25841000 0 0 12427000 0 0 51197000 0 0 13600000 12900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the liability related to employee termination benefits as of December 31, 2022: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"/><td style="width:82.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Employee Termination Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee termination benefits charges incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued employee termination benefits as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,401 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the liability related to contract termination costs as of December 31, 2022: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Contract Termination Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract termination costs incurred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amounts paid or otherwise settled during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(11,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued contract termination costs as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 12929000 11528000 1401000 17800000 4100000 18500000 -8000000 25800000 12400000 0 12427000 11040000 1387000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14. Subsequent Events</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 20, 2023, following the conclusion of the Company's review of strategic alternatives, the Company's Board of Directors unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution, which plan is subject to stockholder approval.</span></div> EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 166 338 1 false 48 0 false 10 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.rubiustx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.rubiustx.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY Sheet http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical) Sheet http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITYParenthetical CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 9 false false R10.htm 0000010 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentation Nature of the Business and Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.rubiustx.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 0000012 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities Sheet http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilities Investments and Fair Value of Financial Assets and Liabilities Notes 12 false false R13.htm 0000013 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.rubiustx.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 13 false false R14.htm 0000014 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Debt Sheet http://www.rubiustx.com/role/Debt Debt Notes 15 false false R16.htm 0000016 - Disclosure - Equity Sheet http://www.rubiustx.com/role/Equity Equity Notes 16 false false R17.htm 0000017 - Disclosure - Stock-Based Compensation Sheet http://www.rubiustx.com/role/StockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 0000018 - Disclosure - Income Taxes Sheet http://www.rubiustx.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://www.rubiustx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Leases Sheet http://www.rubiustx.com/role/Leases Leases Notes 20 false false R21.htm 0000021 - Disclosure - Net Loss per Share Sheet http://www.rubiustx.com/role/NetLossperShare Net Loss per Share Notes 21 false false R22.htm 0000022 - Disclosure - Restructuring and Impairment Charges Sheet http://www.rubiustx.com/role/RestructuringandImpairmentCharges Restructuring and Impairment Charges Notes 22 false false R23.htm 0000023 - Disclosure - Subsequent Events Sheet http://www.rubiustx.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 0000024 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.rubiustx.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 0000025 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.rubiustx.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 0000026 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesTables Investments and Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilities 26 false false R27.htm 0000027 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Tables) Sheet http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleTables Property, Plant and Equipment, Net and Assets Held for Sale (Tables) Tables 27 false false R28.htm 0000028 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilities 28 false false R29.htm 0000029 - Disclosure - Debt (Tables) Sheet http://www.rubiustx.com/role/DebtTables Debt (Tables) Tables http://www.rubiustx.com/role/Debt 29 false false R30.htm 0000030 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.rubiustx.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.rubiustx.com/role/StockBasedCompensation 30 false false R31.htm 0000031 - Disclosure - Income Taxes (Tables) Sheet http://www.rubiustx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.rubiustx.com/role/IncomeTaxes 31 false false R32.htm 0000032 - Disclosure - Leases (Tables) Sheet http://www.rubiustx.com/role/LeasesTables Leases (Tables) Tables http://www.rubiustx.com/role/Leases 32 false false R33.htm 0000033 - Disclosure - Net Loss per Share (Tables) Sheet http://www.rubiustx.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://www.rubiustx.com/role/NetLossperShare 33 false false R34.htm 0000034 - Disclosure - Restructuring and Impairment Charges (Tables) Sheet http://www.rubiustx.com/role/RestructuringandImpairmentChargesTables Restructuring and Impairment Charges (Tables) Tables http://www.rubiustx.com/role/RestructuringandImpairmentCharges 34 false false R35.htm 0000035 - Disclosure - Nature of the Business and Basis of Presentation (Details) Sheet http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails Nature of the Business and Basis of Presentation (Details) Details http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentation 35 false false R36.htm 0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 36 false false R37.htm 0000037 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details) Sheet http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails Summary of Significant Accounting Policies - Estimated useful life (Details) Details 37 false false R38.htm 0000038 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Details) Sheet http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails Investments and Fair Value of Financial Assets and Liabilities (Details) Details http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesTables 38 false false R39.htm 0000039 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Details) Sheet http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails Property, Plant and Equipment, Net and Assets Held for Sale (Details) Details http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleTables 39 false false R40.htm 0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables 40 false false R41.htm 0000041 - Disclosure - Debt - Current and Non current (Details) Sheet http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails Debt - Current and Non current (Details) Details 41 false false R42.htm 0000042 - Disclosure - Debt - Narrative (Details) Sheet http://www.rubiustx.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 42 false false R43.htm 0000043 - Disclosure - Equity (Details) Sheet http://www.rubiustx.com/role/EquityDetails Equity (Details) Details http://www.rubiustx.com/role/Equity 43 false false R44.htm 0000044 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 44 false false R45.htm 0000045 - Disclosure - Stock-Based Compensation - Granted to non-employees (Details) Sheet http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails Stock-Based Compensation - Granted to non-employees (Details) Details 45 false false R46.htm 0000046 - Disclosure - Stock-Based Compensation - Option activity (Details) Sheet http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails Stock-Based Compensation - Option activity (Details) Details 46 false false R47.htm 0000047 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details) Sheet http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails Stock-Based Compensation - Restricted Common Stock (Details) Details 47 false false R48.htm 0000048 - Disclosure - Stock-Based Compensation - Compensation expense (Details) Sheet http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails Stock-Based Compensation - Compensation expense (Details) Details 48 false false R49.htm 0000049 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 49 false false R50.htm 0000050 - Disclosure - Income Taxes - U S federal statutory income tax rate (Details) Sheet http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails Income Taxes - U S federal statutory income tax rate (Details) Details 50 false false R51.htm 0000051 - Disclosure - Income Taxes - Net deferred tax assets (Details) Sheet http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails Income Taxes - Net deferred tax assets (Details) Details 51 false false R52.htm 0000052 - Disclosure - Income Taxes - Valuation allowance for deferred tax assets (Details) Sheet http://www.rubiustx.com/role/IncomeTaxesValuationallowancefordeferredtaxassetsDetails Income Taxes - Valuation allowance for deferred tax assets (Details) Details 52 false false R53.htm 0000053 - Disclosure - Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details) Sheet http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details) Details 53 false false R54.htm 0000054 - Disclosure - Commitments and Contingencies - Defined Contribution Plan (Details) Sheet http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails Commitments and Contingencies - Defined Contribution Plan (Details) Details 54 false false R55.htm 0000055 - Disclosure - Leases - Narrative (Details) Sheet http://www.rubiustx.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Leases - Minimum lease payments (Details) Sheet http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails Leases - Minimum lease payments (Details) Details 56 false false R57.htm 0000057 - Disclosure - Leases - Lease Portfolio (Details) Sheet http://www.rubiustx.com/role/LeasesLeasePortfolioDetails Leases - Lease Portfolio (Details) Details 57 false false R58.htm 0000058 - Disclosure - Net Loss per Share - Weighted Average Shares (Details) Sheet http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails Net Loss per Share - Weighted Average Shares (Details) Details 58 false false R59.htm 0000059 - Disclosure - Net Loss per Share - Antidilutive Securities (Details) Sheet http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails Net Loss per Share - Antidilutive Securities (Details) Details 59 false false R60.htm 0000060 - Disclosure - Restructuring and Impairment Charges - Narrative (Details) Sheet http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails Restructuring and Impairment Charges - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - Restructuring and Impairment Charges - Summary of Charges (Details) Sheet http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails Restructuring and Impairment Charges - Summary of Charges (Details) Details 61 false false R62.htm 0000062 - Disclosure - Restructuring and Impairment Charges - Restructuring Reserve Activity (Details) Sheet http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails Restructuring and Impairment Charges - Restructuring Reserve Activity (Details) Details 62 false false All Reports Book All Reports ruby-20221231.htm ruby-20221231.xsd ruby-20221231_cal.xml ruby-20221231_def.xml ruby-20221231_lab.xml ruby-20221231_pre.xml ruby-20221231x10kex211.htm ruby-20221231x10kex311.htm ruby-20221231x10kex312.htm ruby-20221231x10kex321.htm ruby-20221231_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ruby-20221231.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 680, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 166, "dts": { "calculationLink": { "local": [ "ruby-20221231_cal.xml" ] }, "definitionLink": { "local": [ "ruby-20221231_def.xml" ] }, "inline": { "local": [ "ruby-20221231.htm" ] }, "labelLink": { "local": [ "ruby-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ruby-20221231_pre.xml" ] }, "schema": { "local": [ "ruby-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 507, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 5 }, "keyCustom": 44, "keyStandard": 294, "memberCustom": 15, "memberStandard": 32, "nsprefix": "ruby", "nsuri": "http://www.rubiustx.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.rubiustx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Nature of the Business and Basis of Presentation", "menuCat": "Notes", "order": "10", "role": "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "11", "role": "http://www.rubiustx.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities", "menuCat": "Notes", "order": "12", "role": "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilities", "shortName": "Investments and Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Property, Plant and Equipment, Net", "menuCat": "Notes", "order": "13", "role": "http://www.rubiustx.com/role/PropertyPlantandEquipmentNet", "shortName": "Property, Plant and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "14", "role": "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Debt", "menuCat": "Notes", "order": "15", "role": "http://www.rubiustx.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Equity", "menuCat": "Notes", "order": "16", "role": "http://www.rubiustx.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "17", "role": "http://www.rubiustx.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://www.rubiustx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://www.rubiustx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.rubiustx.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Leases", "menuCat": "Notes", "order": "20", "role": "http://www.rubiustx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Net Loss per Share", "menuCat": "Notes", "order": "21", "role": "http://www.rubiustx.com/role/NetLossperShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Restructuring and Impairment Charges", "menuCat": "Notes", "order": "22", "role": "http://www.rubiustx.com/role/RestructuringandImpairmentCharges", "shortName": "Restructuring and Impairment Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "23", "role": "http://www.rubiustx.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "24", "role": "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesTables", "shortName": "Investments and Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleTables", "shortName": "Property, Plant and Equipment, Net and Assets Held for Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ruby:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ruby:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.rubiustx.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "3", "role": "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.rubiustx.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.rubiustx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.rubiustx.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Net Loss per Share (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.rubiustx.com/role/NetLossperShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Restructuring and Impairment Charges (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.rubiustx.com/role/RestructuringandImpairmentChargesTables", "shortName": "Restructuring and Impairment Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Nature of the Business and Basis of Presentation (Details)", "menuCat": "Details", "order": "35", "role": "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails", "shortName": "Nature of the Business and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "iaf0fbb9cfd89427e8e40de940fe67c74_D20221102-20221102", "decimals": "3", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ia9eecd2a692546fd94e9272318c8eb25_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:RestrictedCashForBenefitOfLandlord", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "36", "role": "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ia9eecd2a692546fd94e9272318c8eb25_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:RestrictedCashForBenefitOfLandlord", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ifcbecea5cbcb4414ac671efe793f40fc_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)", "menuCat": "Details", "order": "37", "role": "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails", "shortName": "Summary of Significant Accounting Policies - Estimated useful life (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ifcbecea5cbcb4414ac671efe793f40fc_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Investments and Fair Value of Financial Assets and Liabilities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails", "shortName": "Investments and Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Property, Plant and Equipment, Net and Assets Held for Sale (Details)", "menuCat": "Details", "order": "39", "role": "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "shortName": "Property, Plant and Equipment, Net and Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ruby:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ruby:AccruedEmployeeTerminationBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "40", "role": "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ruby:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ruby:AccruedEmployeeTerminationBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Debt - Current and Non current (Details)", "menuCat": "Details", "order": "41", "role": "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails", "shortName": "Debt - Current and Non current (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Debt - Narrative (Details)", "menuCat": "Details", "order": "42", "role": "http://www.rubiustx.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ie83a320c97d644f8afe59a802c93a74c_D20181221-20181221", "decimals": "INF", "lang": "en-US", "name": "ruby:DebtInstrumentNumberOfTranche", "reportCount": 1, "unique": true, "unitRef": "tranche", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ruby:NumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Equity (Details)", "menuCat": "Details", "order": "43", "role": "http://www.rubiustx.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ruby:NumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Stock-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "44", "role": "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "id2c20ef5a03741509ce2b9eb0cdd594c_D20181001-20181031", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Stock-Based Compensation - Granted to non-employees (Details)", "menuCat": "Details", "order": "45", "role": "http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails", "shortName": "Stock-Based Compensation - Granted to non-employees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i9e152c723dc343b59f28e42c7899e888_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Stock-Based Compensation - Option activity (Details)", "menuCat": "Details", "order": "46", "role": "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails", "shortName": "Stock-Based Compensation - Option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ifec22018a24b4f98b5b11fc86b52f077_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i684e57481f3c4eaf86fca6fe376c8cf3_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details)", "menuCat": "Details", "order": "47", "role": "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails", "shortName": "Stock-Based Compensation - Restricted Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i684e57481f3c4eaf86fca6fe376c8cf3_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Stock-Based Compensation - Compensation expense (Details)", "menuCat": "Details", "order": "48", "role": "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails", "shortName": "Stock-Based Compensation - Compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i06886c9f6644473d802d669faec4d477_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "49", "role": "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:IncomeTaxBenefitsForNetOperatingLossesIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "5", "role": "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Income Taxes - U S federal statutory income tax rate (Details)", "menuCat": "Details", "order": "50", "role": "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails", "shortName": "Income Taxes - U S federal statutory income tax rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Income Taxes - Net deferred tax assets (Details)", "menuCat": "Details", "order": "51", "role": "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails", "shortName": "Income Taxes - Net deferred tax assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "ia9eecd2a692546fd94e9272318c8eb25_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Income Taxes - Valuation allowance for deferred tax assets (Details)", "menuCat": "Details", "order": "52", "role": "http://www.rubiustx.com/role/IncomeTaxesValuationallowancefordeferredtaxassetsDetails", "shortName": "Income Taxes - Valuation allowance for deferred tax assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ruby:ValuationAllowanceDeferredTaxAssetDecreasesRecordedAsBenefitToIncomeTaxProvision", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i713c3c58232f4578aa1f297ea5c6a30a_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:AggregateMilestonePaymentsAchievementOfSpecifiedMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details)", "menuCat": "Details", "order": "53", "role": "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails", "shortName": "Commitments and Contingencies - Collaborative Arrangements and Non-collaborative Arrangement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i713c3c58232f4578aa1f297ea5c6a30a_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ruby:AggregateMilestonePaymentsAchievementOfSpecifiedMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i3ebeea822c7f411b9f0252f51e88cf68_D20180101-20180131", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Commitments and Contingencies - Defined Contribution Plan (Details)", "menuCat": "Details", "order": "54", "role": "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails", "shortName": "Commitments and Contingencies - Defined Contribution Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i3ebeea822c7f411b9f0252f51e88cf68_D20180101-20180131", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ruby:NumberOfOperatingLeases", "reportCount": 1, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "55", "role": "http://www.rubiustx.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "ruby:NumberOfExpirationDates", "reportCount": 1, "unique": true, "unitRef": "date", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Leases - Minimum lease payments (Details)", "menuCat": "Details", "order": "56", "role": "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails", "shortName": "Leases - Minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Leases - Lease Portfolio (Details)", "menuCat": "Details", "order": "57", "role": "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails", "shortName": "Leases - Lease Portfolio (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Net Loss per Share - Weighted Average Shares (Details)", "menuCat": "Details", "order": "58", "role": "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails", "shortName": "Net Loss per Share - Weighted Average Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)", "menuCat": "Details", "order": "59", "role": "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails", "shortName": "Net Loss per Share - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i3139e869374d4230ada12cccfe08bc39_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Restructuring and Impairment Charges - Narrative (Details)", "menuCat": "Details", "order": "60", "role": "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "shortName": "Restructuring and Impairment Charges - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i3139e869374d4230ada12cccfe08bc39_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i29cfe6af626c4a3bb03b4153c69ca293_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Restructuring and Impairment Charges - Summary of Charges (Details)", "menuCat": "Details", "order": "61", "role": "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails", "shortName": "Restructuring and Impairment Charges - Summary of Charges (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Restructuring and Impairment Charges - Restructuring Reserve Activity (Details)", "menuCat": "Details", "order": "62", "role": "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "shortName": "Restructuring and Impairment Charges - Restructuring Reserve Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i75f3bdfb888d45ee9d1d06d83d954968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i9ab4b8e77c0b41f8bff6961e93718eaa_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY", "menuCat": "Statements", "order": "7", "role": "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i9ab4b8e77c0b41f8bff6961e93718eaa_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i232776d068624f4b9519a873c4649d1a_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i232776d068624f4b9519a873c4649d1a_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "9", "role": "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ruby-20221231.htm", "contextRef": "i593c4c6d5bfa406699301fe7fdbf2644_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rubiustx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ruby_A2018ESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 ESPP", "label": "2018 ESPP [Member]", "terseLabel": "2018 ESPP" } } }, "localname": "A2018ESPPMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_A2022RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Restructuring Plan", "label": "2022 Restructuring Plan [Member]", "terseLabel": "2022 Restructuring Plan" } } }, "localname": "A2022RestructuringPlanMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "ruby_A2022StrategicRestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Strategic Restructuring Plan", "label": "2022 Strategic Restructuring Plan [Member]", "terseLabel": "2022 Strategic Restructuring Plan" } } }, "localname": "A2022StrategicRestructuringPlanMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "ruby_AccruedContractTerminationCostsCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Contract Termination Costs, Current", "label": "Accrued Contract Termination Costs, Current", "terseLabel": "Accrued contract termination costs" } } }, "localname": "AccruedContractTerminationCostsCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AccruedEmployeeTerminationBenefitsCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Employee Termination Benefits, Current", "label": "Accrued Employee Termination Benefits, Current", "terseLabel": "Accrued employee termination benefits" } } }, "localname": "AccruedEmployeeTerminationBenefitsCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, excluding current operating lease liabilities, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses And Other Current Liabilities Excluding Current Operating Lease Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ruby_AccruedGeneralAndAdministrativeExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current portion of accrued general and administrative expenses as at the end of the reporting period.", "label": "Accrued General And Administrative Expenses Current", "terseLabel": "Accrued general and administrative expenses" } } }, "localname": "AccruedGeneralAndAdministrativeExpensesCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AccruedManufacturingFacilityExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing facility expenses.", "label": "Accrued Manufacturing Facility Expenses Current", "terseLabel": "Accrued manufacturing facility expenses" } } }, "localname": "AccruedManufacturingFacilityExpensesCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development expenses.", "label": "Accrued Research and Development, Current", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AggregateMilestonePaymentsAchievementOfSpecifiedMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate milestone payments to be made on achieving of specific .", "label": "Aggregate Milestone Payments, Achievement of Specified Milestones", "terseLabel": "Aggregate milestone payments" } } }, "localname": "AggregateMilestonePaymentsAchievementOfSpecifiedMilestones", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "monetaryItemType" }, "ruby_AggregateStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Aggregate Stock, Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "AggregateStockSharesAuthorized", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "ruby_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock by company under the distribution agreement through the Sales Agents, deemed to be an at the market offering.", "label": "At the market offering", "terseLabel": "At the market offering" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ruby_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.rubiustx.com/20221231", "xbrltype": "stringItemType" }, "ruby_DebtInstrumentNumberOfTranche": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of tranche.", "label": "Debt Instrument, Number Of Tranche", "terseLabel": "Number of tranche" } } }, "localname": "DebtInstrumentNumberOfTranche", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "ruby_DebtInstrumentPrepaymentRateOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the prepayment rate if prepayment occurs in first year.", "label": "Debt Instrument, Prepayment Rate One", "terseLabel": "Prepayment fee in first year" } } }, "localname": "DebtInstrumentPrepaymentRateOne", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ruby_DebtInstrumentPrepaymentRateThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the prepayment rate if prepayment occurs in third year.", "label": "Debt Instrument, Prepayment Rate Three", "terseLabel": "Prepayment fee in third year" } } }, "localname": "DebtInstrumentPrepaymentRateThree", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ruby_DebtInstrumentPrepaymentRateTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the prepayment rate if prepayment occurs in second year.", "label": "Debt Instrument, Prepayment Rate Two", "terseLabel": "Prepayment fee in second year" } } }, "localname": "DebtInstrumentPrepaymentRateTwo", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "ruby_DeferredFinancingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred financing costs.", "label": "Deferred Financing Costs [policy Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredFinancingCostsPolicyTextBlock", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ruby_DeferredTaxAssetIncreaseDecreaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in gross deferred tax assets, before valuation allowance.", "label": "\"Deferred Tax Asset, Increase (Decrease), Amount \"", "terseLabel": "Increase in gross deferred tax assets, before valuation allowance" } } }, "localname": "DeferredTaxAssetIncreaseDecreaseAmount", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DeferredTaxAssetValuationAllowanceActivityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Asset, Valuation Allowance Activity", "label": "Deferred Tax Asset, Valuation Allowance Activity [Roll Forward]" } } }, "localname": "DeferredTaxAssetValuationAllowanceActivityRollForward", "nsuri": "http://www.rubiustx.com/20221231", "xbrltype": "stringItemType" }, "ruby_DeferredTaxAssetsCapitalizedIntellectualPropertyCosts": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences, Capitalized Intellectual Property Costs.", "label": "Deferred Tax Assets, Capitalized Intellectual Property Costs", "terseLabel": "Capitalized intellectual property costs" } } }, "localname": "DeferredTaxAssetsCapitalizedIntellectualPropertyCosts", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences, capitalized research and development expense.", "label": "Deferred Tax Assets, Capitalized Research and Development Expense", "terseLabel": "Capitalized research and development expense" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpense", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DeferredTaxAssetsDepreciation": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Depreciation", "label": "Deferred Tax Assets, Depreciation", "terseLabel": "Depreciation" } } }, "localname": "DeferredTaxAssetsDepreciation", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.", "label": "Deferred Tax Assets, Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DeferredTaxLiabilitiesDepreciationAndOther": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation", "label": "Deferred Tax Liabilities Depreciation and Other", "negatedLabel": "Depreciation and other" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndOther", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_DepositForAssetsHeldForSaleCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deposit For Assets Held-For-Sale, Current", "label": "Deposit For Assets Held-For-Sale, Current", "terseLabel": "Deposit received for assets held for sale" } } }, "localname": "DepositForAssetsHeldForSaleCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ruby_EmbeddedLeaseContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to embedded lease contracts.", "label": "Embedded lease contracts", "terseLabel": "Embedded lease contracts" } } }, "localname": "EmbeddedLeaseContractsMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_EquityIncentivePlan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The information pertaining to 2018 Equity Incentive Plan.", "label": "2018 Equity Incentive Plan", "terseLabel": "2018 Equity Incentive Plan" } } }, "localname": "EquityIncentivePlan2018Member", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_ImpairmentOfPropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment Of Property Plant And Equipment", "label": "Impairment Of Property Plant And Equipment [Member]", "terseLabel": "Impairment of property, plant and equipment" } } }, "localname": "ImpairmentOfPropertyPlantAndEquipmentMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "ruby_IncomeTaxBenefitsForNetOperatingLossesIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax benefits for the net operating losses incurred.", "label": "Income Tax Benefits For Net Operating Losses Incurred", "terseLabel": "Income tax benefits - operating losses incurred" } } }, "localname": "IncomeTaxBenefitsForNetOperatingLossesIncurred", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ruby_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts of accrued expenses and other current liabilities.", "label": "Increase (Decrease) in Accrued Expenses and Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_IncreaseDecreaseOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of operating lease liabilities.", "label": "Increase Decrease, Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseOperatingLeaseLiabilities", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_IncreaseDecreaseOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of operating lease, right-of-use-asset.", "label": "Increase Decrease, Operating Lease, Right Of Use Asset", "negatedLabel": "Operating lease, right-of-use-asset" } } }, "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in laboratory.", "label": "Laboratory equipment", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "ruby_LeaseAssetDerecognizedUponLeaseCancellation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in right-of-use asset upon cancellation of lease.", "label": "Lease Asset Derecognized Upon Lease Cancellation", "terseLabel": "Lease asset derecognized upon lease cancellation" } } }, "localname": "LeaseAssetDerecognizedUponLeaseCancellation", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_LoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "localname": "LoanAgreementMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "ruby_LongTermDebtNetOfCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt prior to reduction for unamortized (discount) or premium and debt issuance costs classified as noncurrent.", "label": "Long Term Debt Net Of Current", "terseLabel": "Long\u2011term debt, net of current portion" } } }, "localname": "LongTermDebtNetOfCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "ruby_ManufacturingEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to manufacturing equipment.", "label": "Manufacturing equipment", "terseLabel": "Manufacturing equipment" } } }, "localname": "ManufacturingEquipmentMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "ruby_MarketBasedAndServiceBasedVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to common stock closing prices and service based vesting requirements, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Market based and service based vesting", "terseLabel": "Market based and service based vesting" } } }, "localname": "MarketBasedAndServiceBasedVestingMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_MarketBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options awarded to employees for meeting certain closing prices of its common stock.", "label": "Market-Based Stock Options", "terseLabel": "Market-Based Stock Options" } } }, "localname": "MarketBasedStockOptionsMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_MaximumAggregateOfferingPriceOfStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of aggregate offering price of the Company's common stock sold through Sales Agents under distribution agreement.", "label": "Maximum Aggregate Offering Price Of Stock", "terseLabel": "Aggregate offering price" } } }, "localname": "MaximumAggregateOfferingPriceOfStock", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "ruby_NumberOfDistinctLeasedSpaces": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Distinct Leased Spaces", "label": "Number of Distinct Leased Spaces", "terseLabel": "Number of distinct leased spaces" } } }, "localname": "NumberOfDistinctLeasedSpaces", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ruby_NumberOfExpirationDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of expiration dates.", "label": "Number of Expiration Dates", "terseLabel": "Number of expiration period" } } }, "localname": "NumberOfExpirationDates", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ruby_NumberOfOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non cancellable operating lease contracts.", "label": "Number of Operating Leases", "terseLabel": "Number of leases" } } }, "localname": "NumberOfOperatingLeases", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "ruby_NumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote entitled to common stock holders per share.", "label": "Number of Votes Per Share", "terseLabel": "Number of votes per share" } } }, "localname": "NumberOfVotesPerShare", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "integerItemType" }, "ruby_OfferingCostsAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount represents the offering costs and issuance costs included in accounts payable and accrued expenses", "label": "Offering Costs And Issuance Costs Included In Accounts Payable And Accrued Expenses", "terseLabel": "Offering costs included in accounts payable and accrued expenses" } } }, "localname": "OfferingCostsAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_OfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to an unwritten public offering.", "label": "Offering", "terseLabel": "Offering" } } }, "localname": "OfferingMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "ruby_OperatingLeaseBaseRentIncrementalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base rent increase during the initial term in percentage annually on the anniversary of the commencement date.", "label": "Operating Lease, Base Rent incremental Percentage", "terseLabel": "Base rent incremental (as a percentage)" } } }, "localname": "OperatingLeaseBaseRentIncrementalPercentage", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "ruby_OperatingLeaseTerminationPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Termination Payment", "label": "Operating Lease, Termination Payment", "terseLabel": "Operating lease, termination payment" } } }, "localname": "OperatingLeaseTerminationPayment", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ruby_PatentCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patent Costs [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyTextBlock", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ruby_PrepaidExpenseAndOtherCurrent": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance and other for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherCurrent", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ruby_ProceedsFromStockOptionsExercisedInOtherCurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option in other current assets under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised In Other Current Assets", "terseLabel": "Remeasurement of operating lease liabilities and right-of-use assets due to lease modification" } } }, "localname": "ProceedsFromStockOptionsExercisedInOtherCurrentAssets", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ruby_ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for research and manufacturing contract costs and accruals.", "label": "Research and Manufacturing Contract Costs and Accruals [Policy Text Block]", "terseLabel": "Research and Manufacturing Contract Costs and Accruals" } } }, "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyTextBlock", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ruby_RestrictedCashForBenefitOfLandlord": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "a", "label": "Restricted Cash For The Benefit Of Landlord", "terseLabel": "Restricted cash for the benefit of its leased properties" } } }, "localname": "RestrictedCashForBenefitOfLandlord", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ruby_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities.", "label": "Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "ruby_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual increase of the shares (or other type of equity) for awards under the equity-based compensation plan as as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase Percentage", "terseLabel": "Annual increase of shares reserved for awards (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentage", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "ruby_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount represents the value of share-based compensation arrangement by share-based payment award, options, grant date fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grant Date Fair Value", "terseLabel": "Stock-based compensation, fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ruby_ValuationAllowanceDeferredTaxAssetDecreasesRecordedAsBenefitToIncomeTaxProvision": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Decreases Recorded As Benefit To Income Tax Provision", "label": "Valuation Allowance, Deferred Tax Asset, Decreases Recorded As Benefit To Income Tax Provision", "terseLabel": "Decreases recorded as benefit to income tax provision" } } }, "localname": "ValuationAllowanceDeferredTaxAssetDecreasesRecordedAsBenefitToIncomeTaxProvision", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesValuationallowancefordeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_ValuationAllowanceDeferredTaxAssetIncreaseInIncomeTaxProvision": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase in Income Tax Provision", "terseLabel": "Increases recorded to income tax provision" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseInIncomeTaxProvision", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesValuationallowancefordeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "ruby_VestingBasedOnPerformanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a share based compensation award with vesting based on achievement of performance conditions.", "label": "Performance-based vesting", "terseLabel": "Performance-based vesting" } } }, "localname": "VestingBasedOnPerformanceMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "ruby_WhiteheadInstituteForBiomedicalResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Whitehead Institute for Biomedical Research.", "label": "WIBR", "terseLabel": "WIBR" } } }, "localname": "WhiteheadInstituteForBiomedicalResearchMember", "nsuri": "http://www.rubiustx.com/20221231", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r186", "r187", "r287", "r315", "r516", "r518" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive Officer" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r271", "r272", "r273", "r274", "r338", "r482", "r502", "r513", "r514", "r532", "r539", "r547", "r588", "r634", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails", "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails", "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r271", "r272", "r273", "r274", "r338", "r482", "r502", "r513", "r514", "r532", "r539", "r547", "r588", "r634", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r241", "r483", "r533", "r546", "r583", "r584", "r590", "r644" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r241", "r483", "r533", "r546", "r583", "r584", "r590", "r644" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r271", "r272", "r273", "r274", "r329", "r338", "r369", "r370", "r371", "r458", "r482", "r502", "r513", "r514", "r532", "r539", "r547", "r581", "r588", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails", "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails", "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r271", "r272", "r273", "r274", "r329", "r338", "r369", "r370", "r371", "r458", "r482", "r502", "r513", "r514", "r532", "r539", "r547", "r581", "r588", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails", "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails", "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r186", "r187", "r287", "r315", "r517", "r518" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r339", "r573" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r202", "r339", "r557", "r573" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r202", "r339", "r557", "r558", "r573" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r76", "r156" ], "calculation": { "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r30", "r118", "r447", "r503", "r504", "r561", "r562", "r563", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r378", "r379", "r380", "r570", "r571", "r572", "r625" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r108", "r109", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r91", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Net of commissions, underwriting discounts and offering costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of of diluted weighted average shares outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Diluted net loss per share attributable to common stockholders" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetUnderConstructionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset in process of being built.", "label": "Asset under Construction [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "AssetUnderConstructionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r129", "r141", "r158", "r184", "r226", "r235", "r239", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r405", "r409", "r422", "r545", "r586", "r587", "r632" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r152", "r160", "r184", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r405", "r409", "r422", "r545", "r586", "r587", "r632" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r120" ], "calculation": { "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r2", "r78", "r150", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Disposal group, including discontinued operation, assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r2", "r73", "r78", "r150", "r151" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r68", "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r57", "r58", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property, plant and equipment included in accounts payable or accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r55", "r154", "r515" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r56", "r128" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r50", "r55", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r50", "r123" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r134", "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r87", "r269", "r270", "r509", "r585" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r570", "r571", "r625" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, share authorized (in shares)", "verboseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at December\u00a031, 2022 and December\u00a031, 2021, respectively; 90,387,732 and 90,063,770 shares issued and outstanding at December\u00a031, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r31", "r165", "r167", "r174", "r496", "r500" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r138", "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and of Significant Suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractTerminationMember": { "auth_ref": [ "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Contract Termination [Member]", "terseLabel": "Contract termination costs" } } }, "localname": "ContractTerminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r90", "r182", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r300", "r307", "r308", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r4", "r5", "r6", "r130", "r132", "r140", "r188", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r430", "r527", "r528", "r529", "r530", "r531", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r6", "r132", "r140", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Principal amount of long\u2011term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reference rate used for variable rate of debt instrument.", "label": "Debt Instrument, Description of Variable Rate Basis", "terseLabel": "One-month LIBOR" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r125", "r127", "r284", "r430", "r528", "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r22", "r285" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r24", "r188", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r430", "r527", "r528", "r529", "r530", "r531", "r568" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r92", "r93", "r94", "r95", "r124", "r125", "r127", "r137", "r188", "r284", "r285", "r286", "r287", "r288", "r290", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r309", "r430", "r527", "r528", "r529", "r530", "r531", "r568" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r126", "r296", "r312", "r528", "r529" ], "calculation": { "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Principal amount of each tranche of term loans" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r126", "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r7", "r8", "r131", "r139", "r390" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r391" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r621" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r117", "r622" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r117", "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Federal operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Federal operating loss carryforwards subject to expiration indefinitely" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r117", "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Federal operating loss carryforwards subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r115", "r117", "r622" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails", "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r117", "r622" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock\u2011based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r117", "r622" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r392" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "periodEndLabel": "Valuation allowance as of end of year", "periodStartLabel": "Valuation allowance as of beginning of year" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails", "http://www.rubiustx.com/role/IncomeTaxesValuationallowancefordeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r117", "r622" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Operating lease assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNetdeferredtaxassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Company matching contribution" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Percentage of employee's gross pay match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r53", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r53", "r225" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r343", "r374", "r375", "r377", "r382", "r540" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r72", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal group, including discontinued operation, consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r258", "r566", "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Loss on disposal" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r175", "r194", "r195", "r196", "r197", "r198", "r203", "r205", "r207", "r208", "r209", "r213", "r414", "r415", "r497", "r501", "r519" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r175", "r194", "r195", "r196", "r197", "r198", "r205", "r207", "r208", "r209", "r213", "r414", "r415", "r497", "r501", "r519" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r385" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r185", "r385", "r399" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r620", "r623" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Increase in deferred tax asset valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r620", "r623" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r620", "r623" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Stock\u2011based compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Section 162(m) compensation deduction limitation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r620", "r623" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r620", "r623" ], "calculation": { "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Federal and state research and development tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesUSfederalstatutoryincometaxrateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost expected to be recognized over a weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee termination benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r91", "r149", "r169", "r170", "r171", "r189", "r190", "r191", "r193", "r199", "r201", "r215", "r248", "r328", "r378", "r379", "r380", "r396", "r397", "r413", "r423", "r424", "r425", "r426", "r427", "r428", "r447", "r503", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair value of financial assets and liabilities" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r120", "r121", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r298", "r330", "r331", "r332", "r333", "r334", "r335", "r417", "r455", "r456", "r457", "r528", "r529", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r416", "r417", "r418", "r419", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Investments and Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r298", "r330", "r335", "r417", "r455", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r298", "r330", "r335", "r417", "r456", "r528", "r529", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r298", "r330", "r331", "r332", "r333", "r334", "r335", "r417", "r457", "r528", "r529", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r298", "r330", "r331", "r332", "r333", "r334", "r335", "r455", "r456", "r457", "r528", "r529", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r244", "r245", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r309", "r326", "r411", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r522", "r576", "r577", "r578", "r645", "r646", "r647", "r648", "r649", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Impairment charges" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r53", "r88", "r89" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain on debt extinguishment", "terseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r53", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "negatedTerseLabel": "Impairment charges", "terseLabel": "Impairment charges" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r69", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets, Assets Held for Sale" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r259", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r185", "r386", "r388", "r394", "r398", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r168", "r383", "r384", "r388", "r389", "r393", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r52" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r52" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r126", "r136", "r172", "r224", "r429" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r176", "r179", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued final interest payment" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r36", "r223" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r38" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Amortization (accretion) of premium (discount) on investments" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r246", "r643" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r444", "r544" ], "calculation": { "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease cost and lease liabilities for the Company's lease portfolio" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of minimum lease payments under the Company's operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Payments due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r445" ], "calculation": { "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r184", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r406", "r409", "r410", "r422", "r520", "r586", "r632", "r633" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r133", "r143", "r545", "r569", "r579", "r626" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r153", "r184", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r406", "r409", "r410", "r422", "r545", "r586", "r632", "r633" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndMaintenanceMember": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Maintenance [Member]", "terseLabel": "License and Maintenance" } } }, "localname": "LicenseAndMaintenanceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum amount outstanding" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "One-month U.S. LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Less: Current portion of long\u2011term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r159" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of discount", "totalLabel": "Long\u2011term debt, net of discount and current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/DebtCurrentandNoncurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturingFacilityMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Structure used in the manufacturing of goods.", "label": "Manufacturing Facility [Member]", "terseLabel": "Manufacturing facility" } } }, "localname": "ManufacturingFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "U.S. government money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r178" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r178" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r50", "r51", "r54" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash provided by (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r32", "r54", "r135", "r146", "r151", "r164", "r166", "r171", "r184", "r192", "r194", "r195", "r196", "r197", "r200", "r201", "r206", "r226", "r234", "r238", "r240", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r415", "r422", "r521", "r586" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r226", "r234", "r238", "r240", "r521" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r436", "r544" ], "calculation": { "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Initial annual base rent" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Minimum lease payments" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesMinimumleasepaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r432" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r432" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r433", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Cash paid for leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r431" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease, right-of-use-asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails", "http://www.rubiustx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r443", "r544" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r442", "r544" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "ruby_AccruedExpensesAndOtherCurrentLiabilitiesExcludingCurrentOperatingLeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r161", "r163" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized losses on investments, net of tax of $0" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r29", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "terseLabel": "Unrealized gains (losses) on investments, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "License costs" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r46" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Payment of long-term debt" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r261", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Amounts paid or otherwise settled during the period" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r48" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payments of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r49" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payments of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r43" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r42" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r313" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, share authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r313" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized at December\u00a031, 2022 and December\u00a031, 2021; no shares issued or outstanding at December\u00a031, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r44" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds after deducting underwriting discounts and commissions", "verboseLabel": "Proceeds from underwritten public offering of common stock, net of commissions and underwriting discounts" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r564" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Borrowing" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r45" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from borrowings under loan and security agreement" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r41" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "verboseLabel": "Sales and maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r40" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r44", "r106" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options and under employee stock purchase plan" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r151", "r164", "r166", "r177", "r184", "r192", "r200", "r201", "r226", "r234", "r238", "r240", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r404", "r407", "r408", "r415", "r422", "r498", "r521", "r542", "r543", "r563", "r586" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails", "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r81", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment, Net and Assets Held for Sale" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r75", "r155" ], "calculation": { "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r77", "r144", "r499", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "terseLabel": "Property, Plant and Equipment, Net [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r77", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesNarrativeDetails", "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r336", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r336", "r448", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "terseLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r110", "r148", "r640" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r559", "r567", "r641", "r642" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r559", "r567" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash, current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r508", "r560", "r567" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash (non-current)" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r260", "r263", "r266", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Restructuring and related cost, cost incurred to date" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r260", "r263", "r266", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Restructuring and related cost, number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Restructuring and related cost, number of positions eliminated, period percent" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r53", "r264", "r266", "r582" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r260", "r261", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "auth_ref": [ "r53" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs and Asset Impairment Charges", "terseLabel": "Restructuring and impairment charges" } } }, "localname": "RestructuringCostsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Impairment Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r261", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r96", "r142", "r506", "r507", "r545" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r149", "r189", "r190", "r191", "r193", "r199", "r201", "r248", "r378", "r379", "r380", "r396", "r397", "r413", "r503", "r505" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r173", "r184", "r221", "r222", "r233", "r236", "r237", "r241", "r242", "r243", "r247", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r422", "r498", "r586" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r441", "r544" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CommitmentsandContingenciesCollaborativeArrangementsandNoncollaborativeArrangementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of allocation of share based compensation" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of long term debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Net deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of calculation of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r104", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationCompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesEstimatedusefullifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.", "label": "Public Utility Property, Plant, and Equipment [Table Text Block]", "terseLabel": "Summary of property plant and equipment" } } }, "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r260", "r261", "r262", "r263", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r83", "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r82", "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve by Type of Cost" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/RestructuringandImpairmentChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r340", "r342", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r98", "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to determine the fair value of stock awards granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r52" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Restricted stock units forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value- forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock units issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value- issued (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted common stock end of period (in shares)", "periodStartLabel": "Unvested restricted common stock beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value - end of the period (in dollars per share)", "periodStartLabel": "Weighted average grant date fair value - beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted stock units vested (in shares)", "verboseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value- vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of authorized shares reserved for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Total number of shares of common stock authorized to issue (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares remained available for future issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average contractual term and aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in dollars per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Number of options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding at the end (in dollars)", "periodStartLabel": "Outstanding at the beginning (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end (in dollars per share)", "periodStartLabel": "Outstanding at the beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails", "http://www.rubiustx.com/role/StockBasedCompensationRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "verboseLabel": "Options exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r347", "r366", "r367", "r368", "r369", "r372", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationGrantedtononemployeesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable (in dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the beginning (in years)", "verboseLabel": "Outstanding at the end (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances at end of period (in shares)", "periodStartLabel": "Balances at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r437", "r544" ], "calculation": { "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r61", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r27", "r91", "r149", "r169", "r170", "r171", "r189", "r190", "r191", "r193", "r199", "r201", "r215", "r248", "r328", "r378", "r379", "r380", "r396", "r397", "r413", "r423", "r424", "r425", "r426", "r427", "r428", "r447", "r503", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r189", "r190", "r191", "r215", "r483" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r10", "r91", "r96" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r91", "r96" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r91", "r96", "r353" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY", "http://www.rubiustx.com/role/StockBasedCompensationNarrativeDetails", "http://www.rubiustx.com/role/StockBasedCompensationOptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r10", "r91", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r91", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock from public offering, net of commissions, underwriting discounts and offering costs of $800" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r27", "r91", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Equity Option" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r67", "r545", "r569", "r579", "r626" ], "calculation": { "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances at end of period", "periodStartLabel": "Balances at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r183", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r328", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r439", "r544" ], "calculation": { "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/EquityDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Nature of the business and basis of presentation", "verboseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/EquityDetails", "http://www.rubiustx.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of changes in the valuation allowance for deferred tax assets" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r244", "r245", "r309", "r326", "r411", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r576", "r577", "r578", "r645", "r646", "r647", "r648", "r649", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/InvestmentsandFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r260", "r261", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/PropertyPlantandEquipmentNetandAssetsHeldforSaleDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesNarrativeDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesRestructuringReserveActivityDetails", "http://www.rubiustx.com/role/RestructuringandImpairmentChargesSummaryofChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized losses on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r64", "r65", "r66", "r216", "r217", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r438", "r544" ], "calculation": { "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/LeasesLeasePortfolioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r204", "r209" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r203", "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rubiustx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.rubiustx.com/role/NetLossperShareWeightedAverageSharesDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r548": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r549": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r551": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r552": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r553": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r554": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r555": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r556": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 81 0001709401-23-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001709401-23-000005-xbrl.zip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